

A

NEW APPLICATION TRANSMITTAL Page 1 of 5

### 3. Declaration or oath

☒ Enclosed 8 pages  
\_\_\_\_ Newly executed (original or copy)  
☒ Copies from prior application (continuation/divisional with page 5 of 5 completed)  
\_\_\_\_ Deletion of Inventor(s) (signed statement attached deleting inventor(s) of prior application)  
\_\_\_\_ Not enclosed

### 4. Inventorship Statement

The inventorship for all the claims in this application are:

☒ the same

**OR**

\_\_\_\_ are not the same and an explanation, including the ownership of the various claims at the time the last claimed invention was made, is submitted.

### 5. Language

☒ English ☐ Non-English

A verified English translation of the

[check applicable item(s)]

\_\_\_\_ specification and claims

\_\_\_\_ declaration

is attached.

### 6. Assignment

\_\_\_\_ An assignment of the invention to  
\_\_\_\_ is filed under separate cover sheet  
\_\_\_\_ was filed in the prior application  
\_\_\_\_ will follow

### 7. Certified Copy

(Country) \_\_\_\_\_ (Application No.) \_\_\_\_\_ (Filed) \_\_\_\_\_

from which priority is claimed

\_\_\_\_ is attached

\_\_\_\_ will follow

## 8. Fee Calculation

### CLAIMS

	Number Filed	Provided with Basic Fee	Number Extra	Rate	Basic Fee \$760
Total Claims	4	20	0	X \$18.00	\$ .00
Independent Claims	2	3	0	X \$78.00	\$ .00
Multiple Dependent Claim(s), if any	0	0	0	X \$260.00	\$ .00

☒ Amend application by canceling claims 2 through 20 and 24 through 31 before calculating the filing fee. This would leave pending in the application claims 1 and 21 through 23.

☐ Amendment deleting multiple dependencies enclosed

☐ Fee for extra claims is not being paid at this time

Filing Fee Calculation

\$ 760.00

## 9. Small Entity Statement

☐ verified statement that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is attached.

Filing Fee Calculation (50% of above)

\$ \_\_\_\_\_

## 10. Fee Payment Being Made At This Time

☒ Enclosed

☒ basic filing fee

\$ 760.00

Total fees enclosed

\$ 760.00

## 11. Method of Payment of Fees

☒ check in the amount of \$ 760.00

**12. Authorization to Charge Additional Fees**

  X   The Commissioner is hereby authorized to charge the following additional fees which may be required to Account No. 18-1829;

  X   37 CFR 1.16 (filing fees and presentation of extra claims)

  X   37 CFR 1.17 (application processing fees)

       37 CFR 1.18 (issue fee at or before Mailing of Notice of Allowance, pursuant to 37 CFR 1.311(b)).

**13. Instructions As To Overpayment**

  X   credit Account No. 18-1829

**14. Correspondence Address**



Elie H. Gendloff  
Reg. No. 44,704  
HOWELL & HAFERKAMP, L.C.  
7733 Forsyth Boulevard  
Suite 1400  
St. Louis, Missouri 63105  
(314) 727-5188



**ADDED PAGE FOR NEW APPLICATION WHERE BENEFIT  
OF A PRIOR U.S. APPLICATION CLAIMED**

**15. Benefits of Prior U.S. Application**

This application is a  
☐ continuation  
☐ continuation-in-part  
☒ divisional

of prior U.S. application Serial No. 08/931,858 filed September 16, 1997, which is a Continuation-in-Part of U.S. application Serial No., 08/881,172, filed June 23, 1997, which is a Continuation-in-Part of U.S. application Serial No. 08/615,944, filed March 14, 1996 (now abandoned) and a Continuation-in-Part of PCT/US97/03461, filed March 14, 1997.

International Application ☐ filed

☒ Incorporation by Reference  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under item 3., is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

**16. Maintenance of Copendency of Prior Application**

☐ A petition, fee and response has been filed to extend the term in the pending prior application until

**17. Conditional Petition for Extension of Time in Parent Application**

☐ A conditional petition for extension of time is being filed in the pending parent application.

**18. Relate Back -- 35 U.S.C. 120**

☒ Amend the specification by inserting before the first line the sentence:

This is a  
☐ continuation  
☐ continuation-in-part  
☒ divisional  
☐ provisional

of copending application

☒ Serial number 08/931,858 ; filed on September 16, 1997, which is a Continuation-in-Part of U.S. application Serial No., 08/881,172, filed June 23, 1997, which is a Continuation-in-Part of U.S. application Serial No. 08/615,944, filed March 14, 1996 (now abandoned) and a Continuation-in-Part of PCT/US97/03461, filed March 14, 1997.

☐ PCT International Application ☐; filed on

**19. Abandonment of Prior Application (if applicable)**

☐ Please abandon the prior application at a time while the prior application is pending or when the petition for extension of time in that application is granted and when this application is granted a filing date so as to make this application copending with said prior application.

PATENT

PERSEPHIN AND RELATED GROWTH FACTORS

Reference to Government Grant

This invention was made with government support under Grant Numbers NS24679 and CA53524. The government  
5 has certain rights in this invention.

Related Applications

This application is a continuation-in-part of Application Serial No. 08/881,172 filed June 23, 1997  
10 which is a continuation-in-part of Application Serial No. 08/615,944 filed March 14, 1996 and a continuation-in part of Application PCT/US97/03461 filed March 14, 1997.

Background of the Invention

15 (1) Field of the Invention

This invention relates generally to trophic or growth factors and, more particularly, to novel growth factors of the neurturin-GDNF family of growth factors.

(2) Description of the Related Art

20 The development and maintenance of tissues in complex organisms requires precise control over the processes of cell proliferation, differentiation, survival and function. A major mechanism whereby these processes are controlled is through the actions of  
25 polypeptides known as "growth factors". These structurally diverse molecules act through specific cell surface receptors to produce these actions.

Growth factors, termed "neurotrophic factors" promote the differentiation, growth and survival of  
30 neurons and reside in the nervous system or in innervated tissues. Nerve growth factor (NGF) was the first neurotrophic factor to be identified and characterized (Levi-Montalcini et al , J. Exp. Zool. 116:321, 1951

which is incorporated by reference). NGF exists as a non-covalently bound homodimer that promotes the survival and growth of sympathetic, neural crest-derived sensory, and basal forebrain cholinergic neurons. In sympathetic  
 5 neurons this substance produces neurite outgrowth in vitro and increased axonal and dendritic growth in vivo. (See Levi-Montalcini and Booker, *Proc Nat'l Acad Sci* 46:384-391, 1960; Johnson et al. *Science* 210: 916-918, 1980; Crowley et al., *Cell* 76:1001-12, 1994 which are  
 10 incorporated by reference). NGF has effects on cognition and neuronal plasticity, and can promote the survival of neurons that have suffered damage due to a variety of mechanical, chemical, viral, and immunological insults (Snider and Johnson, *Ann Neurol* 26:489-506, 1989; Hefti,  
 15 *J Neurobiol* 25:1418-35, 1994 which are incorporated by reference). NGF also is known to extensively interact with the endocrine system and in immune and inflammatory processes. (Reviewed in Scully and Otten, *Cell Biol Int* 19:459-469, 1995; Otten and Gadiant, *Int. J. Devl*  
 20 *Neurosci* 13:147-151, 1995 which are incorporated by reference). For example, NGF promotes the survival of mast cells. (Horigome et al. *J Biol Chem* 269:2695-2707, 1994 which is incorporated by reference).

In recent years it has become apparent that growth  
 25 factors fall into classes, i.e. families or superfamilies based upon the similarities in their amino acid sequences. These families include, for example, the fibroblast growth factor family, the neurotrophin family and the transforming growth factor-beta (TGF- $\beta$ ) family.  
 30 As an example of family member sequence similarities, TGF- $\beta$  family members have 7 canonical framework cysteine residues which identify members of this superfamily.

NGF is the prototype of such a family of growth factors. Brain-derived neurotrophic factor (BDNF), the  
 35 second member of this family to be discovered, was shown to be related to NGF by virtue of the conservation of all

six cysteines that form the three internal disulfides of the NGF monomer (Barde, *Prog Growth Factor Res* 2:237-248, 1990 and Liebrock et al. *Nature* 341:149-152, 1989 which are incorporated by reference). By utilizing the

5 information provided by BDNF of the highly conserved portions of two factors, additional members (NT-3, NT-4/5) of this neurotrophin family were rapidly found by several groups (Klein, *FASEB J* 8:738-44, 1994 which is incorporated by reference).

10 Neurotrophic factors structurally unrelated to NGF have been recently identified. These include factors originally isolated based upon a "neurotrophic action" such as ciliary neurotrophic factor (CNTF) (Lin et al., *Science* 246:1023-5, 1989 which is incorporated by  
15 reference) along with others originally isolated as a result of non-neuronal activities (e.g. fibroblast growth factors (Cheng and Mattson *Neuron* 1:1031-41, 1991 which is incorporated by reference), IGF-I (Kanje et al, *Brain Res* 486:396-398, 1989 which is incorporated by reference)  
20 leukemia inhibitory factor (Kotzbauer et al, *Neuron* 12:763-773, 1994 which is incorporated by reference).

Glial-derived neurotrophic factor (GDNF), is one such neurotrophic factor structurally unrelated to NGF. GDNF was, thus, a unique factor, which, up until now, was  
25 not known to be a member of any subfamily of factors. The discovery, purification and cloning of GDNF resulted from a search for factors crucial to the survival of midbrain dopaminergic neurons, which degenerate in Parkinson's disease. GDNF was purified from rat B49  
30 glial cell conditioned media (Lin et al., *Science* 260:1130-2, 1993 which is incorporated by reference). Sequence analysis revealed it to be a distant member of the TGF- $\beta$  superfamily of growth factors, having approximately 20% identity based primarily on the  
35 characteristic alignment of the 7 canonical framework cysteine residues (Lin et al., *Science* 260:1130-2, 1993

which is incorporated by reference). Thus, GDNF could possibly have represented a new subfamily within the TGF- $\beta$  superfamily.

Recombinant GDNF produced in bacteria specifically promotes the survival and morphological differentiation of dopaminergic neurons (Lin et al., *Science* 260:1130-2, 1993); Tomac et al., *Nature* 373:335-9, 1995; Beck et al., *Nature* 373:339-41, 1995 and Ebendal et al., *J Neurosci Res* 40:276-84, 1995 which are incorporated by reference) and motor neurons (Henderson et al., *Science* 266:1062-4, 1994; Yan et al., *Nature* 373:341-4, 1995; and Oppenheim et al., *Nature* 373:344-6, 1995 which are incorporated by reference). Overall, GDNF was a more potent factor for promoting the survival of motor neurons than the other factors, and it was the only factor that prevented neuronal atrophy in response to these lesions, thereby positioning it as a promising therapeutic agent for motor neuron diseases.

It is now generally believed that neurotrophic factors regulate many aspects of neuronal function, including survival and development in fetal life, and structural integrity and plasticity in adulthood. Since both acute nervous system injuries as well as chronic neurodegenerative diseases are characterized by structural damage and, possibly, by disease-induced apoptosis, it is likely that neurotrophic factors play some role in these afflictions. Indeed, a considerable body of evidence suggests that neurotrophic factors may be valuable therapeutic agents for treatment of these neurodegenerative conditions, which are perhaps the most socially and economically destructive diseases now afflicting our society. Nevertheless, because different neurotrophic factors can potentially act preferentially through different receptors and on different neuronal or non-neuronal cell types, there remains a continuing need for the identification of new members of neurotrophic

factor families for use in the diagnosis and treatment of a variety of acute and chronic diseases of the nervous system.

5 Summary of the Invention:

Briefly, therefore, the present invention is directed to the identification and isolation of substantially purified factors that promote the survival and growth of neurons as well as non-neuronal cells.

10 Accordingly, the inventors herein have succeeded in discovering novel protein growth factors belonging to a family of growth factors for which GDNF was the first known member. The first such newly discovered family member was neurturin and this is the subject of copending  
15 application serial Number 08/519,777. Based upon the sequence of GDNF and neurturin the inventors herein have discovered another member of the GDNF-Neurturin family of growth factors referenced herein as persephin (PSP). This growth factor is believed to show at least 75%  
20 sequence identity among homologous sequences from different mammalian species although sequence homology may be as low as 65% in non-mammalian species such as avian species. Indeed, the mouse, rat and human mature persephin sequences show from about 80% to about 94%  
25 sequence identity. Mature persephin proteins identified herein comprise mouse sequences as set forth in SEQ ID NOS:79 and 187 (Figure 17B amino acids 66 through 154 and 61 through 156, respectively), rat sequences as set forth in SEQ ID NOS:82 and 196 (Figure 18B amino acids 6  
30 through 94 and 1 through 96, respectively), and human sequences as set forth in SEQ ID NOS:221 and 223 (Figure 24; amino acids 61-156 and 66-154, respectively).

Persephin has been identified and obtained by a method based upon the conserved regions of the GDNF-  
35 Neurturin family discovered by the inventors herein. Accordingly, a new method has been devised that utilizes

degenerate primers constructed from the sequences of these conserved regions for use in the polymerase chain reaction procedure. By utilizing this method the mouse, rat and human orthologs of the new family member, persephin, have been identified and obtained.

The present invention thus provides both amino acid sequences and nucleotide sequences that encode mouse, rat and human persephin including amino acid sequences of SEQ ID NOS:79, 82, 187, 196, 221 and 223 and nucleotide sequences of SEQ ID NOS: 183, 193 and 199 and 201 as well as the complements of such nucleotide sequences (SEQ ID NOS:184, 194, 200 and 202). In addition, the present invention includes pre-, pro- and prepro- regions as well as pre-pro persephin amino acid and nucleotide sequences.

Expression vectors and stably transformed cells comprising persephin polynucleotides are also within the scope of this invention. The transformed cells can be used in a method for producing persephin.

In another embodiment, the present invention provides a method for preventing or treating cellular degeneration comprising administering to a patient in need thereof a therapeutically effective amount of persephin. A patient may also be treated by implanting transformed cells which express persephin or a DNA sequence which encodes persephin into a patient, or cells cultured and expanded by growth in persephin.

The present invention also provides compositions and methods for detecting persephin. One method is based upon persephin antibodies and other methods are based upon detecting mRNA or cDNA or genomic DNA encoding persephin using recombinant DNA techniques.

In still further embodiments, the present invention includes pan-growth factors comprising a segment of a persephin sequence and a segment of at least one growth factor other than persephin. Also included

are polynucleotides encoding the pan-growth factors, vectors containing such polynucleotides and host cells comprising the polynucleotides.

Among the several advantages found to be achieved  
5 by the present invention, therefore, may be noted the provision of a new growth factor, persephin, for use in preventing the atrophy, degeneration or death of certain cells, in particular neurons; the provision of human persephin; the provision of other members of the  
10 neurturin-persephin-GDNF family of growth factors by making available new methods capable of obtaining other family members; the provision of methods for obtaining persephin by recombinant techniques; the provision of methods for preventing or treating diseases producing  
15 cellular degeneration and, particularly neuronal degeneration; the provision of methods that can detect and monitor persephin levels in a patient; and the provision of methods that can detect alterations in the persephin gene.

20

#### Brief Description of the Drawings

Figure 1 illustrates the purification scheme for preparing neurturin from CHO cells;

Figure 2 illustrates the characterization of  
25 fractions eluted from Mono S column in purifying neurturin showing (a) electrophoresis of each fraction on a SDS-polyacrylamide gel and visualization of the proteins by silver stain and (b) the neurotrophic activity present in each fraction in the superior  
30 cervical ganglion survival assay;

Figure 3 illustrates the ability of neurturin to maintain survival of superior cervical ganglionic cells in culture showing (a) positive control cells maintained with nerve growth factor (NGF) (b) negative control cells  
35 treated with anti-NGF antibodies showing diminished survival and (c) cells treated with anti-NGF and



neurturin (approximately 3 ng/ml) showing survival of neurons;

Figure 4 illustrates the concentration-response effect of neurturin in the superior cervical ganglion survival assay;

Figure 5 illustrates the homology of the amino acid sequences for the mature growth factors, human neurturin (hNTN), mouse neurturin (mNTN), rat GDNF (rGDNF), mouse GDNF (mGDNF) and human GDNF (hGDNF) with identical amino acid residues enclosed in boxes;

Figure 6 illustrates the tissue distribution of neurturin mRNA and the mRNA for GDNF using RT/PCR analysis on RNA samples obtained from embryonic day 21 (E21) and adult rats;

Figure 7 illustrates the cDNA and encoded amino acid sequence of human pre-pro neurturin (SEQ ID NO:11) showing the pre- region from nucleic acid 1 through 57 (SEQ ID NO:17), the pro- region from nucleic acid 58 through 285 (SEQ ID NO:20), human neurturin from nucleic acid 286 through 591 (SEQ ID NO:9) and the splice site between nucleic acids 169 and 170 which defines the coding sequence portion of two exons from nucleic acids 1 through 169 (SEQ ID NO:27) and 170 through 594 (SEQ ID NO:28);

Figure 8 illustrates the cDNA and encoded amino acid sequence of mouse pre-pro neurturin (SEQ ID NO:12) showing the pre- region from nucleic acid 1 through 57 (SEQ ID NO:18), the pro- region from nucleic acid 58 through 285 (SEQ ID NO:21), mouse neurturin from nucleic acid 286 through 585 (SEQ ID NO:10) and the splice site between nucleic acids 169 and 170 which defines the coding sequence portion of two exons from nucleic acids 1 through 169 (SEQ ID NO:29) and 170 through 588 (SEQ ID NO:30);

Figure 9 illustrates the mouse cDNA sequence containing a 5' non-coding region (SEQ ID NO:13) and a 3'

non-coding region (SEQ ID NO:14) each of which are contiguous to the coding region of pre-pro neurturin;

Figure 10 illustrates the percent neuronal survival in E18 rat nodose ganglia neurons treated 24 hours post-plating for NTN, GDNF, BDNF, NGF and AMO;

Figure 11 illustrates the nucleotide and amino acid sequence of murine persephin (SEQ ID NOS:79, 80 and 81; amino acid residues 52 through 140, 47 through 142, and 9 through 142, respectively);

Figure 12 illustrates the family member sequence identity in the region between the first and seventh canonical framework cysteine residues aligned beginning with the first canonical framework cysteine for murine GDNF (SEQ ID NO:87), murine neurturin (NTN) (SEQ ID NO:88) and murine persephin (PSP) (SEQ ID NO:89);

Figure 13 illustrates the partial sequence of rat persephin cDNA (SEQ ID NO:97) obtained by the technique of rapid amplification of cDNA ends;

Figure 14 illustrates the partial sequence beginning with the first canonical framework cysteine for rat persephin (SEQ ID NO:83) and the corresponding polynucleotide sequence (SEQ ID NO:86);

Figure 15 shows (A) the family member aligned partial amino acid sequences from the first through the seventh canonical framework cysteine residues illustrating family member sequence homology of the mature growth factors, human GDNF (SEQ ID NO:240), rat GDNF (SEQ ID NO:241), mouse GDNF (SEQ ID NO:242), human neurturin (NTN (human); SEQ ID NO:31), mouse neurturin (NTN (mouse); SEQ ID NO:32), rat persephin (PSP (rat); SEQ ID NO:79), and mouse persephin (PSP(mouse); SEQ ID NO:82) in which boxes enclose the 28 conserved amino acid residues present in all and (B) the aligned sequences of mature mouse persephin (mPSP; SEQ ID NO:187), mature rat persephin (mPSP; SEQ ID NO:198) and mature human persephin (hPSP; SEQ ID NO:221);

Figure 16 illustrates the sequences of TGF- $\beta$  superfamily members aligned using the Clustal method, from the first canonical framework cysteine to the end of the sequence for transforming growth factor- $\beta$ 1 (TGF $\beta$ 1),  
 5 transforming growth factor- $\beta$ 2 (TGF $\beta$ 2), transforming growth factor- $\beta$ 3 (TGF $\beta$ 3), inhibin  $\beta$  A (INH $\beta$ A), inhibin  $\beta$  B (INH $\beta$ B), the nodal gene (NODAL), bone morphogenetic proteins 2 and 4 (BMP2 and BMP4), the *Drosophila* decapentaplegic gene (*dpp*), bone morphogenetic proteins  
 10 5-8 (BMP5, BMP6, BMP7 and BMP8), the *Drosophila* 60A gene family (60A), bone morphogenetic protein 3 (BMP3), the *Vgl* gene, growth differentiation factors 1 and 3 (GDF1 and GDF3), dorsalin (*drsln*), inhibin  $\alpha$  (INH $\alpha$ ), the MIS gene (MIS), growth factor 9 (GDF-9), glial-derived  
 15 neurotropic growth factor (GDNF) and neurturin (NTN);

Figure 17 illustrates (A) full length murine persephin gene (SEQ ID NO:177) with arrows indicating an 88 nt intron from positions 155-242 and (B) the nucleotide sequence of murine pre-pro persephin (SEQ ID  
 20 NO:179) with encoded amino acid sequence (SEQ ID NO:185);

Figure 18 illustrates (A) full length rat persephin gene (SEQ ID NO:188) with arrows indicating an 88 nt intron from positions 155-242 and (B) the nucleotide sequence of rat pre-pro persephin (SEQ ID  
 25 NO:190) with encoded amino acid sequence (SEQ ID NO:196);

Figure 19 illustrates a western blot analysis using anti-persephin antibodies to detect persephin protein in cell lysates from COS monkey cells transfected with the murine persephin gene (lane 2) or the rat  
 30 persephin gene (lane 3) compared to cells transfected with the non-recombinant vector alone (pCB6, lane 4) and the mature protein produced by *E. Coli* (lane 1);

Figure 20 illustrates the murine chimeric molecules (A) PSP/NTN containing the persephin fragment  
 35 (residues 1-63) and the neurturin fragment (residues 68-100) and (B) NTN/PSP containing the neurturin fragment

(residues 1-67) and the persephin fragment (residues 64-96) with the arrow indicating the crossover point in each;

Figure 21 illustrates the survival promoting effect of persephin in murine embryonic day-14 mesencephalic cells cultured for three days (a) in the absence of persephin where almost all of the cells are dead and (b) in the presence of persephin (100 ng/ml) where substantial neuronal cell survival is evident;

Figure 22 illustrates the survival promoting effect of persephin (PSP) in murine embryonic day-14 mesencephalic cells compared to effects of neurturin (NTN) and GDNF, measured by the number of cells stained with tyrosine hydroxylase (TOH);

Figure 23 illustrates RT/PCT survey for persephin expression in adult mouse tissues showing persephin expression by Kidney cells; and

Figure 24 illustrates the cDNA sequence of human pre-pro persephin (SEQ ID NO:203) with two silent mutations indicated at positions 30 and 360 and the encoded amino acid sequence (SEQ ID NO:217) with the first amino acid of the pro- region indicated by the double asterisks (\*\*) at amino acid position 24 and the first amino acid of mature human persephin indicated by the single asterisk (\*) at amino acid position 61.

#### Description of the Preferred Embodiments

The present invention is based upon the identification, isolation and sequencing of a DNA molecule that encodes a new growth factor, persephin. Persephin promotes cell survival and, in particular, the survival of neuronal cells. Prior to this invention, persephin was unknown and had not been identified as a discrete biological substance nor had it been isolated in pure form.

The growth factor, neurturin (NTN) was identified and isolated as set forth in copending application Serial Number 08/519,777 filed August 28, 1995, which is incorporated in its entirety by reference. From the  
5 sequence of neurturin and the sequence of the closely related growth factor, glial-derived neurotrophic factor (GDNF), the inventors herein have devised and pursued strategies to find additional related factors. Neurturin is approximately 40% identical to GDNF, but less than 20%  
10 identical to any other member of the TGF- $\beta$  superfamily. Together these two proteins define a new subfamily within the TGF- $\beta$  superfamily. Several sequence regions within neurturin and GDNF were identified that are highly conserved, such that they are likely to be present in any  
15 additional members of this subfamily. This sequence information can, therefore, be used to isolate previously unknown members of this subfamily by designing degenerate oligonucleotides to be used as either primers in PCR reactions or as probes in hybridization studies.

20 Using the new degenerate primer PCR strategy described in Example 11 of copending application Serial Number 08/519,777, the inventors herein have succeeded in identifying a third factor, persephin, that is approximately 40-50% identical to both GDNF and  
25 neurturin. Primers corresponding to the amino acid sequence from conserved regions of neurturin and GDNF (SEQ ID NO:42 and SEQ ID NO:44) were used to amplify a 77 nt fragment from rat genomic DNA. The resulting products were subcloned into the Bluescript KS plasmid and  
30 sequenced. The sequence of one of the amplified products predicted amino acid sequence data internal to the PCR primers that was different from that of GDNF or neurturin but had more than 20% identity with GDNF and neurturin, whereas the sequences of other amplified products we  
35 obtained corresponded to GDNF or neurturin, as would be expected. The 22 nucleotide sequence (SEQ ID NO:90) was

then aligned with the rat sequences of GDNF and neurturin and found to be unique. This novel sequence, thus, suggested that we had identified a new family member referenced herein as persephin.

5           To obtain additional persephin sequence information, primers containing the unique 22 nucleotide sequence of the amplified fragment were used in the rapid amplification of cDNA ends (RACE) technique (Frohman, M.A. Methods in Enzymology 218:340-356, 1993) using cDNA  
10 obtained from neonatal rat brain. An approximately 350 nt fragment was obtained from this PCR reaction which constituted a partial rat persephin cDNA sequence of approximately 350 nucleotides (SEQ ID NO:106). The predicted amino acid sequence of this cDNA was compared  
15 to that of GDNF and neurturin, and found to have approximately 40% identity with each of these proteins. Importantly, the characteristic spacing of the canonical framework cysteine residues in members of the TGF- $\beta$  superfamily was present. Furthermore, in addition to the  
20 region of similarity encoded by the degenerate primers used to isolate persephin, another region of high homology shared between GDNF and neurturin, but absent in other members of the TGF- $\beta$  superfamily, was also present in persephin

25

GDNF	ACCRPVAFDDDLFLDD	(aa 60-76) (SEQ ID NO:98)
NTN	PCCRPTAYEDEVSKDV	(aa 61-77) (SEQ ID NO:99)
PSP	PCCQPTSYAD-VTFLDD	(aa 57-72) (SEQ ID NO:100)

30 (Amino acid numbering uses the first Cys residue as amino acid 1).

With the confirmation that persephin was indeed a new member of the GDNF/NTN subfamily, we isolated murine  
35 genomic clones of persephin to obtain additional sequence information. Primers corresponding to rat cDNA sequence were used in a PCR reaction to amplify a 155 nucleotide (nt) fragment from mouse genomic DNA which was homologous to the rat persephin cDNA sequence. These primers were

then used to obtain murine persephin genomic clones from a mouse 129/Sv library in a P1 bacteriophage vector (library screening service of Genome Systems, Inc., St. Louis, MO).

5        Restriction fragments (3.4 kb Nco I and a 3.3 kb Bam H1) from this P1 clone containing the persephin gene were identified by hybridization with a 210 nt fragment of persephin obtained by PCR using mouse genomic DNA and  
10        fragments were sequenced and found to encode a stretch of amino acids corresponding to that present in the rat persephin RACE product, as well as being homologous to the mature regions of both neurturin and GDNF (Figure 11).

15        Human persephin was obtained in a manner similar to that of mouse persephin. Degenerate PCR primers were used to amplify human genomic DNA and one clone was determined to have a sequence homologous to mouse  
20        persephin. Primers based upon the identified sequence were then used to screen cDNA libraries. Positive clones were identified by hybridization with a DNA probe derived from the identified sequence and these clones were then sequenced.

When the amino acid sequences of mature murine GDNF,  
25        NTN and PSP are aligned using the first canonical framework cysteine as the starting point, which is done because alterations in the cleavage sites between family members creates variability in the segments upstream of the first cysteine, persephin (91 amino acids) is  
30        somewhat smaller than either neurturin (95 amino acids) or GDNF (94 amino acids). The overall identity within this region is about 50% with neurturin and about 40% with GDNF (Figure 12).

Further nucleotide sequencing of the murine  
35        persephin NcoI fragment revealed the nucleotide sequence of the entire murine persephin gene as shown in Figure

17. In addition, the entire rat persephin gene has been determined by sequencing a PCR amplified fragment of rat genomic DNA as shown in Figure 18. In both the murine and rat persephin gene, an open reading frame extends  
 5 from the sequence coding for an initiator methionine up to a stop codon at positions 244-246. However, somewhere in this sequence an apparent anomaly was found to occur such that the sequence encoding the RXXR cleavage site (positions 257-268) and the sequence corresponding to the  
 10 mature persephin protein (positions 269-556) are not co-linear with this open reading frame. Instead, a second reading frame encodes the cleavage site and the mature persephin. Irrespective of this apparent anomaly, mammalian cells were found to express persephin from  
 15 either the murine or rat full length genomic sequence (see Example 14 below).

To pursue the genesis of this anomaly, we prepared mammalian expression vectors for both murine and rat persephin. To construct the murine plasmid, a P1 clone  
 20 containing the murine persephin gene was used as a template in a PCR assay. Primers were designed such that the resulting fragment would contain the persephin gene extending from the initiator Methionine to the stop codon. The PCR reaction utilized a forward primer M3175  
 25 [5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA]<sup>140</sup> and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]<sup>138</sup>. To construct the analogous rat plasmid, rat genomic DNA was used as a template in a PCR assay. The PCR reaction utilized a forward primer M3175 [5'-  
 30 TGCTGTCACCATGGCTGCAGGAAGACTTCGGA] and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]. The amplified products were cloned into BSKS and sequenced to verify that the correct clone had been obtained. The rat and murine persephin fragments were excised using Sma I  
 35 and Hind III and cloned into a Asp718 (blunted) and Hind III sites of the mammalian expression vector pCB6.



COS monkey cells were transfected with either the rat or murine persephin expression vectors or the non-recombinant vector (pCB6) itself. Forty eight hr later the cells were lysed, the samples were loaded onto a 15% SDS-polyacrylamide gel, and the proteins were separated by electrophoresis. The proteins were then transferred to nitrocellulose by electroblotting. This nitrocellulose membrane was incubated with anti-persephin antibodies (which we raised to mature persephin produced in bacteria from a pET plasmid) to detect the presence of persephin in the lysates. Lysates from cells transfected with either the rat or murine persephin expression vectors, but not the lysate from cells transfected with pCB6, contain high amounts of persephin. The size of the persephin detected was 10-15 kD, consistent with the size predicted for the processed (i.e. mature form of persephin). Conditioned media harvested from these cells also contained mature persephin. These results demonstrate that both the murine and rat persephin genes are capable of directing the synthesis of a properly processed persephin molecule.

To pursue the mechanism by which this occurred, we isolated RNA from cells transfected with either rat or murine persephin expression vector. RT/PCR analysis was performed using primers corresponding to the initiator Met and the stop codon. We detected two fragments: one corresponding to the predicted size of the persephin gene and the other somewhat smaller, suggesting that RNA splicing had occurred. We confirmed this with a number of other primer pairs. Both the large and small persephin fragments were cloned and sequenced. As expected, the larger fragment corresponded to the persephin gene. The small fragment corresponded to a spliced version of persephin. A small 88 nt intron within the pro-domain (situated 154 nt downstream of the start codon) had been spliced out. After this splicing

event, the "frameshift" was no longer present (i.e. the initiator Met and the mature region are in-frame) in either rat or mouse persephin.

The N-terminus of persephin was predicted by  
5 reference to the N-terminal regions of neurturin or GDNF. Using neurturin sequence homology and cleavage signals, a characteristic RXXR cleavage motif is present beginning 9 residues upstream of the first canonical framework cysteine of persephin which would suggest that mature  
10 murine persephin would contain 5 amino acids (ALAGS) (SEQ ID NO:103) upstream of this cysteine (as does neurturin). The corresponding 5 amino acids in rat persephin are ALPGL (SEQ ID NO:112) and those in human persephin are ALSGP (SEQ ID NO:224). Using these parameters, mature  
15 persephin would consist of 96 amino acids and have a predicted molecular mass of 10.4 kD.

By "mature" growth factor reference is made to the secreted form of the growth factor in which any pre- or pro- regions have been cleaved and which may exist as a  
20 monomer or, by analogy to other members of the TGF- $\beta$  superfamily, in the form of a homodimer linked by disulfide bonds.

The discovery of the new growth factor, persephin, as described above is a result of the prior discovery by  
25 the inventors herein of neurturin. Thus, the experiments leading to the discovery of neurturin are relevant to the current discovery of persephin as well as to the biological activity of persephin. The isolation, identification and characterization of neurturin is  
30 described in detail in Examples 1-5 below.

Reference to persephin herein is intended to be construed to include growth factors of any origin which are substantially homologous to and which are  
biologically equivalent to the persephin characterized  
35 and described herein. Such substantially homologous growth factors may be native to any tissue or species

and, similarly, biological activity can be characterized in any of a number of biological assay systems.

Reference to pre-pro persephin is intended to be construed to include pre-pro growth factors containing a  
5 pre- or leader or signal sequence region, a pro- sequence region and persephin as defined herein.

The terms "biologically equivalent" are intended to mean that the compositions of the present invention are capable of demonstrating some or all of the same growth  
10 promoting properties in a similar fashion, although not necessarily to the same degree as the recombinantly produced human, mouse or rat persephin as identified herein.

By "substantially homologous" it is meant that the  
15 degree of sequence identity of persephin orthologs including human, mouse and rat persephin as well as persephin from any other species, is greater than that between paralogs such as persephin and neurturin or persephin and GDNF, and greater than that reported  
20 previously for members of the TGF- $\beta$  superfamily (For discussion of homology of TGF- $\beta$  superfamily members see Kingsley, *Genes and Dev* 8:133-46, 1994 which is incorporated by reference).

Sequence identity or percent identity is intended to  
25 mean the percentage of same residues between two sequences. The reference sequence is human persephin when determining percent identity with mouse or rat persephin and with the non-persephin growth factors, human neurturin or human GDNF. The reference sequence is  
30 mouse persephin when determining percent identity with mouse GDNF and mouse neurturin and rat persephin when determining percent identity with rat GDNF and rat neurturin. Referencing is to human neurturin when  
35 determining percent identity with non-human neurturin and to human GDNF. In all of the above comparisons, the two sequences being compared are aligned using the Clustal

method (Higgins et al, Cabios 8:189-191, 1992) of multiple sequence alignment in the Lasergene biocomputing software (DNASTAR, INC, Madison, WI). In this method, multiple alignments are carried out in a progressive manner, in which larger and larger alignment groups are assembled using similarity scores calculated from a series of pairwise alignments. Optimal sequence alignments are obtained by finding the maximum alignment score, which is the average of all scores between the separate residues in the alignment, determined from a residue weight table representing the probability of a given amino acid change occurring in two related proteins over a given evolutionary interval. Penalties for opening and lengthening gaps in the alignment contribute to the score. The default parameters used with this program are as follows: gap penalty for multiple alignment = 10; gap length penalty for multiple alignment = 10; k-tuple value in pairwise alignment = 1; gap penalty in pairwise alignment = 3; window value in pairwise alignment = 5; diagonals saved in pairwise alignment = 5. The residue weight table used for the alignment program is PAM250 (Dayhoff et al., in *Atlas of Protein Sequence and Structure*, Dayhoff, Ed., NBRF, Washington, Vol. 5, suppl. 3, p. 345, 1978).

Percent conservation is calculated from the above alignment by adding the percentage of identical residues to the percentage of positions at which the two residues represent a conservative substitution (defined as having a log odds value of greater than or equal to 0.3 in the PAM250 residue weight table). Using this criterion, preferred conservative amino acid changes are: R-K; E-D, Y-F, L-M; V-I, Q-H. Conservation is referenced to human persephin when determining percent conservation with persephin from other species or with non-persephin growth factors; referenced to human neurturin when determining

percent conservation with non-human neurturin or with non-persephin, non-neurturin growth factors.

Table 1 shows the calculations of identity (I) and conservation (C) for comparisons of mature persephin, mature neurturin and mature GDNF from various species. Comparisons were made between mature human persephin (hPSP) and mature mouse and rat persephin (mPSP and rPSP, respectively) and between mature human persephin and mature human GDNF or neurturin (hGDNF and hNTN respectively). Neurturin comparisons were between mature human and mature mouse neurturin (hNTN and mNTN, respectively) and between each of these and mature human, rat and mouse GDNF (hGDNF, rGDNF and mGDNF, respectively) as shown in the table.

Table 1.

	COMPARISON	% IDENTITY	% CONSERVATION
20	hPSP v. mPSP	81	81
	hPSP v. rPSP	80	81
	mPSP v. rPSP	94	96
	hPSP v. hNTN	49	50
	hPSP v. hGDNF	40	43
25	hNTN v. mNTN	90	93
	hNTN v. rGDNF	44	53
	hNTN v. mGDNF	43	52
	hNTN v. hGDNF	43	53
30	mNTN v. rGDNF	42	52
	mNTN v. mGDNF	41	51
	mNTN v. hGDNF	41	52

The degree of homology between the human persephin and mouse or rat persephin is about 80% whereas the degree of homology between mouse and rat persephin is about 94%. The neurturin comparisons as shown in Table 1 indicate mature mouse and human neurturin proteins have about 90% sequence identity. Furthermore, all persephin and neurturin homologs of non-human mammalian species are believed to similarly have at least about 75% sequence

identity with human persephin, human neurturin, or human GDNF. For non-mammalian species such as avian species, it is believed that the degree of homology with persephin is at least about 65% identity with human persephin, or

5 neurturin human neurturin or human GDNF. By way of comparison, the variations between family members of the neurturin-persephin-GDNF family of growth factors can be seen by the comparison of persephin and GDNF or neurturin and GDNF. Human persephin has about 40% sequence

10 identity and about 43% sequence conservation with human GDNF; and about 49% sequence identity and about 50% sequence conservation with human neurturin. Similarly, human neurturin has about 40% sequence identity and about 50% sequence conservation with human GDNF. It is

15 believed that the different family members also have a similar sequence identity of about 40% of that of neurturin, about 40% of that of persephin or about 40% of that of GDNF and within a range of about 30% to about 75% identity with neurturin, within a range of about 30% to

20 about 75% identity with persephin or within a range of about 30% to about 75% sequence identity with GDNF.

Thus, a given member of the GDNF-neurturin-persephin family would be expected to have lesser sequence identity with any other family member of the same species than is

25 present in orthologs of that family member in other species just as human GDNF and human neurturin are more closely related to mouse GDNF and mouse neurturin, respectively, than to each other or to GDNF and any given family member would be expected to have greater sequence

30 identity with another family member than to any other known member of the TGF- $\beta$  superfamily (Kingsley, *supra*).

Homologs of pre-pro persephin in non-human mammalian species can be identified by virtue of the persephin portion of the amino acid sequence having at least about

35 75% sequence identity with human persephin and homologs of pre-pro persephin in non-mammalian species can be

identified by virtue of the persephin portion of the amino acid sequence having at least about 65% identity with human persephin.

Persephin as used herein, can also include hybrid  
5 and modified forms of persephin, respectively, including fusion proteins and persephin fragments and hybrid and modified forms in which certain amino acids have been deleted or replaced and modifications such as where one or more amino acids have been changed to a modified amino  
10 acid or unusual amino acid and modifications such as glycosolations so long as the hybrid or modified form retains the biological activity of persephin. By retaining the biological activity, it is meant that neuronal survival is promoted, although not necessarily  
15 at the same level of potency as that of the human, mouse or rat persephin identified herein.

Also included within the meaning of substantially homologous is any persephin which may be isolated by virtue of cross-reactivity with antibodies to the  
20 persephin or whose encoding nucleotide sequences including genomic DNA, mRNA or cDNA may be isolated through hybridization with the complementary sequence of genomic or subgenomic nucleotide sequences or cDNA of the persephin or fragments thereof. It will also be  
25 appreciated by one skilled in the art that degenerate DNA sequences can encode human persephin and these are also intended to be included within the present invention as are allelic variants of persephin.

Conservatively substituted persephin proteins are  
30 also within the scope of the present invention. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. Conservatively substituted amino acids can be grouped according to the chemical properties of their  
35 side chains. For example, one grouping of amino acids includes those amino acids have neutral and hydrophobic

side chains (A, V, L, I, P, W, F, and M); another grouping is those amino acids having neutral and polar side chains (G, S, T, Y, C, N, and Q); another grouping is those amino acids having basic side chains (K, R, and H); another grouping is those amino acids having acidic side chains (D and E); another grouping is those amino acids having aliphatic side chains (G, A, V, L, and I); another grouping is those amino acids having aliphatic-hydroxyl side chains (S and T); another grouping is those amino acids having amine-containing side chains (N, Q, K, R, and H); another grouping is those amino acids having aromatic side chains (F, Y, and W); and another grouping is those amino acids having sulfur-containing side chains (C and M). Preferred conservative amino acid substitutions groups are: R-K; E-D, Y-F, L-M; V-I, and Q-H. In addition, Q-R-H and A-V are believed to be preferred substitutions for persephin inasmuch as they occur among the human, mouse and rat paralogs of persephin (see Figure 15B).

In the case of pre-pro neurturin, alternatively spliced protein products, resulting from an intron located in the coding sequence of the pro region, may exist. The intron is believed to exist in the genomic sequence at a position corresponding to that between nucleic acids 169 and 170 of the cDNA which, in turn, corresponds to a position within amino acid 57 in both the mouse and human pre-pro neurturin sequences (see Figures 7 and 8). Thus, alternative splicing at this position might produce a sequence that differs from that identified herein for human and mouse pre-pro neurturin (SEQ ID NO:11 and SEQ ID NO:12, respectively) at the identified amino acid site by addition and/or deletion of one or more amino acids. Any and all alternatively spliced pre-pro neurturin proteins are intended to be included within the terms pre-pro neurturin and, similarly, any and all alternatively spliced pre-pro



persephin proteins are also intended to be included within the terms pre-pro persephin as used herein.

Although it is not intended that the inventors herein be bound by any theory, it is thought that the  
5 human, mouse and rat persephin proteins identified herein as well as homologs from other tissues and species may exist as dimers in their biologically active form in a manner consistent with what is known for other factors of the TGF- $\beta$  superfamily.

10 In addition to homodimers, the monomeric units of the dimers of persephin can be used to construct stable growth factor heterodimers or heteromultimers comprising at least one monomer unit derived from persephin. This can be done by dissociating a homodimer of persephin into  
15 its component monomeric units and reassociating in the presence of a monomeric unit of a second or subsequent homodimeric growth factor. This second or subsequent homodimeric growth factor can be selected from a variety of growth factors including neurturin, GDNF, a member of  
20 the NGF family such as NGF, BDNF, NT-3 and NT-4/5, a member of the TGF- $\beta$  superfamily, a vascular endothelial growth factor, a member of the CNTF/LIF family and the like.

Growth factors are thought to act at specific  
25 receptors. For example, the receptors for TGF- $\beta$  and activins have been identified and make up a family of Ser/Thr kinase transmembrane proteins (Kingsley, *Genes and Dev* 8:133-146, 1994; Bexk et al *Nature* 373:339-341, 1995 which are incorporated by reference). In the NGF  
30 family, NGF binds to the TrkA receptor in peripheral sensory and sympathetic neurons and in basal forebrain neurons; BDNF and NT-4/5 bind to trkB receptors; and NT-3 binds primarily to trkC receptors that possess a distinct distribution within the CNS (Tuszynski et al., *Ann Neurol*  
35 35:S9-S12, 1994). Members of the persephin-neurturin-GDNF family also appear to act through specific receptors

having distinct distributions as has been shown for other growth factor families. Recently, it was shown that GDNF acts through a multicomponent receptor complex in which a transmembrane signal transducing component, the Ret tyrosine kinase protein (Ret PTK), is activated upon the binding of GDNF with another protein, called GDNF Receptor  $\alpha$  (GDNFR- $\alpha$ ) which has no transmembrane domain and is attached to the cell surface via a glycosyl-phosphatidylinositol (GPI) linkage (Durbec et al., *Nature* 381:789-793, 1996; Jing et al., *Cell* 85:1113-1124, 1996; Treanor et al., *Nature* 382:80-83, 1996; Trupp et al., *Nature* 381:785-789, 1996, which are incorporated herein by reference). Furthermore, it has been shown that the signaling of neurturin and GDNF through the Ret tyrosine kinase receptor is mediated by a family of co-receptors, including the co-receptor protein GDNFR- $\alpha$ , also referred to as TrnR1, and the co-receptor protein, TrnR2, either of which can form a functional receptor complex with Ret for both neurturin and GDNF (Baloh et al., *Neuron* 18:793-802, 1997 which is incorporated by reference). By forming heterodimers or heteromultimers of persephin and one or more other growth factors, the resultant growth factor would be expected to be able to bind to at least two distinct receptor types preferentially having a different tissue distribution. The resultant heterodimers or heteromultimers would be expected to show a different and, possibly, an enlarged spectrum of cells upon which it could act or to provide greater potency. It is also possible that the heterodimer or heteromultimer might provide synergistic effects not seen with homodimers or homomultimers. For example, the combination of factors from different classes has been shown to promote long-term survival of oligodendrocytes whereas single factors or combinations of factors within the same class promoted short-term survival (Barres et al., *Development* 118:283-295, 1993).

Heterodimers can be formed by a number of methods. For example, homodimers can be mixed and subjected to conditions in which dissociation/unfolding occurs, such as in the presence of a dissociation/unfolding agent, followed by subjection to conditions which allow monomer reassociation and formation of heterodimers. Dissociation/unfolding agents include any agent known to promote the dissociation of proteins. Such agents include, but are not limited to, guanidine hydrochloride, urea, potassium thiocyanate, pH lowering agents such as buffered HCl solutions, and polar, water miscible organic solvents such as acetonitrile or alcohols such as propanol or isopropanol. In addition, for homodimers linked covalently by disulfide bonds as is the case with TGF- $\beta$  family members, reducing agents such as dithiothreitol and  $\beta$ -mercaptoethanol can be used for dissociation/unfolding and for reassociation/refolding.

Heterodimers can also be made by transfecting a cell with two or more factors such that the transformed cell produces heterodimers as has been done with the neurotrophins. (Heymach and Shooter, *J Biol Chem* 270:12297-12304, 1995).

Another method of forming heterodimers is by combining persephin homodimers and a homodimer from a second growth factor and incubating the mixture at 37°C.

When heterodimers are produced from homodimers, the heterodimers may then be separated from homodimers using methods available to those skilled in the art such as, for example, by elution from preparative, non-denaturing polyacrylamide gels. Alternatively, heterodimers may be purified using high pressure cation exchange chromatography such as with a Mono S cation exchange column or by sequential immunoaffinity columns.

It is well known in the art that many proteins are synthesized within a cell with a signal sequence at the N-terminus of the mature protein sequence and the protein

carrying such a leader sequence is referred to as a preprotein. The pre- portion of the protein is cleaved during cellular processing of the protein. In addition to a pre- leader sequence, many proteins contain a

5 distinct pro sequence that describes a region on a protein that is a stable precursor of the mature protein. Proteins synthesized with both pre- and pro- regions are referred to as preproproteins. In view of the processing events known to occur with other TGF- $\beta$  family members as

10 well as the sequences determined herein, the inventors believe that the form of the persephin protein as synthesized within a cell is the pre-pro persephin. Human pre-pro persephin is believed to contain an N-terminal 23 amino acid signal sequence (human pre- signal sequence,

15 SEQ ID NO:219, Figure 24, amino acids 1 through 23 encoded by SEQ ID NOS:208 and 209, Figure 24, nucleic acids 1 through 69). It is known that the full length of a leader sequence is not necessarily required for the sequence to act as a signal sequence and, therefore,

20 within the definition of pre- region of persephin is included fragments thereof, usually N-terminal fragments, that retain the property of being able to act as a signal sequence, that is to facilitate co-translational insertion into the membranes of one or more cellular

25 organelles such as endoplasmic reticulum, mitochondria, golgi, plasma membrane and the like.

The persephin signal sequence is followed by a pro-domain which contains an RXXR proteolytic processing site immediately before the N-terminal amino acid sequence for

30 the mature persephin. (human pro- region sequence, SEQ ID NO:220, Figure 24, amino acids 24 through 60 encoded by the nucleic acid sequence SEQ ID NO:211, Figure 24 nucleic acids 70 through 180).

The persephin pre- and pro- regions together

35 comprise a pre-pro sequence identified as the human pre-pro region sequence (SEQ ID NO:219, Figure 24, amino

acids 1 through 60 encoded by SEQ ID NOS:213 and 215, nucleic acids 1 through 285). The pre- region sequences and pro- region sequences as well as the pre-pro region sequences can be identified and obtained for non-human  
5 mammalian species and for non-mammalian species by virtue of the sequences being contained within the pre-pro persephin as defined herein.

Using the above landmarks, the human persephin cDNA has a 471 bp open reading frame encoding a 156 amino acid  
10 long protein (predicted Mr 16.6kDa). Cleavage of the 23 amino acid long predicted signal peptide will lead to a 133 amino acid pro-persephin molecule (Mr 14.2 kDa), Proteolytic cleavage of the pro-persephin at a RXXR consensus sequence should yield a 96 amino acid mature  
15 protein with a molecular weight of 10.3 kDa. The mature, secreted persephin molecule is likely to form a disulfide linked homodimer by analogy to other members of the TGF- $\beta$  family.

The nucleotide sequences of persephin pre- and/or  
20 pro- regions or similar regions that are believed to be associated with persephin DNA can be used to construct chimeric genes with the coding sequences of other growth factors or proteins. (Booth et al., *Gene* 146:303-8, 1994; Ibanez, *Gene* 146:303-8, 1994; Storici et al., *FEBS Letters* 337:303-7, 1994; Sha et al *J Cell Biol* 114:827-839, 1991 which are incorporated by reference). Such  
25 chimeric proteins can exhibit altered production or expression of the active protein species.

A preferred persephin according to the present  
30 invention is prepared by recombinant DNA technology although it is believed that persephin can be isolated in purified form from cell-conditioned medium as was done for neurturin.

By "pure form" or "purified form" or "substantially  
35 purified form" it is meant that a persephin composition is substantially free of other proteins which are not

persephin. Preferably, a substantially purified persephin composition comprises at least about 50 percent persephin on a molar basis compared to total proteins or other macromolecular species present. More preferably, a substantially purified persephin composition will comprise at least about 80 to about 90 mole percent of the total protein or other macromolecular species present and still more preferably, at least about 95 mole percent or greater.

10       Recombinant persephin may be made by expressing the DNA sequences encoding persephin in a suitable transformed host cell. Using methods well known in the art, the DNA encoding persephin may be linked to an expression vector, transformed into a host cell and  
15       conditions established that are suitable for expression of persephin by the transformed cell.

Any suitable expression vector may be employed to produce recombinant human persephin such as, for example, the mammalian expression vector pCB6 (Brewer, *Meth Cell Biol* 43:233-245, 1994) or the *E. coli* pET expression  
20       vectors, specifically, pET-30a (Studier et al., *Methods Enzymol* 185:60-89, 1990 which is incorporated by reference) both of which were used herein. Other suitable expression vectors for expression in mammalian  
25       and bacterial cells are known in the art as are expression vectors for use in yeast or insect cells. Baculovirus expression systems can also be employed.

Persephin may be expressed in the monomeric units or such monomeric form may be produced by preparation under  
30       reducing conditions. In such instances refolding and renaturation can be accomplished using one of the agents noted above that is known to promote dissociation/association of proteins. For example, the monomeric form can be incubated with dithiothreitol  
35       followed by incubation with oxidized glutathione disodium

salt followed by incubation with a buffer containing a refolding agent such as urea.

Persephin may exist as a dimer or other multimer and may be glycosylated or chemically modified in other ways.

5 Mature human persephin contains no N-linked glycosylation sites (see Figure 15B and SEQ ID NO:221). Potential O-linked glycosylation sites occur in mature human persephin at positions 3, 10, 12, 14, 24, 36, 43, 67, 70 and 88 in SEQ ID NO:221 (Figure 15B).

10 As noted above, the human nucleic acid sequence suggests that persephin is initially translated as a pre-pro polypeptide and that proteolytic processing of the signal sequence and the "pro" portion of this molecule results in the mature sequence, referenced herein as  
15 "mature persephin" exists in human and in non-human species in homologous form. Therefore, persephin includes any and all "mature persephin" sequences from human and non-human species and any and all pre-pro persephin polypeptides that may be translated from the  
20 persephin gene.

By analogy to the neurturin protein, it is possible that isoforms of persephin may exist. For example, different possible cleavage sites (such as RXXR sites) may be present in the pre-pro neurturin sequence so that  
25 more than one possible isoform of pre-pro neurturin may exist. Thus, the mature neurturin protein may have a variable number of amino acids preceding the first canonical cysteine. Such alternate cleavage sites could be utilized differently among different organisms and  
30 among different tissues of the same organism. The N-terminal amino acids preceding the first of the seven conserved cysteines in the mature forms of members of the TGF- $\beta$  family vary greatly in both length and sequence. Furthermore, insertion of a ten amino acid sequence two  
35 residues upstream of the first conserved cysteine does not affect the known biological activities of one family

member, dorsalin (Basler et al., Cell 73:687-702, 1993).  
By analogy, it is also possible that persephin proteins  
containing sequences of different lengths preceding the  
first canonical cysteine may exist or could be made and  
5 that these would retain their biological activity.

The inventors herein believe that at a minimum the  
sequence of a persephin-neurturin-GDNF growth factor that  
will show biological activity will contain the sequence  
from the first through the seventh canonical cysteine.  
10 This sequence of human persephin is from cysteine 66  
through cysteine 154 as shown in Figure 24 (SEQ ID  
NO:223). The comparable sequence for murine persephin as  
shown in Figure 12 is from cysteine 1 through cysteine 87  
(SEQ ID NO:79) and that for rat persephin as shown in  
15 Figure 14, from cysteine 1 through cysteine 87  
(identified as SEQ ID NO:82). Thus, within the scope of  
persephin proteins of the present invention are amino  
acid sequences containing SEQ ID NO:223, SEQ ID NO:79 or  
SEQ ID NO:82 and nucleic acid molecules containing  
20 sequences encoding these amino acid sequences.

The present invention also encompasses nucleic acid  
molecules comprising sequences that encode mouse, rat and  
human persephin (Figures 11, 14 and 23). Also included  
within the scope of this invention are sequences that are  
25 substantially the same as the nucleic acid sequences  
encoding persephin. Such substantially the same  
sequences may, for example, be substituted with codons  
more readily expressed in a given host cell such as *E.*  
*coli* according to well known and standard procedures.  
30 Such modified nucleic acid sequences are included within  
the scope of this invention.

Specific nucleic acid sequences can be modified by  
those skilled in the art and, thus, all nucleic acid  
sequences which encode for the amino acid sequences of  
35 pre-pro persephin or the pre- region or the pro- region  
of persephin can likewise be so modified. The present



invention also includes nucleic acid sequence having one or more substitutions, deletions or additions wherein the nucleic acid sequence will hybridize with a persephin nucleic acid sequences -- or complement thereof where  
5 appropriate.

Specific hybridization is defined herein as the formation of hybrids between a polynucleotide (e.g. a persephin polynucleotide which may include one or more substitutions, deletions, and/or additions) and a  
10 specific reference polynucleotide (e.g. polynucleotides encoding mature persephin and having the sequences of SEQ ID NO:183, 184, 194, 195, 199, 200, 201 or 202) wherein the polynucleotide preferentially hybridizes to the specific reference polynucleotide. For example, a  
15 polynucleotide encoding a mature persephin will specifically hybridize to a reference persephin polynucleotide (e.g. SEQ ID NO:183, 184, 194, 195, 199, 200, 201 or 202) and not to a reference neurturin polynucleotide (e.g. SEQ ID NO:9 or 10 or sequences  
20 complementary thereto). Specific hybridization is preferably done under high stringency conditions which is well understood by those skilled in the art to be determined by a number of factors during hybridization and during the washing procedure, including temperature,  
25 ionic strength, length of time and concentration of formamide (see for example, Sambrook et al., 1989, *supra*).

The present invention also includes nucleic acid sequences which encode for polypeptides that have  
30 survival or growth promoting activity and that are recognized by antibodies that bind to persephin.

The present invention also encompasses vectors comprising an expression regulatory element operably linked to any of the nucleic acid sequences included  
35 within the scope of the invention. This invention also

includes host cells -- of any variety -- that have been transformed with such vectors.

Methods are also provided herein for producing persephin. Preparation can be by isolation from  
5 conditioned medium from a variety of cell types so long as the cell type produces persephin. A second and preferred method involves utilization of recombinant methods by isolating a nucleic acid sequence encoding  
10 regulatory sequences into suitable vectors and cell types, and expressing the sequence to produce persephin.

A mammalian gene family comprised of four neurotrophic factors has been identified including nerve growth factor (NGF), brain derived neurotrophic factor  
15 (BDGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). These factors share approximately 60 percent nucleic acid sequence homology (Tuszynski and Gage, *Ann Neurol* 35:S9-S12, 1994 which is incorporated by reference). The persephin protein and the neurturin  
20 protein display no significant homology to the NGF family of neurotrophic factors. Either persephin or neurturin shares less than about 20% homology with the TGF- $\beta$  superfamily of growth factors. However, both persephin and neurturin show approximately 40% sequence identity  
25 with GDNF and approximately 50% sequence identity with each other. In particular, the positions of the seven cysteine residues present in persephin, neurturin and GDNF are nearly exactly conserved. The inventors herein believe that other unidentified genes may exist that  
30 encode proteins that have substantial amino acid sequence homology to persephin, neurturin and GDNF and which function as growth factors selective for the same or different tissues and the same or different biological activities and may act at the same or different  
35 receptors. A different spectrum of activity with respect to tissues affected and/or response elicited could result

from preferential activation of different receptors by different family members as is known to occur with members of the NGF family of neurotrophic factors (Tuszynski and Gage, 1994, *supra*).

5       As a consequence of members of a particular gene family showing substantial conservation of amino acid sequence among the protein products of the family members, there is considerable conservation of sequences at the DNA level. This forms the basis for a new  
10 approach for identifying other members of the gene family to which GDNF, neurturin and persephin belong. The method used for such identification is cross-hybridization using nucleic acid probes derived from one family member to form a stable hybrid duplex molecule  
15 with nucleic acid sequence from different members of the gene family or to amplify nucleic acid sequences from different family members. (see for example, Kaisho et al. *FEBS Letters* 266:187-191, 1990 which is incorporated by reference). The sequence from the different family  
20 member may not be identical to the probe, but will, nevertheless be sufficiently related to the probe sequence to hybridize with the probe. Alternatively, PCR using primers from one family member can be used to identify additional family members.

25       The above approaches have not heretofore been successful in identifying other gene family members because only one family member, GDNF was known. With the identification of neurturin in copending application Serial No. 08/519,777, however, unique new probes and  
30 primers were made that contain sequences from the conserved regions of this gene family. The same conserved regions are also found in the third family member, persephin. In particular, three conserved regions have been identified herein which can be used as  
35 a basis for constructing new probes and primers. The new probes and primers made available from the work with

neurturin and persephin make possible this powerful new approach which can now successfully identify other gene family members. Using this new approach, one may screen for genes related to GDNF, neurturin and persephin in  
 5 sequence homology by preparing DNA or RNA probes based upon the conserved regions in the GDNF and neurturin molecules. Therefore, one embodiment of the present invention comprises probes and primers that are unique to or derived from a nucleotide sequence encoding such  
 10 conserved regions and a method for identifying further members of the neurturin-persephin-GDNF gene family.

Conserved-region amino acid sequences have been identified herein to include Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser, Thr or Ala and Xaa<sub>2</sub> is Glu or  
 15 Asp (SEQ ID NO:108); Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>4</sub>-Gly-Xaa<sub>5</sub>-Cys in which Xaa<sub>1</sub> is Thr, Glu or lys, Xaa<sub>2</sub> is Val, Leu or Ile, Xaa<sub>3</sub> is Leu or Ile, Xaa<sub>4</sub> is Ala or Ser, and Xaa<sub>5</sub> is Ala or Ser, (SEQ ID NO:113); and Cys-Cys-Xaa<sub>1</sub>-Pro-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Xaa<sub>5</sub>-Asp-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>-Phe-Leu-Asp-Xaa<sub>9</sub>,  
 20 in which Xaa<sub>1</sub> is Arg or Gln, Xaa<sub>2</sub> is Thr or Val or Ile, Xaa<sub>3</sub> is Ala or Ser, Xaa<sub>4</sub> is Tyr or Phe, Xaa<sub>5</sub> is Glu, Asp or Ala, Xaa<sub>6</sub> is Glu, Asp or no amino acid, Xaa<sub>7</sub> is val or leu, Xaa<sub>8</sub> is Ser or Thr, and Xaa<sub>9</sub> is Asp or Val (SEQ ID NO:114). Nucleotide sequences containing a coding  
 25 sequence for the above conserved sequences or fragments of the above conserved sequences can be used as probes. Exemplary probe and primer sequences encoding amino acid sequences and SEQ ID NOS:125-129; primers whose reverse complementary sequences encode amino acid sequences SEQ  
 30 ID NO:126, SEQ ID NO:127, SEQ ID NO:130; and, in particular, nucleotide sequences, SEQ ID NOS:115-124. Additional primers based upon GDNF and neurturin include nucleic acid sequences encoding amino acid sequences, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:40 and SEQ ID NO:41;  
 35 primers whose reverse complementary sequences encode SEQ

ID NO:37, SEQ ID NO:38 and SEQ ID NO 39; and, in particular, nucleic acid sequences, SEQ ID NOS:42-48.

Hybridization using the new probes from conserved regions of the nucleic acid sequences would be performed under reduced stringency conditions. Factors involved in determining stringency conditions are well known in the art (for example, see Sambrook et al., *Molecular Cloning*, 2nd Ed., 1989 which is incorporated by reference). Sources of nucleic acid for screening would include genomic DNA libraries from mammalian species or cDNA libraries constructed using RNA obtained from mammalian cells cloned into any suitable vector.

PCR primers would be utilized under PCR conditions of reduced annealing temperature which would allow amplification of sequences from gene family members other than GDNF, neurturin and persephin. Sources of nucleic acid for screening would include genomic DNA libraries from mammalian species cloned into any suitable vector, cDNA transcribed from RNA obtained from mammalian cells, and genomic DNA from mammalian species.

DNA sequences identified on the basis of hybridization or PCR assays would be sequenced and compared to GDNF, neurturin and persephin. The DNA sequences encoding the entire sequence of the novel factor would then be obtained in the same manner as described herein. Genomic DNA or libraries of genomic clones can also be used as templates because the intron/exon structures of GDNF and neurturin are conserved and coding sequences of the mature proteins are not interrupted by introns.

Using this approach as described above, the primers designed from the conserved regions of neurturin and GDNF have been used to identify and obtain the sequence of the new family member described herein, persephin. Degenerate primers designed from persephin, neurturin and

GDNF can be further used to identify and obtain additional family members.

It is believed that all GDNF-neurturin-persephin family members will have a high degree of sequence identity with one or more of the three identified family-member consensus regions in the portion of the sequence between the first and seventh canonical framework cysteines (see Figure 12). In particular, a new family member is anticipated to have at least a 62.5% identity with the consensus region octapeptide, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser, Thr or Ala and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:108) or at least a 62.5 percent sequence identity with the consensus region octapeptide, Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys where Xaa<sub>1</sub> and Xaa<sub>2</sub> are alanine or serine (SEQ ID NO:109) or at least a 50 percent sequence identity with the consensus region octapeptide, Asp-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Asp-Xaa<sub>4</sub> where Xaa<sub>1</sub> is aspartic acid or glutamic acid or no amino acid, Xaa<sub>2</sub> is valine or leucine, Xaa<sub>3</sub> is serine or threonine; and Xaa<sub>4</sub> is valine or aspartic acid (SEQ ID NO:110). The inventors herein believed that any new family member will have 28 amino acids in the aligned sequence between the first and seventh canonical framework cysteine residues as set forth in Figure 15 with residues numbered from the N-terminal end of the family member aligned sequence being (1) Cys, (3) Leu, (10) Val, (13) Leu, (14) Gly, (15) Leu, (16) Gly, (17) Tyr, (21) Glu, (25) Phe, (26) Arg, (27) Tyr, (28) Cys, (30) Gly, (32) Cys, (44) Leu, (47) Leu, (58) Cys, (59) Cys (61) Pro, (66) Asp, (69) Phe, (70) Leu, (71) Asp, (83) Ser, (84) Ala, (87) Cys, and (89) Cys, however, it is possible that there may be as many as three mismatches.

On the basis of the structural similarities of persephin to the sequences of neurturin and GDNF, persephin would be expected to promote the survival and growth of neuronal as well as non-neuronal cells. For

example, neurturin has been shown to promote the survival of superior cervical ganglion cells as well as nodose sensory ganglia neurons (see Examples 1-3). Furthermore, GDNF has been shown to act on dopaminergic, sympathetic, motor and several sensory neurons (Henderson et al. *supra*, 1994; Miles et al, *J Cell Biol* 130:137-148, 1995; Yan et al, *Nature* 373:341-344, 1995; Lin et al, *Science* 260:1130-1132, 1993; Trupp et al, *J Cell Biol* 130:137-148, 1995; Martin et al *Brain Res* 683:172-178, 1995; Bowenkamp et al *J Comp Neurol* 355:479-489, 1995 which are incorporated by reference). Moreover, all other growth factors isolated to date have been shown to act on many different cell types (for example see Scully and Otten, *Cell Biol Int* 19:459-469, 1995; Hefti, *Neurotrophic Factor Therapy* 25:1418-1435, 1994 which are incorporated by reference). Thus, it is likely that persephin will show activity on a variety of different neuronal cells, both peripheral and central, as well as on non-neuronal cells. With respect to peripheral neuronal cells, the profile of cells for which persephin will show a survival promoting activity appears to be different from that of neurturin or GDNF. In contrast to the survival-promoting activity produced by neurturin and GDNF in sympathetic and sensory neurons, persephin showed no activity in these tissues at concentrations tested. Nevertheless, persephin showed survival-promoting activity in mesencephalic cells obtained from rat embryo brains. Furthermore, persephin activity on any particular target cell type can be determined by routine experimentation using standard reference models. Moreover, the inventors herein have identified brain and heart tissues as tissues expressing persephin, which further supports the conclusion that persephin can act to promote survival and growth in a variety of neuronal and non-neuronal cells.

As an example of the actions of neurotrophic factors on non-neuronal tissues, the prototypical neurotrophic

factor, NGF, also acts upon mast cells to increase their number when injected into newborn rats (Aloe, *J Neuroimmunol* 18:1-12, 1988). In addition, mast cells express the trk receptor and respond to NGF such that NGF is a mast cell secretagogue and survival promoting factor (Horigome et al., *J Biol Chem* 269:2695-2707, 1994 which is incorporated by reference). Moreover, members of the TGF- $\beta$  superfamily act on many cell types of different function and embryologic origin.

10       The inventors herein have identified brain and heart as tissues in which persephin is expressed and it is further believed that persephin is expressed in a number of other neuronal and non-neuronal tissues. The related family member, neurturin, is expressed in a number of  
15 non-neuronal tissues including blood, bone marrow, neonatal liver and mast cells. This suggests a role for neurturin in hematopoiesis, inflammation, allergy, and cardiomyopathy. Similarly, persephin may also have a similar profile of activity.

20       Neurotrophic factors of the NGF family are thought to act through factor-specific high affinity receptors (Tuszynski and Gage, 1994, *supra*). Only particular portions of the protein acting at a receptor site are required for binding to the receptor. Such particular  
25 portions or discrete fragments can serve as an agonist where the substance activates a persephin receptor to elicit the promoting action on cell survival and growth and antagonists to persephin where they bind to, but do not activate, the receptor or promote survival and  
30 growth. Such portions or fragments that are agonists and those that are antagonists are also within the scope of the present invention.

      Synthetic, pan-growth factors can also be constructed by combining the active domains of persephin  
35 with the active domains of one or more other non-persephin growth factors. (For example, see Ilag et al.,



*Proc Nat'l Acad Sci* 92:607-611, 1995 which is incorporated by reference). These pan-growth factors would be expected to have the combined activities or other advantageous properties of persephin and the one or  
5 more other growth factors. As such, these pan-growth factors are believed to be potent and multispecific growth factors that are useful in the treatment of a wide spectrum of degenerative diseases and conditions including conditions that can be treated by any or all of  
10 the parent factors from which the active domains were obtained. Such pan-growth factors might also provide synergistic effects beyond the activities of the parent factors (Barres et al., *supra*).

Pan-growth factors within the scope of the present  
15 invention can include chimeric or hybrid polypeptides that are constructed from portions of fragments of at least two growth factors. Growth factors of the TGF- $\beta$  superfamily are structurally related having highly conserved sequence landmarks whereby family members are  
20 identified. In particular, seven canonical framework cysteine residues are nearly invariant in members of the superfamily (Kingsley, *Genes & Dev* 8:133-146, 1994 which is incorporated by reference)(see Figure 17). Chimeric polypeptide molecules can, therefore, be constructed from  
25 a sequence that is substantially identical to a portion of the persephin molecule, up to one or more crossover points, and one or more sequences each of which is substantially identical with a portion of another TGF- $\beta$  superfamily member extending on the other side of the  
30 corresponding one or more crossover points. For example, a portion of the amino terminal end of the persephin polypeptide can be combined with a portion of the carboxy terminal end of a neurturin polypeptide or alternatively a portion of the amino terminal end of a neurturin  
35 polypeptide can be combined with a portion of the carboxy terminal end of a persephin polypeptide. Such portions

of persephin or neurturin polypeptides are preferably from about 5 to about 95, more preferably from about 10 to about 90, still more preferably from about 20 to about 80 and most preferably from about 30 to about 70

- 5 contiguous amino acids and such portions of another, non-persephin or, as the case may be, non-neurturin TGF- $\beta$  superfamily member are preferably from about 5 to about 95, more preferably from about 10 to about 90, still more preferably from about 20 to about 80 and most preferably
- 10 from about 30 to about 70 contiguous amino acids. For example, a particular crossover point might be between the third and fourth canonical framework cysteine residues. One such exemplary construct would contain at the 5' end a sequence comprised of a persephin sequence
- 15 from residue 1 through the third canonical framework cysteine residue 37 and up to a cross-over point somewhere between residue 37 and residue 63 but not including the fourth canonical framework cysteine residue 64 (for reference, see mature persephin, SEQ ID NO:80).
- 20 The 3' end of the hybrid construct would constitute a sequence derived from another TGF- $\beta$  superfamily member such as, for example, neurturin which is another TGF- $\beta$  superfamily member that is closely related to persephin. Using neurturin as the other TGF- $\beta$  family member, the
- 25 hybrid construct beyond the crossover point would be comprised of a sequence beginning at the desired crossover point in the neurturin sequence between the third canonical framework cysteine residue 37 and the fourth canonical framework cysteine residue 67 of
- 30 neurturin and continuing through residue 100 at the 3' end of neurturin (for alignment, see figure 12). A second exemplary hybrid construct would be comprised of residue 1 through a crossover point between residues 37 and 67 of neurturin contiguously linked with residues
- 35 from the crossover point between residues 37 and 64 through residue 96 of persephin. The above constructs

with persephin and neurturin are intended as examples only with the particular TGF- $\beta$  family member being selected from family members including but not limited to transforming growth factor- $\beta$ 1 (TGFB1), transforming growth factor- $\beta$ 2 (TGFB2), transforming growth factor- $\beta$ 3 (TGFB3), inhibin  $\beta$  A (INHBA), inhibin  $\beta$  B (INHBB), the nodal gene (NODAL), bone morphogenetic proteins 2 and 4 (BMP2 and BMP4), the *Drosophila decapentaplegic* gene (*dpp*), bone morphogenetic proteins 5-8 (BMP5, BMP6, BMP7 and BMP8), the *Drosophila* 60A gene family (60A), bone morphogenetic protein 3 (BMP3), the *Vgl* gene, growth differentiation factors 1 and 3 (GDF1 and GDF3), dorsalin (*drsln*), inhibin  $\alpha$  (INH $\alpha$ ), the *MIS* gene (MIS), growth factor 9 (GDF-9), glial-derived neurotropic growth factor (GDNF), neurturin (NTN) and persephin (see Figure 16).

In addition, the crossover point can be any residue between the first and seventh canonical framework cysteines molecules of neurturin and the particular other family member. Furthermore, additional crossover points can be used to incorporate any desired number of persephin portions or fragments with portions or fragments of any one or more other family members.

In constructing a particular chimeric molecule, the portions of persephin and portions of the other, non-persephin growth factor are amplified using PCR, mixed and used as template for a PCR reaction using the forward primer from one and the reverse primer from the other of the two component portions of the chimeric molecule. Thus, for example a forward and reverse primers are selected to amplify the portion of persephin from the beginning to the selected crossover point between the third and fourth canonical cysteine residues using a persephin plasmid as template. A forward primer with a 5' portion overlapping with the persephin sequence and a reverse primer are then used to amplify the portion of the other, non-persephin growth factor member of the TGF-

$\beta$  superfamily from the corresponding crossover point through the 3' end using a plasmid template containing the coding sequence for the non-persephin TGF- $\beta$  family member. The products of the two PCR reactions are gel  
5 purified and mixed together and a PCR reaction performed. Using an aliquot of this reaction as template a PCR reaction is performed using the persephin forward primer and the reverse primer for the non-persephin growth factor. The product is then cloned into an expression  
10 vector for production of the chimeric molecule.

Chimeric growth factors would be expected to be effective in promoting the growth and development of cells and for use in preventing the atrophy, degeneration or death of cells, particular in neurons. The chimeric  
15 polypeptides may also act as receptor antagonists of one or both of the full length growth factors from which the chimeric polypeptide was constructed or as an antagonist of any other growth factor that acts at the same receptor or receptors.

20 The present invention also includes therapeutic or pharmaceutical compositions comprising persephin in an effective amount for treating patients with cellular degeneration or dysfunction and a method comprising administering a therapeutically effective amount of  
25 persephin. These compositions and methods are useful for treating a number of degenerative diseases. Where the cellular degeneration involves neuronal degeneration, the diseases include, but are not limited to peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's  
30 disease, Parkinson's disease, Huntington's disease, ischemic stroke, acute brain injury, acute spinal chord injury, nervous system tumors, multiple sclerosis, peripheral nerve trauma or injury, exposure to neurotoxins, metabolic diseases such as diabetes or renal  
35 dysfunctions and damage caused by infectious agents. In particular, the ability of persephin to promote survival

in mesencephalic cells suggests an applicability of this growth factor in treating neuronal degenerative diseases of the CNS such as Parkinson's disease.

Where the cellular degeneration involves bone marrow cell degeneration, the diseases include, but are not limited to disorders of insufficient blood cells such as, for example, leukopenias including eosinopenia and/or basopenia, lymphopenia, monocytopenia, neutropenia, anemias, thrombocytopenia as well as an insufficiency of stem cells for any of the above. The cellular degeneration can also involve myocardial muscle cells in diseases such as cardiomyopathy and congestive heart failure. The above cells and tissues can also be treated for depressed function.

The compositions and methods herein can also be useful to prevent degeneration and/or promote survival in other non-neuronal tissues as well. One skilled in the art can readily determine using a variety of assays known in the art for identifying whether persephin would be useful in promoting survival or functioning in a particular cell type.

In certain circumstances, it may be desirable to modulate or decrease the amount of persephin expressed. Thus, in another aspect of the present invention, persephin anti-sense oligonucleotides can be made and a method utilized for diminishing the level of expression of persephin, respectively, by a cell comprising administering one or more persephin anti-sense oligonucleotides. By persephin anti-sense oligonucleotides reference is made to oligonucleotides that have a nucleotide sequence that interacts through base pairing with a specific complementary nucleic acid sequence involved in the expression of persephin such that the expression of persephin is reduced. Preferably, the specific nucleic acid sequence involved in the expression of persephin is a genomic DNA molecule or mRNA

molecule that contains sequences of the persephin gene. This genomic DNA molecule can comprise flanking regions of the persephin gene, untranslated regions of persephin mRNA, the pre- or pro- portions of the persephin gene or  
5 the coding sequence for mature persephin protein. The term complementary to a nucleotide sequence in the context of persephin antisense oligonucleotides and methods therefor means sufficiently complementary to such a sequence as to allow hybridization to that sequence in  
10 a cell, i.e., under physiological conditions. The persephin antisense oligonucleotides preferably comprise a sequence containing from about 8 to about 100 nucleotides and more preferably the persephin antisense oligonucleotides comprise from about 15 to about 30  
15 nucleotides. The persephin antisense oligonucleotides can also contain a variety of modifications that confer resistance to nucleolytic degradation such as, for example, modified internucleoside linkages (Uhlmann and Peyman, *Chemical Reviews* 90:543-548, 1990; Schneider and  
20 Banner, *Tetrahedron Lett* 31:335, 1990 which are incorporated by reference), modified nucleic acid bases and/or sugars and the like.

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable  
25 route known in the art including for example intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of slow release formulation. For treating  
30 tissues in the central nervous system, administration can be by injection or infusion into the cerebrospinal fluid (CSF). When it is intended that persephin be administered to cells in the central nervous system, administration can be with one or more agents capable of  
35 promoting penetration of persephin across the blood-brain barrier.

Persephin can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, persephin can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor, and administered by intravenous injection. (See for example, Friden et al., *Science* 259:373-377, 1993 which is incorporated by reference). Furthermore, persephin can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other pharmaceutically advantageous properties. (See for example Davis et al. *Enzyme Eng* 4:169-73, 1978; Burnham, *Am J Hosp Pharm* 51:210-218, 1994 which are incorporated by reference).

The compositions are usually employed in the form of pharmaceutical preparations. Such preparations are made in a manner well known in the pharmaceutical art. One preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. Persephin can also be incorporated into a solid or semi-solid biologically compatible matrix which can be implanted into tissues requiring treatment.

The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the

formulation. Similarly, the carrier may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or penetration across the blood-brain barrier. Such

5 excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dosage or multi-dose form or for direct infusion into the cerebrospinal fluid by continuous or periodic infusion.

10 Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

It is also contemplated that certain formulations containing persephin are to be administered orally. Such  
15 formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,  
20 calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating  
25 agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the active ingredients after administration to the patient by  
30 employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and promote absorption such as, for example, surface active agents.

The specific dose is calculated according to the  
35 approximate body weight or body surface area of the patient or the volume of body space to be occupied. The



dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art in light of the activity of persephin. The activity of neurturin in target cells data is disclosed herein and in copending application Serial Number 08/519,777 and the concentration of persephin required for activity at the cellular level is believed to be similar to that of neurturin. The activity of persephin on mesencephalic cells is reported in Example 17 below. Persephin activity on a particular target cell type can be determined by routine experimentation. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

In one embodiment of this invention, persephin may be therapeutically administered by implanting into patients vectors or cells capable of producing a biologically-active form of persephin or a precursor of persephin, i.e. a molecule that can be readily converted to a biological-active form of persephin by the body. In one approach cells that secrete persephin may be encapsulated into semipermeable membranes for implantation into a patient. The cells can be cells that normally express persephin or a precursor of persephin or the cells can be transformed to express persephin or a precursor thereof. It is preferred that the cell be of

human origin and that the persephin be human persephin when the patient is human. However, the formulations and methods herein can be used for veterinary as well as human applications and the term "patient" as used herein  
5 is intended to include human and veterinary patients.

Cells can be grown *ex vivo* for use in transplantation or engraftment into patients (Muench et al., *Leuk & Lymph* 16:1-11, 1994 which is incorporated by reference). In another embodiment of the present  
10 invention, persephin can be used to promote the *ex vivo* expansion of a cells for transplantation or engraftment. Current methods have used bioreactor culture systems containing factors such as erythropoietin, colony stimulating factors, stem cell factor, and interleukins  
15 to expand hematopoietic progenitor cells for erythrocytes, monocytes, neutrophils, and lymphocytes (Verfaillie, *Stem Cells* 12:466-476, 1994 which is incorporated by reference). These stem cells can be isolated from the marrow of human donors, from human  
20 peripheral blood, or from umbilical cord blood cells. The expanded blood cells are used to treat patients who lack these cells as a result of specific disease conditions or as a result of high dose chemotherapy for treatment of malignancy (George, *Stem Cells* 12(Suppl  
25 1):249-255, 1994 which is incorporated by reference). In the case of cell transplant after chemotherapy, autologous transplants can be performed by removing bone marrow cells before chemotherapy, expanding the cells *ex vivo* using methods that also function to purge malignant  
30 cells, and transplanting the expanded cells back into the patient following chemotherapy (for review see Rummel and Van Zant, *J Hematotherapy* 3:213-218, 1994 which is incorporated by reference). Since persephin and the related growth factor, neurturin, may be expressed in the  
35 developing animal in particular tissues where proliferation and differentiation of progenitor cells

occur, it is believed that persephin can function to regulate the proliferation of hematopoietic stem cells and the differentiation of mature hematopoietic cells. Thus, the addition of persephin to culture systems used  
5 for ex vivo expansion of cells could stimulate the rate at which certain populations of cells multiply or differentiate, and improve the effectiveness of these expansion systems in generating cells needed for transplant.

10 It is also believed that persephin can be used for the ex vivo expansion of precursor cells in the nervous system. Transplant or engraftment of cells is currently being explored as a therapy for diseases in which certain populations of neurons are lost due to degeneration such  
15 as, for example, in parkinson's disease (Bjorklund, *Curr Opin Neurobiol* 2:683-689, 1992 which is incorporated by reference). Neuronal precursor cells can be obtained from animal or human donors or from human fetal tissue and then expanded in culture using persephin. These  
20 cells can then be engrafted into patients where they would function to replace some of the cells lost due to degeneration. Because neurotrophins have been shown to be capable of stimulating the survival and proliferation of neuronal precursors cells such as, for example, NT-3  
25 stimulation of sympathetic neuroblast cells (Birren et al., *Develop* 119:597-610, 1993 which is incorporated by reference), persephin could also function in similar ways during the development of the nervous system and could be useful in the ex vivo expansion of neuronal cells.

30 In a number of circumstances it would be desirable to determine the levels of persephin in a patient. The identification of persephin along with the present report that persephin is expressed by certain tissues provides the basis for the conclusion that the presence of  
35 persephin serves a normal physiologic function related to cell growth and survival. Indeed, other neurotrophic

factors are known to play a role in the function of neuronal and non-neuronal tissues. (For review see Scully and Otten, *Cell Biol Int* 19:459-469, 1995; Otten and Gadiant, *Int J Devl Neurosciences* 13:147-151, 1995 which are incorporated by reference). Endogenously produced persephin may also play a role in certain disease conditions, particularly where there is cellular degeneration such as in neurodegenerative conditions or diseases. Other neurotrophic factors are known to change during disease conditions. For example, in multiple sclerosis, levels of NGF protein in the cerebrospinal fluid are increased during acute phases of the disease (Bracci-Laudiero et al., *Neuroscience Lett* 147:9-12, 1992 which is incorporated by reference) and in systemic lupus erythematosus there is a correlation between inflammatory episodes and NGF levels in sera (Bracci-Laudiero et al. *NeuroReport* 4:563-565, 1993 which is incorporated by reference).

Given that persephin is expressed in certain tissues, it is thus likely that the level of persephin may be altered in a variety of conditions and that quantification of persephin levels would provide clinically useful information. Furthermore, in the treatment of degenerative conditions, compositions containing persephin can be administered and it would likely be desirable to achieve certain target levels of persephin in sera, in cerebrospinal fluid or in any desired tissue compartment. It would, therefore, be advantageous to be able to monitor the levels of persephin in a patient. Accordingly, the present invention also provides methods for detecting the presence of persephin in a sample from a patient.

The term "detection" as used herein in the context of detecting the presence of persephin in a patient is intended to include the determining of the amount of persephin or the ability to express an amount of

persephin in a patient, the distinguishing of persephin from other growth factors, the estimation of prognosis in terms of probable outcome of a degenerative disease and prospect for recovery, the monitoring of the persephin  
5 levels over a period of time as a measure of status of the condition, and the monitoring of persephin levels for determining a preferred therapeutic regimen for the patient.

To detect the presence of persephin in a patient, a  
10 sample is obtained from the patient. The sample can be a tissue biopsy sample or a sample of blood, plasma, serum, CSF or the like. Persephin is expressed in kidney and brain tissues as shown in example 18 and it is believed that persephin is expressed in other tissues not tested  
15 as well. Samples for detecting persephin can be taken from any tissue expressing persephin. When assessing peripheral levels of persephin, it is preferred that the sample be a sample of blood, plasma or serum or alternatively from a tissue biopsy sample. When  
20 assessing the levels of persephin in the central nervous system a preferred sample is a sample obtained from cerebrospinal fluid.

In some instances it is desirable to determine whether the persephin gene is intact in the patient or in  
25 a tissue or cell line within the patient. By an intact persephin gene it is meant that there are no alterations in the gene such as point mutations, deletions, insertions, chromosomal breakage, chromosomal rearrangements and the like wherein such alteration might  
30 alter production of persephin or alter its biological activity, stability or the like to lead to disease processes or susceptibility to cellular degenerative conditions. Conversely, by a non-intact persephin gene it is meant that such alterations are present. Thus, in  
35 one embodiment of the present invention a method is provided for detecting and characterizing any alterations

in the persephin gene. The method comprises providing an oligonucleotide that contains the persephin cDNA, genomic DNA or a fragment thereof or a derivative thereof. By a derivative of an oligonucleotide, it is meant that the  
5 derived oligonucleotide is substantially the same as the sequence from which it is derived in that the derived sequence has sufficient sequence complementarity to the sequence from which it is derived to hybridize to the persephin gene. The derived nucleotide sequence is not  
10 necessarily physically derived from the nucleotide sequence, but may be generated in any manner including for example, chemical synthesis or DNA replication or reverse transcription or transcription.

Typically, patient genomic DNA is isolated from a  
15 cell sample from the patient and digested with one or more restriction endonucleases such as, for example, TaqI and AluI. Using the Southern blot protocol, which is well known in the art, this assay determines whether a patient or a particular tissue in a patient has an intact  
20 persephin gene or a persephin gene abnormality.

Hybridization to the persephin gene would involve denaturing the chromosomal DNA to obtain a single-stranded DNA; contacting the single-stranded DNA with a gene probe associated with the persephin gene sequence;  
25 and identifying the hybridized DNA-probe to detect chromosomal DNA containing at least a portion of the human persephin gene.

The term "probe" as used herein refers to a structure comprised of a polynucleotide which forms a  
30 hybrid structure with a target sequence, due to complementarity of probe sequence with a sequence in the target region. The probes need not reflect the exact sequence of the target sequence, but must be sufficiently complementary to selectively hybridize with the strand  
35 being amplified. By selective hybridization or specific hybridization it is meant that a polynucleotide

preferentially hybridizes to a target polynucleotide. Oligomers suitable for use as probes may contain a minimum of about 8-12 contiguous nucleotides which are complementary to the targeted sequence and preferably a minimum of about 15 nucleotides although polynucleotide probes up to about 20 nucleotides and up to about 100 nucleotides or even greater are within the scope of this invention.

The persephin gene probes of the present invention can be DNA or RNA oligonucleotides and can be made by any method known in the art such as, for example, excision, transcription or chemical synthesis. Probes may be labelled with any detectable label known in the art such as, for example, radioactive or fluorescent labels or enzymatic marker. Labeling of the probe can be accomplished by any method known in the art such as by PCR, random priming, end labelling, nick translation or the like. One skilled in the art will also recognize that other methods not employing a labelled probe can be used to determine the hybridization. Examples of methods that can be used for detecting hybridization include Southern blotting, fluorescence *in situ* hybridization, and single-strand conformation polymorphism with PCR amplification.

Hybridization is typically carried out at 25-45°C, more preferably at 32-40°C and more preferably at 37-38°C. The time required for hybridization is from about 0.25 to about 96 hours, more preferably from about one to about 72 hours, and most preferably from about 4 to about 24 hours.

Persephin gene abnormalities can also be detected by using the PCR method and primers that flank or lie within the persephin gene. The PCR method is well known in the art. Briefly, this method is performed using two oligonucleotide primers which are capable of hybridizing to the nucleic acid sequences flanking a target sequence

that lies within a persephin gene and amplifying the target sequence. The terms "oligonucleotide primer" as used herein refers to a short strand of DNA or RNA typically ranging in length from about 8 to about 30  
5 bases. The upstream and downstream primers are preferably a minimum of from about 15 nucleotides to about 20 nucleotides and up to about 30 nucleotides or even greater in length. The primers can hybridize to the flanking regions for replication of the nucleotide  
10 sequence. The polymerization is catalyzed by a DNA-polymerase in the presence of deoxynucleotide triphosphates or nucleotide analogs to produce double-stranded DNA molecules. The double strands are then separated by any denaturing method including physical,  
15 chemical or enzymatic. Commonly, the method of physical denaturation is used involving heating the nucleic acid, typically to temperatures from about 80°C to 105°C for times ranging from about 1 to about 10 minutes. The process is repeated for the desired number of cycles.

20 The primers are selected to be substantially complementary to the strand of DNA being amplified. Therefore, the primers need not reflect the exact sequence of the template, but must be sufficiently complementary to selectively hybridize or specifically  
25 hybridize with the strand being amplified. By selective hybridization or specific hybridization it is meant that a polynucleotide preferentially hybridizes to a target polynucleotide.

After PCR amplification, the DNA sequence comprising  
30 persephin or pre-pro persephin or a fragment thereof is then directly sequenced and analyzed by comparison of the sequence with the sequences disclosed herein to identify alterations which might change activity or expression levels or the like.

35 In another embodiment a method for detecting persephin is provided based upon an analysis of tissue



expressing the persephin gene. Certain tissues such as those identified below in example 18 have been found to express the persephin gene. The method comprises hybridizing a polynucleotide probe to mRNA from a sample  
5 of tissues that normally express the persephin gene or from a cDNA produced from the mRNA of the sample. The sample is obtained from a patient suspected of having an abnormality in the persephin gene or from a particular patient tissue or cell type suspected of having an  
10 abnormality in the persephin gene. The reference persephin polynucleotide probe can comprise SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NOS:203-206 or derivatives thereof or fragments thereof so long as such derivatives or fragments  
15 specifically hybridize to persephin mRNA or from a cDNA produced from a persephin mRNA.

To detect the presence of mRNA encoding persephin protein, a sample is obtained from a patient. The sample can be from blood or from a tissue biopsy sample. The  
20 sample may be treated to extract the nucleic acids contained therein. The resulting nucleic acid from the sample is subjected to gel electrophoresis or other size separation techniques.

The mRNA of the sample is contacted with a nucleic  
25 acid serving as a probe to form hybrid duplexes. The use of a labeled probes as discussed above allows detection of the resulting duplex.

When using the cDNA encoding persephin protein or a derivative of the cDNA as a probe, high stringency  
30 conditions can be used in order to prevent false positives, that is the hybridization and apparent detection of persephin nucleotide sequences when in fact an intact and functioning persephin gene is not present. When using sequences derived from the persephin cDNA,  
35 less stringent conditions could be used, however, this would be a less preferred approach because of the

likelihood of false positives. The stringency of hybridization is determined by a number of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time and concentration of formamide. These factors are outlined in, for example, Sambrook et al. (Sambrook, et al., 1989, *supra*).

In order to increase the sensitivity of the detection in a sample of mRNA encoding the persephin protein, the technique of reverse transcription/polymerization chain reaction (RT/PCR) can be used to amplify cDNA transcribed from mRNA encoding the persephin protein. The method of RT/PCR is well known in the art (see example 9 and figure 6 below).

The RT/PCR method can be performed as follows. Total cellular RNA is isolated by, for example, the standard guanidium isothiocyanate method and the total RNA is reverse transcribed. The reverse transcription method involves synthesis of DNA on a template of RNA using a reverse transcriptase enzyme and a 3' end primer. Typically, the primer contains an oligo(dT) sequence. The cDNA thus produced is then amplified using the PCR method and persephin specific primers. (Belyavsky et al, *Nucl Acid Res* 17:2919-2932, 1989; Krug and Berger, *Methods in Enzymology*, Academic Press, N.Y., Vol.152, pp. 316-325, 1987 which are incorporated by reference).

The polymerase chain reaction method is performed as described above using two oligonucleotide primers that are substantially complementary to the two flanking regions of the DNA segment to be amplified.

Following amplification, the PCR product is then electrophoresed and detected by ethidium bromide staining or by phosphoimaging.

The present invention further provides for methods to detect the presence of the persephin protein in a sample obtained from a patient. Any method known in the

art for detecting proteins can be used. Such methods include, but are not limited to immunodiffusion, immunoelectrophoresis, immunochemical methods, binder-ligand assays, immunohistochemical techniques,  
5 agglutination and complement assays. (for example see *Basic and Clinical Immunology*, Sites and Terr, eds., Appleton & Lange, Norwalk, Conn. pp 217-262, 1991 which is incorporated by reference). Preferred are binder-ligand immunoassay methods including reacting antibodies  
10 with an epitope or epitopes of the persephin protein or derivative thereof and competitively displacing the labeled persephin protein or derivative thereof.

As used herein, a derivative of persephin protein is intended to include a polypeptide in which certain amino  
15 acids have been deleted or replaced with other amino acids or changed to modified or unusual amino acids wherein the persephin derivative is biologically equivalent to persephin and/or wherein the polypeptide derivative cross-reacts with antibodies raised against  
20 the persephin protein. By cross-reaction it is meant that an antibody reacts with an antigen other than the one that induced its formation.

Numerous competitive and non-competitive protein binding immunoassays are well known in the art.  
25 Antibodies employed in such assays may be unlabeled, for example as used in agglutination tests, or labeled for use in a wide variety of assay methods. Labels that can be used include radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates or co-factors, enzyme  
30 inhibitors, particles, dyes and the like for use in radioimmunoassay (RIA), enzyme immunoassays, e.g., enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassays and the like.

Polyclonal or monoclonal antibodies to the persephin  
35 protein or to an epitope thereof can be made for use in immunoassays by any of a number of methods known in the

art. By epitope reference is made to an antigenic determinant of a polypeptide. The term epitope can also include persephin-specific B cell epitopes or T helper cell epitopes. An epitope could comprise 3 amino acids in a spacial conformation which is unique to the epitope. Generally an epitope consists of at least 5 such amino acids. Methods of determining the spatial conformation of amino acids are known in the art, and include, for example, x-ray crystallography and 2 dimensional nuclear magnetic resonance.

One approach for preparing antibodies to a protein is the selection and preparation of an amino acid sequence of all or part of the protein, chemically synthesizing the sequence and injecting it into an appropriate animal, usually a rabbit or a mouse (See Example 10).

Oligopeptides can be selected as candidates for the production of an antibody to the persephin protein based upon the oligopeptides lying in hydrophilic regions, which are thus likely to be exposed in the mature protein.

Antibodies to persephin can also be raised against oligopeptides that include one or more of the conserved regions identified herein such that the antibody can cross-react with other family members. Such antibodies can be used to identify and isolate the other family members.

Methods for preparation of the persephin protein or an epitope thereof include, but are not limited to chemical synthesis, recombinant DNA techniques or isolation from biological samples. Chemical synthesis of a peptide can be performed, for example, by the classical Merrifield method of solid phase peptide synthesis (Merrifield, *J Am Chem Soc* 85:2149, 1963 which is incorporated by reference) or the Fmoc strategy on a Rapid Automated Multiple Peptide Synthesis system (DuPont

Company, Wilmington, DE) (Caprino and Han, *J Org Chem* 37:3404, 1972 which is incorporated by reference).

Polyclonal antibodies can be prepared by immunizing rabbits or other animals by injecting antigen followed by  
5 subsequent boosts at appropriate intervals. The animals are bled and sera assayed against purified persephin protein usually by ELISA or by bioassay based upon the ability to block the action of persephin. When using  
10 avian species, e.g. chicken, turkey and the like, the antibody can be isolated from the yolk of the egg. Monoclonal antibodies can be prepared after the method of Milstein and Kohler by fusing splenocytes from immunized mice with continuously replicating tumor cells such as myeloma or lymphoma cells. (Milstein and Kohler *Nature*  
15 256:495-497, 1975; Gutfre and Milstein, *Methods in Enzymology: Immunochemical Techniques* 73:1-46, Langone and Banatis eds., Academic Press, 1981 which are incorporated by reference). The hybridoma cells so formed are then cloned by limiting dilution methods and  
20 supernates assayed for antibody production by ELISA, RIA or bioassay.

The unique ability of antibodies to recognize and specifically bind to target proteins provides an approach for treating an over expression of the protein. Thus,  
25 another aspect of the present invention provides for a method for preventing or treating diseases involving over expression of the persephin protein by treatment of a patient with specific antibodies to the persephin protein.

30 Specific antibodies, either polyclonal or monoclonal, to the persephin protein can be produced by any suitable method known in the art as discussed above. For example, murine or human monoclonal antibodies can be produced by hybridoma technology or, alternatively, the  
35 persephin protein, or an immunologically active fragment thereof, or an anti-idiotypic antibody, or fragment

thereof can be administered to an animal to elicit the production of antibodies capable of recognizing and binding to the persephin protein. Such antibodies can be from any class of antibodies including, but not limited  
5 to IgG, IgA, IgM, IgD, and IgE or in the case of avian species, IgY and from any subclass of antibodies.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one  
10 skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims  
15 which follow the examples.

#### Example 1

This example illustrates the isolation and purification of neurturin from CHO cell conditioned  
20 medium.

##### Preparation of CHO cell conditioned medium:

A derivative of DG44 Chinese hamster ovary cells, DG44CHO-pHSP-NGFI-B (CHO) cells, was used (Day et al, *J Biol Chem* 265:15253-15260, 1990 which is incorporated by  
25 reference). The inventors herein have also obtained neurturin in partially purified form from other derivatives of DG44 Chinese hamster ovary cells. The CHO cells were maintained in 20 ml medium containing minimum essential medium (MEM) alpha (Gibco-BRL No. 12561,  
30 Gaithersburg, MD) containing 10% fetal calf serum (Hyclone Laboratories, Logan, UT), 2 mM l-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 25nM methotrexate using 150 cm<sup>2</sup> flasks (Corning Inc., Corning NY). For passage and expansion, medium from a confluent  
35 flask was aspirated; the cells were washed with 10 ml phosphate buffered saline (PBS) containing in g/l, 0.144

$\text{KH}_2\text{PO}_4$ , 0.795  $\text{Na}_2\text{HPO}_4$  and 9.00  $\text{NaCl}$ ; and the flask was then incubated for 2-3 minutes with 2 ml 0.25% trypsin in PBS. Cells were then knocked off the flask surface, 8 ml of medium were added and cells were triturated several times with a pipette. The cells were split 1:5 or 1:10, incubated at 37°C under an atmosphere of 5%  $\text{CO}_2$  in air and grown to confluence for 3-4 days.

The cell culture was then expanded into 850  $\text{cm}^2$  roller bottles (Becton Dickinson, Bedford, MA). A confluent 150  $\text{cm}^2$  flask was trypsinized and seeded into one roller bottle containing 240 ml of the above modified MEM medium without methotrexate. The pH was maintained either by blanketing the medium with 5%  $\text{CO}_2$  in air or by preparing the medium with 25 mM HEPES pH 7.4 (Sigma, St. Louis, MO). The roller bottles were rotated at 0.8-1.0 revolutions per minute. Cells reached confluence in 4 days.

For collecting conditioned medium, serum-free CHO cell (SF-CHO) medium was used. SF-CHO was prepared using 1:1 DME/F12 base medium, which was prepared by mixing 1:1 (v/v) DMEM (Gibco-BRL product No. 11965, Gibco-BRL, Gaithersburg, MD) with Ham's F12 (Gibco-BRL product No. 11765). The final SF-CHO medium contained 15 mM HEPES pH 7.4 (Sigma, St. Louis, MO), 0.5 mg/ml bovine serum albumin (BSA, Sigma, St. Louis MO), 25  $\mu\text{g}/\text{ml}$  heparin, (Sigma, St. Louis, MO), 1X insulin-transferrin-selenite supplement (bovine insulin, 5  $\mu\text{g}/\text{ml}$ ; human transferrin, 5  $\mu\text{g}/\text{ml}$ ; sodium selenite, 5 ng/ml; Sigma, St. Louis, MO), 2 mM l-glutamine, 100 U/ml penicillin, and 100  $\mu\text{g}/\text{ml}$  streptomycin. The medium from the confluent roller bottles was removed and the cells washed once with 30 ml SF-CHO medium to remove serum proteins. Cells were then incubated at 37°C for 16-24 hrs in 80 ml SF-CHO medium to further remove serum proteins. The 80 ml medium was removed and discarded. A volume of 120 ml of SF-CHO medium was added to the flask and the cells incubated at

37°C. Every 48 hrs thereafter, 120 ml was collected and replaced with the same volume of SF-CHO medium.

Collected media was pooled and centrifuged at 4°C in polypropylene conical tubes to remove cellular debris and the supernatant stored at -70°C. Media was collected 5 times over 10 days to yield a total of approximately 600 ml conditioned medium per roller bottle.

Fractions collected from the columns at each stage of purification were assayed for biological activity using the neuronal survival assay and for protein content by the dye binding assay of Bradford (*Anal Biochem* 72:248 et seq., 1976 which is incorporated by reference). The total mg of protein in the starting volume, typically 50 liters, of conditioned medium was determined.

#### 15 Superior Cervical Ganglion Survival Assay:

The neurotrophic activity of CHO conditioned medium starting material and at various stages of purification was assessed using the superior cervical ganglion survival assay system previously reported (Martin, et al *J of Cell Biology* 106:829-844; Deckwerth and Johnson, *J Cell Bio* 123:1207-1222, 1993 which are incorporated by reference). Primary cultures of sympathetic neurons from superior cervical ganglion (SCG) were prepared by dissecting tissue from Day 20-21 rat embryo (E20-E21). The SCG's were placed in Leibovitz's L15 with l-glutamine medium (Cat #11415-023 Gibco-BRL, Gaithersburg, MD), digested for 30 minutes with 1 mg/ml collagenase (Cat #4188 Worthington Biochemical, Freehold, NJ) in Leibovitz's L15 medium at 37°C, followed by a 30 minute digestion in trypsin-lyophilized & irradiated (Type TRLVMF Cat #4454 Worthington Biochemical, Freehold, NJ) which was resuspended in modified Hanks' Balanced Salt Solution (Cat #H-8389 Sigma Chemical Co., St. Louis, MO). The digestion was stopped using AM50 which contains Minimum Essential Medium with Earle's salts and without l-glutamine (Cat #11090-016 Gibco-BRL), 10% fetal calf



serum (Cat #1115 Hyclone Laboratories, Logan, UT), 2mM l-glutamine (Cat #G5763 Sigma Chemical Co., St. Louis, MO), 20  $\mu$ M FuDr (F-0503 Sigma Chemical Co., St. Louis, MO), 20  $\mu$ M Uridine (Cat #3003 Sigma Chemical Co., St. Louis, MO), 5 100 U/ml penicillin, 100  $\mu$ g/ml Streptomycin, and 50 ng/ml 2.5 S NGF. The cells were dissociated into a suspension of single cells using a silanized and flame-polished Pasteur pipet. After filtration of the suspension through a nitex filter (size 3-20/14, Tetko Inc., 10 Elmsford, NY), the cells were placed in AM50 medium as above and preplated on a 100 mm Falcon or Primaria culture dish (Becton Dickinson Labware, Lincoln Park, NJ) to reduce the number of non-neuronal cells. After 2 hours, the medium containing the unattached neuronal 15 cells was removed from these dishes and triturated again through a silanized and flame-polished Pasteur pipet. The single cell suspension was plated on 24-well tissue culture plates (Costar, Wilmington, MA) that have been previously coated with a double layer of collagen, one 20 layer of collagen that had been ammoniated and a second layer of collagen that had been air dried. They were allowed to attach for 30 minutes to 2 hours. A specific number of viable cells, usually about 1200 to about 3000 total cells per well, or a specific percentage of the 25 ganglion, usually 25% of the cells obtained per ganglion were plated into each well. When cell counts were to be performed they were placed in the 24-well dishes as stated above or alternatively, on 2-well chamber slides (Nunc, Naperville, IL). Cultures were then incubated for 30 5-6 days at 37° in AM50 medium in a 5% CO<sub>2</sub>/95% air atmosphere. The death of the cultured neurons was induced by exchanging the medium with medium without NGF and with 0.05% goat anti-NGF (final titer in the wells is 1:10). This NGF-deprivation results in death of the 35 neurons over a period of 24-72 hours. Aliquots of partially purified or purified factor, or appropriate

controls, were added to the cultures at the time of NGF removal to determine the ability to prevent the neuronal death.

Evaluation of the ability of column fraction, gel eluates, or purified factor to prevent neuronal death was by visual inspection of cultures under phase contrast microscopy. Viable neurons remained phase bright with intact neurites, whereas dead neurons were shrunken, phase dark, had irregular membranes and neurites were fragmented (Figure 3). Where precise quantitation of neuronal survival was required, the cultures were fixed in 4% paraformaldehyde or 10% Formalin in PBS, and stained with crystal violet solution, (Huntoon Formula Harleco E.M. Diagnostics Systems, Gibbstown, NJ). When using 24 well dishes, 1  $\mu$ l crystal violet solution was added to each well containing 10% formalin and the cells were counted using a phase contrast microscope. If the 2-well chamber slides were used, the cultures were fixed, stained with crystal violet, destained with water, dehydrated in increasing ethanol concentrations to toluene, and mounted in a toluene-based mounting solution. Neurons were scored as viable if they had a clear nucleolus and nuclei and were clearly stained with crystal violet.

The neuronal death at 72 hours is shown in Figure 3B. Also shown are (A) the positive control cells maintained with nerve growth factor and (C) the cells treated with anti-NGF and neurturin (approximately 3 ng/ml) showing survival of neurons.

Activity was quantitated by calculation of a "survival unit". The total survival units in a sample were defined as the minimal volume of an aliquot of the sample which produced maximal survival divided into the total volume of that sample. Specific activity was calculated as the survival units divided by the mg total protein.

Survival units were determined in an assay using approximately 1200 viable neurons in a 0.5 ml culture assay and a culture period of 48 hours following addition of the fraction. Survival was assessed visually after 5 the 48 hours. Intrinsic activity as shown in Figure 4 was determined in an assay using approximately 2700 neurons and a culture period of 72 hours. Survival was assessed by fixing the neurons and counting the number of surviving neurons. Because the stability, as assessed by 10 half-life of activity, for neurturin decreases as the number of neurons increases, the intrinsic activity measurement would be expected to be lower than that predicted by Specific Activity determinations. The intrinsic activity measurement would also be expected to 15 be lower than that predicted by specific activity because the survival was measured after 72 hours instead of 48 hours.

To ensure the reproducibility of these activity unit assays, it was necessary to plate the primary neuronal 20 cultures at reproducible cell densities, as the stability of the activity decreases significantly with increasing neuronal density. The range of cell densities was from about 1200 to about 2700 cells per well. The presence of soluble heparin in the assay medium had no effect on the 25 short-term (~3 days) stability of the survival activity.

#### Purification of Neurturin:

Pooled conditioned medium was filtered through 0.2 µl pore bottle-top filters (cellulose acetate membrane, Corning Inc., Corning, NY). Typically 50 liters of 30 conditioned medium was used and processed in 25 liter batches. Each 25 liter batch was introduced at a rate of 20 ml/min onto a 5 x 5 cm column containing 100 ml heparin-agarose (Sigma, St. Louis, MO) equilibrated with 25 mM HEPES, pH 7.4 buffer with 150 mM NaCl. The column 35 was then washed with approximately 1000 ml 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl at 20 ml/min and the

activity was then eluted with 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl. After switching to the 1.0M NaCl elution buffer, the first 50 ml of buffer was discarded and, thereafter, one 300 ml fraction was collected.

5 Pooled material eluted from the Heparin-agarose column was then diluted 1:1 (v/v) with 25 mM HEPES, pH 7.4 buffer containing 0.04% TWEEN 20 to a NaCl concentration of 0.5 M and introduced into a 1.5 cm x 9 cm column containing 16 ml SP SEPHAROSE® High Performance  
10 ion exchange resin (Pharmacia, Piscataway, NJ) equilibrated in 25 mM HEPES 7.4 containing 0.5 M NaCl and 0.02% TWEEN 20. The column was then washed with 160 ml 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl and 0.02% TWEEN 20 and the activity was eluted with 25 mM  
15 HEPES, pH 7.4 buffer containing 1.0 M NaCl and 0.02% TWEEN 20 at a flow rate of 2 ml/min. One 50 ml fraction was collected after the first 7 ml of eluate from the column.

Material eluted from the SP SEPHAROSE® column was  
20 fractionated using fast protein liquid chromatography (FPLC) on a Chelating Superose HR 10/2 column charged with Cu<sup>++</sup> (Pharmacia, Piscataway, NJ). The column had been prepared by washing with 10 ml water, charging with 3 ml of 2.5 mg/ml CuSO<sub>4</sub>·5H<sub>2</sub>O, washing with 10 ml water,  
25 and equilibrating with 10 ml of 25 mM HEPES pH 7.4 buffer containing 1.0 M NaCl and 0.02% TWEEN 20. The eluate was introduced into the column in 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl at a rate of 1.0 ml/min. The bound proteins were eluted with a linear gradient of increasing  
30 glycine concentration (0-300 mM) in 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl at a rate of 1.0 ml/min. The gradient was produced by a Pharmacia FPLC system using an LCC-500 controller and P-500 pumps to establish a 0-300 mM glycine gradient in 40 ml at 1.0 ml/min, thus  
35 increasing the gradient by 7.5 mM glucine per min. One ml fractions were collected and assayed for SCG survival

promotion. Peak activity was observed in fractions 17-20, i.e. 17-20 min or ml from the start of the gradient.

Absorbance measurements at 280 nm by an in-line UV monitor indicated that most proteins eluted prior to the survival activity in fractions 17-20. Thus, significant purification was achieved at this step. A 25 kD band co-purified with the survival activity.

The combined eluted fractions from the  $\text{Cu}^{++}$  superose column were diluted to 0.45 M NaCl using 25 mM HEPES pH 7.4 buffer containing 0.02% TWEEN 20 and introduced into a Mono S HR 5/5 cation exchange column (Pharmacia, Piscataway, NJ) for further FPLC purification. The column had been equilibrated with 25 mM HEPES pH 7.4 buffer containing 0.45 M NaCl containing 0.02% TWEEN 20. Bound proteins were eluted with a linear gradient of increasing NaCl concentration (0.45-1.0 M). The gradient was produced as described above from 0.45 M - 1.0 M NaCl in 35 mls at 1.0 ml/min, thus increasing concentration at 0.0157 M per ml or min. Thirteen 1.0 ml fractions (fractions 1-13) were collected followed by 44 0.5 ml fractions (fractions 14-53). Peak activity in SCG assay was in fractions 26-29. Each fraction was assayed in the SCG survival assay over a range of volumes of from 0.1 to 1.0  $\mu\text{l}$  per 0.5 ml culture medium.

One percent (5  $\mu\text{l}$ ) of each fraction was loaded onto a non-reducing, 14% SDS polyacrylamide gel and electrophoresed for 750 V-hr at 25°C. Proteins were visualized by silver stain. The results are shown in Figure 2. Markers shown in lane M on the gel represent 20 ng of Bovine serum albumin, carbonic anhydrase, B-lactoglobulin, and lysozyme in the order of descending molecular weight.

A 25 kD band appeared in fractions 25-30, a 28 kD protein elutes earlier in the gradient and an 18 kD elutes later in the gradient. Figure 2 illustrates the survival activity in each of the fractions. The survival

activity is noted to correspond with the presence and apparent intensity of the 25 kD protein in fractions 25-30.

To demonstrate that the 25 kD band was responsible for survival promoting activity, the 25 kD protein was eluted from the polyacrylamide gel after electrophoresis and assayed for survival activity in the SCG assay. After electrophoresis of 150  $\mu$ l of the SP SEPHAROSE® 1.0 M NaCl fraction in one lane of a non-reducing 14% SDS-polyacrylamide gel as above, the lane was cut into 12 slices and each slice was crushed and eluted by diffusion with rocking in buffer containing 25 mM HEPES, pH 7.4, 0.5 M NaCl, 0.02% Tween-20 for 18 hr at 25°C. BSA was added to the eluate to a final concentration of 200  $\mu$ g/ml and the eluate was filtered through a 0.45 micron filter to remove acrylamide gel fragments. The filtrate was then added to a SP SEPHAROSE® column to concentrate and purify the sample. Before eluting the sample, the column was washed once in 400  $\mu$ l 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl, 0.02% Tween-20 and 200  $\mu$ g BSA per ml and once in 400  $\mu$ l 25 mM HEPES, pH 7.4 buffer containing 0.02% Tween-20 and 200  $\mu$ g BSA per ml. The column was then washed again in 400  $\mu$ l of 25 mM HEPES, pH 7.4 buffer containing 0.5 M NaCl, 0.02% TWEEN 20 and 200  $\mu$ g BSA per ml. The sample was eluted with 25 mM HEPES, pH 7.4 buffer containing 1.0 M NaCl, 0.02% Tween-20 and 200  $\mu$ g BSA per ml. Samples were then analyzed for survival activity. Only the slice corresponding to the 25 kD band showed evidence of survival activity. The 25 kD protein purified from CHO cell conditioned media is believed to be a homodimer.

The yield from the purification above was typically 1-1.5  $\mu$ g from 50 liters of CHO cell conditioned medium. Overall recovery is estimated to be 10-30%, resulting in a purification of approximately 390,000 fold.

The progressive purification using the above steps is shown in table 2.

Table 2

	Protein <sup>a</sup> (mg)	Activity <sup>b</sup> (units)	Specific Activity <sup>d</sup> (units/mg)	Yield (%)	Purification (fold)
Conditioned Medium	5000	48000 <sup>c</sup>	9.6	—	—
Heparin Agarose	45	48000	1068	100	111
SP Sepharose	5.3	48000	9058	100	943
Cu++ Superose	0.31	30000	96700	62	10070
Mono S	0.004	15000	3750000	31	390000

a. mg protein was determined using the dye binding method of Bradford (*Anal Biochem* 72:248, 1976).

b. The total activity units or survival units in a sample were defined as the minimal volume of an aliquot of the sample which produced maximal survival divided into the total volume of that sample.

c. Activity for Conditioned Medium was derived from the assumption that 100% of the activity was recovered in the heparin agarose fraction because the activity of conditioned medium was too low to be directly assayed.

d. Specific Activity was the Activity units divided by the mg total protein.

### Example 2

This example illustrates the characterization of neurturin and several members of the TGF- $\beta$  family of growth factors in the SCG assay and the lack of cross reactivity of anti-GDNF antibodies with neurturin.

The SCG assay of the purified protein indicated that the factor is maximally active at a concentration of approximately 3 ng/ml or approximately 100 pM and the EC<sub>50</sub> was approximately 1.5 ng/ml or approximately 50 pM in the

expected range for a diffusible peptide growth factor (Figure 4).

Several members of the TGF- $\beta$  family influence neuropeptide gene expression in sympathetic neurons, while others promote survival of different neuronal populations. Neurturin, which is a distant member of this family of proteins, is capable of promoting virtually complete survival of sympathetic neurons for 3 days. In addition, further culturing of the SCG cells revealed that neurturin could continue to maintain these neurons for at least 10 days after withdrawal of NGF.

We tested several other members of the TGF- $\beta$  family for their ability to promote survival in the SCG assay including TGF- $\beta$ 1, activin, BMP-2, BMP-4, BMP-6 and GDNF. Of these factors, only GDNF had survival promoting activity, however, the activity of GDNF was much less potent than neurturin in this activity showing an  $EC_{50}$  of 2-4 nM in the 3-day survival assay. The GDNF tested in this assay was rhGDNF produced in *E. Coli* obtained from Prepro Tech, Inc., Rocky Hill, N.J. The duration of action of GDNF was also less than that of neurturin inasmuch as the ability of GDNF (50 ng/ml) to maintain survival longer than 3 days was substantially diminished. These experiments suggest the possibility that GDNF is a weak agonist for the neurturin receptor. Furthermore, the inability of activin and BMP-2 to promote survival, in contrast to their strong induction of transmitter-related gene expression in these neurons (Fann and Paterson, *Int J Dev Neurosci* 13:317-330, 1995; Fann and Patterson, *J Neurochem* 61:1349-1355, 1993) suggests that they signal through alternate receptors or signal transduction pathways.

To determine the cross-reactivity of anti-GDNF antibodies with partially purified neurturin, SCG neurons, that had been dissected and plated as described in Example 1 were treated on Day 6 with 1 ng/ml, 3 ng/ml,



10 ng/ml, or 30 ng/ml GDNF (Prepro Tech, Inc, Rocky Hill, N.J.) in the presence of anti-NGF alone, or in the presence of anti-NGF and anti-GDNF (goat IgG antibody to *E. coli*-derived rhGDNF, R & D Systems, Minneapolis, Minn). A partially purified 1.0 M SP Sepharose fraction of neurturin was used in the assay at the approximate concentrations of 375 pg/ml, 750 pg/ml, 1.5 ng/ml and 3 ng/ml. This fraction was tested in the presence of anti-NGF alone, and in the presence of anti-NGF and anti-GDNF. The anti-GDNF antibody blocked the survival promoting activity of GDNF at a concentration up to 30 ng/ml, but did not block the survival promoting activity of neurturin.

### 15 Example 3

This example illustrates the effect of neurturin on sensory neurons in a nodose ganglion survival assay.

CHO cell conditioned media that had been partially purified on the SP Sepharose column was assayed for neurotrophic activity on sensory neurons using nodose ganglia. The survival assay is a modification of that previously reported above for superior cervical ganglia. Primary dissociated cultures of nodose ganglia were prepared by dissecting tissue from E18 Sprague Dawley rat pups. The nodose ganglia were placed in Leibovitz's L15 with 2 mM l-glutamine (Cat# 11415-023, GIBCO-BRL, Gaithersburg, MD) as the tissues was dissected, digested for 30 min with 1 mg/ml collagenase (Cat#4188, Worthington Biochemical, Freehold, New Jersey) in Leibovitz's L15 medium at 37°C, followed by 30 min digestion in trypsin (lyophilized and irradiated, type TRLVMF, Cat #4454 Worthington Biochemical, Freehold, NJ), and resuspension to a final concentration of 0.25% in modified Hank's Balanced Salt Solution (Cat#H8389, Sigma Chemical Co., St. Louis, Mo). The digestion was stopped using AMO-BDNF100, a medium containing Minimum Essential

Medium with Earle's salts and without l-glutamine (#11090-016 GIBCO-BRL), 10% fetal Calf Serum (Cat#1115, Hyclone Laboratories, Logan, UT), 2 mM l-glutamine (Cat#G5763 Sigma Chemical Co., St. Louis, Mo.), 20  $\mu$ M FuDr (F-0503, Sigma Chemical Co.), 20  $\mu$ M Uridine (Cat #3003, Sigma Chemical Co., St. Louis, Mo.) 100 U/ml penicillin, 100  $\mu$ g/ml Streptomycin, and 100 ng Brain Derived Neurotropic Factor (BDNF, Amgen, Thousand Oaks, CA). The cells were dissociated into a suspension of single cells using a silanized and flame-polished Pasteur pipet in the AMO-BDNF100 medium, and preplated on a 100 mm Falcon or Primaria culture dish (Becton Dickinson Labware, Lincoln Park, NJ) to remove non-neuronal cells. After 2 hours, the medium containing the unattached neuronal cells was removed from these dishes and triturated again through a silanized and flame-polished Pasteur pipet. The single cell suspension was plated on 24-well tissue culture plates (Costar, Wilmington, MA) that have been previously coated with a double layer of collagen, one layer of which had been ammoniated and a second layer that had been air dried. Ganglia from ten E18 rat embryos were dissociated into 2.5 mls of media and 100  $\mu$ l of this suspension was added to each well. The cells were allowed to attach for 30 min in a 37°C incubator with 5% CO<sub>2</sub>/95% air. The wells were fed with AMO-BDNF100 media overnight.

The next day the cells were washed 3 times for 20 min each time with AMO medium containing no BDNF. The wells were fed with 0.5 ml of this media alone or this media containing either 50 ng/ml NGF, 100 ng/ml BDNF (Amgen, Thousand Oaks, CA), 100 ng/ml GDNF (Prepro Tech, Inc., Rocky Hill, N.J) or 3 ng/ml Neurturin. The cells were incubated at 37°C in a 5% CO<sub>2</sub>/95% air incubator for 3 days, fixed with 10% formalin, stained with crystal violet (1  $\mu$ l/ml 10% formalin) and counted. Survival was ascertained as noted previously.

The neuronal Death at 72 hours is shown in Figure 10. Neuronal survival of nodose neurons cultured in BDNF has been previously reported (Thaler et al, *Develop Biol* 161:338-344, 1994 which is incorporated by reference). This was used as the standard for survival for these neurons and given the value of 100% survival. Nodose ganglia that had no trophic support (AMO) showed 20%-30% survival, as did neurons that were cultured in the presence of 50 ng/ml NGF. Neurons cultured in the presence of 3 ng/ml neurturin and absence of BDNF showed survival similar to those neurons cultured in the presence of BDNF (100 ng/ml). GDNF at a concentration of 100 ng/ml promoted greater survival of nodose neurons than did BDNF (100 ng/ml). Similar findings with GDNF were recently reported for sensory neurons from chicken (Ebendal, T. et al, *J Neurosci Res* 40:276-284 1995 which is incorporated by reference).

#### Example 4

This example illustrates the determination of partial amino acid sequences of neurturin isolated from CHO cell conditioned medium.

To obtain N-terminal amino acid sequence from a purified preparation of approximately 1 µg of neurturin, the Mono S fractions 26-29 containing the peak of activity were concentrated to 25 µl by centrifuge ultrafiltration in a microcon-3 concentrators (Amicon, Inc., Beverley, MA) and loaded onto a non-reducing 14% SDS polyacrylamide gel. After electrophoretic separation, proteins were electroblotted to a PVDF membrane (Bio-Rad, Hercules, CA) and stained with 0.1% Coomassie Blue. The 25 kD band was excised and inserted into the reaction cartridge of an automated sequencer (Model 476, Applied Biosystems (Foster City, CA)). Phenylthiohydantoin-amino acid (PTH-aa) recovery in the first 2-3 cycles of automated sequencing by Edman

degradation indicated a sequencing yield of 4 pmoles, which was approximately 10% of the estimated amount of protein loaded on the SDS gel.

Two N-terminal sequencing runs were performed from two 50 liter purification preparations. In the first run, 1 µg of protein in 3 pooled fractions of 1.5 ml total volume were concentrated to 25 µl and electroblotted at 100V for 2 hrs at 25°C using an electroblot buffer of 10 mM CAPS pH 11.0 buffer (Sigma, St. Louis, MO) containing 5% methanol. The amino acid sequence was obtained from 13 cycles of Edman degradation and the sequencing yield was 4 pmoles as above.

In the second run, 1.5 µg of protein in 4 pooled fractions of 2.0 ml total volume were concentrated to 25 µl and electroblotted at 36V for 12 hours at 4°C using an electroblot buffer of 25 mM Tris, 192 mM glycine, 0.04% SDS and 17% MeOH. Sequencing yield was 15 pmoles and the sequence after 16 cycles was SGARPXGLRELEVSVS (SEQ ID NO:3). The sequence obtained after 16 cycles corresponded to the shorter sequence obtained in the first run. Definite assignments could not be made at 3 of the amino acid residues in the sequence (residues 1, 6 and 11 from the N-terminal). A search of protein databases did not detect any significantly homologous sequences, suggesting that the purified factor was a novel protein.

This initial N-terminal amino acid sequence data did not enable the isolation of cDNA clones using degenerate oligonucleotides as PCR primers or probes for screening libraries. To facilitate these approaches, additional protein was purified in order to obtain internal amino acid sequence from proteolytic fragments. To obtain internal amino acid sequence from neuriturin, an additional 50 liters of CHO cell conditioned medium was purified using only the first 3 chromatographic steps as outlined above, except that the gradient used to elute

the Cu++ Chelating Superose column was as follows: 0-60 mM glycine (4 ml), 60mM glycine (10ml), 60-300 mM glycine (32 ml). Fractions No. 20-23 containing neurturin were concentrated to 25 µl by ultrafiltration (Amicon microcon 3, Amicon, Beverley, MA) and loaded on a non-reducing SDS polyacrylamide gel. After electrophoresis, the gel was stained with Coomassie blue and the 25 kD neurturin band was excised. Neurturin was digested in the gel slice with endoproteinase Lys-C, and the eluted proteolytic fragments were purified by reverse phase HPLC. Only one peak was observed upon HPLC separation of the eluted peptides, which yielded amino acid sequence information for 23 cycles at the 1 pmole signal level using the automated sequencer, (internal fragment P2, SEQ ID NO:5).

Amino acid analysis performed on 10% of the above sample before subjecting it to digestion had indicated that 150 pmoles of protein were present in the gel slice, consisting of 7.6% lysine and 19.5% arginine. The single low level peak from the Lys-C digestion suggested that the digestion and elution of peptides were inefficient. The same gel slice was redigested with trypsin and the eluted peptides separated by HPLC. Two peaks were observed on HPLC, resulting in the elucidation of two additional 10 residue amino acid sequences (4-5 pmole signal level, internal fragment P1, SEQ ID NO:4 and internal fragment P3, SEQ ID NO:6) that were distinct from the N-terminal and previous internal amino acid sequences. The in situ digestion, elution and purification of peptides, and peptide sequencing was performed by the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University according to standard protocols for this service.

## Example 5

The following example illustrates the isolation and sequence analysis of mouse and human neurturin cDNA clones.

- 5 Degenerate oligonucleotides corresponding to various stretches of confident amino acid sequence data were synthesized and used as primers in the polymerase chain reaction (PCR) to amplify cDNA sequences from reverse transcribed mRNA. A forward primer (M1676;  
10 5'-CCNACNGCNTAYGARGA, SEQ ID NO:50) corresponding to peptide sequence P2 Xaa<sub>1</sub>-Xaa<sub>2</sub>-Val-Glu-Ala-Lys-Pro-Cys-Cys-Gly-Pro-Thr-Ala-Tyr-Glu-Asp-Xaa<sub>3</sub>-Val-Ser-Phe-Leu-Ser-Val where Xaa<sub>1</sub> and Xaa<sub>2</sub> were unknown, Xaa<sub>3</sub> was Gln or Glu (SEQ ID NO:5) in combination with a reverse primer (M1677;  
15 5'-ARYTCYTGARNGTRTGRTA (SEQ ID NO:52) corresponding to peptide sequence P3 (Tyr-His-Thr-Leu-Gln-Glu-Leu-Ser-Ala-Arg) (SEQ ID NO:6) were used to amplify a 69 nucleotide product from cDNA templates derived from E21 rat and adult mouse brain.  
20 The PCR parameters were: 94°C for 30 sec; 55°C for 30 sec; 72°C for 1 min for 35 cycles. The product was subcloned into the Bluescript KS plasmid and sequenced. All nucleotide sequencing was performed using fluorescent dye terminator technology per manufacturer's instructions  
25 on an Applied Biosystems automated sequencer Model #373 (Applied Biosystems, Foster City, CA). Plasmid DNA for sequencing was prepared using the Wizard Miniprep kit (Promega Corp., Madison, WI) according to the manufacturer's instructions. The sequence of the  
30 amplified product correctly predicted amino acid sequence data internal to the PCR primers.

- Primers corresponding to the amplified sequence were used in combination with the degenerate primers in the rapid amplification of cDNA ends (RACE) technique  
35 (Frohman, M.A. *Methods in Enzymology* 218:340-356, 1993) using the Marathon RACE kit (CLONTECH, Palo Alto, CA) per

the manufacturer's instructions, except that first strand cDNA synthesis was carried out at 50°C using Superscript II reverse transcriptase (Gibco-BRL). Briefly, a double stranded adaptor oligonucleotide was ligated to the ends of double stranded cDNA synthesized from postnatal day 1 rat brain mRNA. Using nested forward neurturin PCR primers (M1676; 5'-CCNACNGCNTAYGARGA, SEQ ID NO:50 and 1678; 5'-GACGAGGGTCCTTCCTGGACGTACACA, SEQ ID NO:53) in combination with primers to the ligated adaptor supplied in the kit (AP1, AP2), the 3' end of the neurturin cDNA was amplified by two successive PCR reactions (1st: M1676 and AP1, using 94°C for 30 sec, 55°C for 30 sec and 72°C for 2 min for 35 cycles; 2nd: M1678 and AP2 using 94°C for 30 sec and 68°C for 2 min for 35 cycles). A 5' portion of the rat neurturin cDNA was obtained by two successive PCR reactions using the linkered cDNA as template. The 1st reaction utilized primers M1677 (SEQ ID NO:52) and AP1; using 94°C for 30 sec; 55°C for 30 sec; and 72°C for 2 min for 35 cycles. The 2nd reaction used M1679 5'-TAGCGGCTGTGTACGTCCAGGAAGGACACCTCGT (SEQ ID NO:54) and AP2 at 94°C for 30 sec and 68°C for 2 min for 35 cycles. These reactions resulted in a truncated form of the 5' end of the neurturin cDNA, apparently the result of premature termination of the cDNA during reverse transcription. The 5' and 3' RACE products were subcloned into the plasmid Bluescript KS and sequenced. The sequence of these 3' and 5' RACE products resulted in a partial rat neurturin cDNA sequence of 220 nt. Primers (#467921 5'-CAGCGACGACGCGTGCGCAAAGAGCG, SEQ ID NO:55; and M1679 (SEQ ID NO:54) corresponding to the partial rat cDNA sequence were used (PCR parameters 94°C for 30 sec and 68°C for 1 min for 35 cycles) to amplify a 101 nucleotide PCR product from mouse genomic DNA which was homologous to rat neurturin cDNA sequence.

These primers were then used to obtain murine neurturin genomic clones by amplifying gene fragments in

a mouse 129/Sv library in a P1 bacteriophage vector (library screening service of Genome Systems, Inc., St. Louis, MO). A 1.6 kb Nco I fragment from this P1 clone containing the neurturin gene was identified by

5 hybridization with primer (#465782;  
5'-TAYGARGACGAGGTGTCCTTCCTGGACGTACACAGCCGCTAYCAYAC, SEQ  
ID NO:56). This Nco I fragment was sequenced and found  
to contain a stretch of coding sequence corresponding to  
the N-terminal and internal amino acid sequences obtained

10 from sequencing the active protein isolated from CHO cell  
conditioned media. Beginning at the N-terminal amino  
acid sequence of the purified protein, this nucleotide  
sequence encodes a 100 amino acid protein with a  
predicted molecular mass of 11.5 kD. A search of protein

15 and nucleic acid databases identified neurturin as a  
novel protein that is approximately 40% identical to  
glial derived neurotrophic factor (GDNF). GDNF was  
purified and cloned as a factor which promotes the  
survival of midbrain dopaminergic neurons and is a

20 distantly related member of the TGF- $\beta$  superfamily, which  
now includes more than 25 different genes that possess a  
wide variety of proliferative and differentiative  
activities. Although GDNF is less than 20% identical to  
any other member of the TGF- $\beta$  family, it contains the 7

25 cysteine residues which are conserved across the entire  
family and believed to be the basis of a conserved  
cysteine knot structure observed in the crystal structure  
determination of TGF- $\beta$ 2. Neurturin also contains these 7  
cysteine residues, but like GDNF is less than 20%

30 homologous to any other member of the TGF- $\beta$  family.  
Thus, neurturin and GDNF appear to represent a subfamily  
of growth factors which have significantly diverged from  
the rest of the TGF- $\beta$  superfamily.

To determine the sequence of the full length mouse

35 neurturin cDNA, 5' and 3' RACE PCR was performed as  
above for the rat, using nested primers predicted from



the mouse genomic sequence and cDNA from neonatal mouse brain. The 1st reaction for the 3' end used primers: M1777 5'-GCGGCCATCCGCATCTACGACCGGG (SEQ ID NO:57) and AP1 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 35 cycles. The 2nd reaction used primer #467921 (SEQ ID NO:55) and AP2 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 20 cycles. The 5' end was obtained using for the 1st reaction primer M1759, 5'-CRTAGGCCGTCGGGCGRCARCACGGGT (SEQ ID NO:58) and AP1 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 35 cycles. The 2nd reaction used primer M1785, 5'-GCGCCGAAGGCCAGGTCGTAGATGCG (SEQ ID NO:59) and AP2 at 94°C for 30 sec; 65°C for 15 sec; and 68°C for 2 min for 20 cycles. Both sets of PCR reactions included 5% DMSO.

The 5' and 3' mouse RACE products were subcloned into the plasmid Bluescript KS and sequenced. Using the sequence of RACE products, a 1.0 kb mouse neurturin cDNA sequence can be assembled. This cDNA sequence contains an open reading frame of 585 nucleotides that encodes a protein with a molecular mass of 24 kD. This full length mouse cDNA sequence is shown in Figure 7 (SEQ ID NO:12).

Consistent with the processing events known to occur for TGF- $\beta$  family members, the 24 kD neurturin protein contains an amino terminal 19 amino acid signal sequence followed by a pro-domain which contains an RXXR proteolytic processing site immediately before the N-terminal amino acid sequence obtained when sequencing the protein purified from CHO cell conditioned media. Using these landmarks, the 11.5 kD mature neurturin molecule is predicted to be 11.5 kD and, by analogy to other members of the TGF- $\beta$  family, is predicted to form a disulfide linked homodimer of 23 kD, consistent with the 25 kD mass of the protein purified from CHO cell conditioned media as estimated by SDS-PAGE analysis.

For isolation of human genomic clones, primers (#467524; 5'-CGCTACTGCGCAGGCGGTGCGARGCGGC, SEQ ID NO:60

and #10005, 5'-CGCCGACAGCTCTTGCAGCGTRTGGTA, SEQ ID NO:61) predicted from the sequence of mouse neurturin were used to amplify (PCR parameters: Initial denaturation at 95°C for 1 min 30 sec followed by 94°C for 30 sec; 60°C for 15 sec; and 68°C for 60 sec for 35 cycles) a 192 nucleotide fragment from human genomic DNA. The sequence of the PCR product demonstrated that it was the human homolog of mouse neurturin. The primers were then used to screen a human genomic library constructed in the P1 vector (library screening service, Genome Systems, Inc.) and two clones containing the human neurturin genomic locus were obtained.

The same strategy was used to determine the human sequence as discussed above for the mouse sequence. An oligo (#30152, GACCTGGGCCTGGGCTACGCGTCCGACGAG, SEQ ID NO:62) was used as a probe in a Southern blot analysis to identify restriction fragments of the P1 Clones which contained the human neurturin coding sequence. These restriction fragments (Eag I, Pvu II, Hind III, Kpn I) were subcloned into the Bluescript KS plasmid and sequenced.

The results of subcloning and sequencing of human genomic fragments were as follows. The Eag I fragment was found to be approximately 6 kb in size with the 3' Eag I site located 60 bp downstream from the stop codon. The Pvu II fragment was approximately 3.5 kb in size with the 3' Pvu II site located 250 bp downstream from the stop codon. The Hind III fragment was approximately 4.8 kb in size with the 3' Hind III site located 3kb downstream from the stop codon. The Kpn I fragment was approximately 4.2 kb in size with the 3' Kpn I site located 3.1 kb downstream from the stop codon.

The second coding exon was sequenced using these subcloned fragments. In addition, sequence was obtained from 250 bp flanking the 3' side of the second exon. The sequence was also obtained from 1000 bp flanking the 5'

side of the coding exon. From these flanking sequences, forward primer 30341 (5'-CTGGCGTCCCAMCAAGGGTCTTCG-3', SEQ ID NO:71) and reverse primer 30331 (5'-GCCAGTGGTGCCGTCGAGGCGGG-3', SEQ ID NO:72) were designed  
 5 so that the entire coding sequence of the second exon could be amplified by PCR.

The first coding exon was not mapped relative to the restriction sites above but was contained in the Eag I fragment. The sequence of this exon was obtained from  
 10 the subcloned Eag I fragment using the mouse primer 466215 (5'-GGCCCAGGATGAGGCGCTGGAAGG-3', SEQ ID NO:73), which contains the ATG initiation codon. Further sequence of the first coding exon was obtained with reverse primer 20215 (5'-CCACTCCACTGCCTGAWATTCWACCCC-3',  
 15 SEQ ID NO:74), designed from the sequence obtained with primer 466215. Forward primer 20205 (5'-CCATGTGATTATCGACCATTCGGC-3', SEQ ID NO:75) was designed from sequence obtained with primer 20215. Primers 20205 and 20215 flank the coding sequence of the first coding  
 20 exon and can be used to amplify this coding sequence using PCR.

The human cDNA and inferred amino acid sequence is shown in Figure 7 and the mouse cDNA and inferred amino acid sequence is shown in Figure 8.

25

#### Example 6

This example illustrates the preparation of expression vectors containing neurturin cDNA.

30 For expression of recombinant neurturin in mammalian cells the neurturin vector pCMV-NTN-3-1 was constructed. The 585 nucleotide open reading frame of the neurturin cDNA was amplified by PCR using a primer containing the first 27 nucleotides of the neurturin  
 35 coding sequence  
 (5'-GCGACGCGTACCATGAGGCGCTGGAAGGCAGCGGCCCTG, SEQ ID

NO:63) and a primer containing the last 5 codons and the stop codon (5'-GACGGATCCGCATCACACGCACGCGCACTC) (SEQ ID NO:64) using reverse transcribed postnatal day 1 mouse brain mRNA as template using (PCR parameters: 94°C for 30  
 5 sec; 60°C for 15 sec; and 68°C for 2 min for 35 cycles and including 5% DMSO in the reaction). The PCR product was subcloned into the Eco RV site of BSKS and sequenced to verify that it contained no PCR generated mutations. The neurturin coding sequence was then excised from this  
 10 vector using Mlu I (5' end) and Bam HI (3' end) and inserted downstream of the CMV IE promoter/enhancer in the mammalian expression vector pCB6 (Brewer, C.B. *Methods in Cell Biology* 43:233-245, 1994) to produce the pCMV-NTN-3-1 vector using these sites.

15 For expression of recombinant protein in E. Coli, the mature coding region of mouse neurturin was amplified by PCR using a primer containing the first 7 codons of the mature coding sequence (5'-GACCATATGCCGGGGGCTCGGCCTTGTGG) (SEQ ID NO:65) and a  
 20 primer containing the last 5 codons and the stop codon 5'-GACGGATCCGCATCACACGCACGCGCACTC (SEQ ID NO:66) using a fragment containing the murine neurturin gene as template using (PCR parameters: 94°C for 30 sec; 60°C for 15 sec and 68°C for 90 sec for 25 cycles with 5% DMSO added  
 25 into the reaction). The amplified product was subcloned into the Eco RV site of BSKS, the nucleotide sequence was verified, and this fragment was then transferred to the expression vector pET-30a (Novagen, Madison, WI) using an Nde I site (5' end) and an Eco RI site (3' end). The  
 30 pET-neurturin (pET-NTN) vector codes for an initiator methionine in front of the first amino acid of the mature mouse neurturin protein predicted from the N-terminal amino acid sequence of neurturin purified from the CHO cell conditioned media.

## Example 7

This example illustrates the transient transfection of NIH3T3 cells with the neurturin expression vector pCMV-NTN-3-1 and that the product of the genomic sequence in Example 5 is biologically active.

To demonstrate that the cloned neurturin cDNA was sufficient to direct the synthesis of biologically active neurturin we transiently introduced the pCMV-NTN-3-1 plasmid into NIH3T3 cells using the lipofectamine method of transfection. NIH3T3 cells were plated at a density of 400,000 cells per well (34.6 mm diameter) in 6 well plates (Corning, Corning, NY) 24 hours before transfection. DNA liposome complexes were prepared and added to the cells according to the manufacturer's protocol using 1.5 µg CMV-neurturin plasmid DNA (isolated and purified using a Qiagen (Chatsworth, CA) tip-500 column according to manufacturer's protocol) and 10 µl lipofectamine reagent (Gibco BRL, Gaithersburg, MD) in 1:1 DME/F12 medium containing 5 µg/ml insulin, 5 µg/ml transferrin, and 5 ng/ml sodium selenite (Sigma, St. Louis, MO). Five hours after the addition of DNA liposome complexes in 1 ml medium per well, 1 ml DME medium containing 20% calf serum was added to each well. Twenty-four hours after the addition of DNA-liposome complexes, the 2 ml medium above was replaced with 1 ml DME medium containing 10% calf serum, 2 mM glutamine, 100 U/ml penicillin, 100 µ/ml streptomycin, and 25 µg/ml heparin. The cells were incubated for an additional 24 hours before the conditioned medium was harvested, centrifuged to remove cellular debris, and frozen.

As a control, NIH3T3 cells were transfected as above using 1.5 µg CMV-neo expression plasmid (containing no cDNA insert) in place of the 1.5 µg CMV-neurturin plasmid. Conditioned medium from NIH3T3 cells transfected with either control plasmid or CMV-neurturin plasmid was assayed by direct addition to the SCG culture

medium at the time of NGF deprivation. Addition of 0.25 ml conditioned medium from CMV-neurturin-transfected cells promoted 70% survival of sympathetic neurons, and >90% survival could be obtained with 0.45 ml of this  
5 conditioned medium. No significant survival promoting activity was detected in the conditioned medium of control transfected NIH3T3 cells.

#### Example 8

10 This example illustrates the preparation of Chinese hamster ovary cells stably transformed with neurturin cDNA.

DG44 cells, a Chinese hamster ovary cell derivative that is deficient in dihydrofolate reductase  
15 (DHFR) (Urlaub et al *Cell* 3:405-412, 1983 which is incorporated by reference), were stably co-transfected with expression plasmid (pCMV-NTN-3-1) and a DHFR expression plasmid (HLD) (McArthur, and Stanners *J. Biol. Chem.* 266:6000-6005, 1991 which is incorporated by  
20 reference).

On day 1 DG44 cells were plated at  $1 \times 10^6$  cells per 10 cm plate in Ham's F12 medium with 10% fetal calf serum (FCS). This density must not be exceeded or cells will overgrow before selection media is added on day 5.

25 On day 2 cells were transfected with a 9:1 ratio of pCMV-NTN to DHFR expression plasmid using the calcium phosphate method (10 ug DNA /10 cm plate) (Chen and Okayama, *Mol Cell Biol* 7:2745-2752, 1987 which is incorporated by reference).

30 On day 3 the transfected cells were washed with Ham's F12 medium and fed Ham's F12 with 10% FCS.

On day 5 the cells were washed with MEM alpha medium and fed selection medium, which is MEM alpha with 10% FCS and 400 ug/ml G418. The cells were maintained in  
35 selection media, feeding every 4 days. Colonies began to appear approximately 14 days after transfection.

Colonies growing in selection media were then transferred to a 24 well plate and trypsinized the next day to disperse the cells. The cells were grown to confluence in either 24 well or 6 well plates in order to screen the cells for expression of recombinant protein. Expression of neuriturin was examined in 10 clonal lines and two high expressing lines were detected using the SCG survival assay. These clonal lines were expanded and expression in these selected cell lines was amplified by selection in 50 nM methotrexate (MTX). For selection in MTX, cells were grown to 50% confluence in a 150 cm<sup>2</sup> flask in selection medium. The medium was changed to MEM alpha containing 50 nM MTX concentration (it was not necessary to use G418 during MTX amplification). After placement in 50 nM MTX, the majority of cells died and colonies of resistant cells reappeared in 1-2 weeks. At this time, the cells were trypsinized to disperse colonies and are split when cells reach confluence. Cells eventually reached the same growth rate as before. The selected cells were screened for expression of recombinant protein. A 2-3 fold increase in expression was observed after selection in 50 nM MTX. Frozen stocks were kept for cell lines obtained from the original selection and the 50 nM MTX selection. Further selection could be continued in increasing MTX until desired levels of expression are obtained.

Using the above method, we isolated cells identified as DG44CHO5-3(G418)(pCMV-NTN-3-1) and DG44CHO5-3(50nMMTX)(pCMV-NTN-3-1). Cells from the DG44CHO5-3(50nMMTX)(pCMV-NTN-3-1) strain expressed levels of approximately 100 µg of biologically active protein per liter of conditioned media determined by direct assay of conditioned medium in SCG assay according to the methods in example 1.

## Example 9

This example illustrates the expression of neurturin in various tissues.

A survey of neurturin and GDNF expression was performed in rat embryonic tissues (E10, day 10 after conception), neonatal tissues (P1, Postnatal Day 1), and adult tissues (> 3 mos) using semi-quantitative RT/PCR (Estus et al., *J Cell Biol* 127:1717-1727, 1994 which is incorporated by reference). The RNA samples were obtained from various tissues and PCR products were detected either by autoradiography after incorporation of  $\alpha$ -<sup>32</sup>P-dCTP in the PCR and electrophoresis on a polyacrylamide gel (Figure 6) or by ethidium bromide staining of DNA after electrophoresis on agarose gels (Tables 3 and 4). The neurturin fragment of 101 base pairs was obtained using the forward primer CAGCGACGACGCGTGCGCAAAGAGCG (SEQ ID NO:67) and reverse primer TAGCGGCTGTGTACGTCCAGGAAGGACACCTCGT (SEQ ID NO:68) and the GDNF fragment of 194 base pairs was obtained using the forward primer AAAAATCGGGGGTGYGTCTTA (SEQ ID NO:69) and the reverse primer CATGCCTGGCCTACYTTGTCA (SEQ ID NO:70).

No neurturin or GDNF mRNA was detected at the earliest embryonic age (embryonic day 10, E10) surveyed.

In neonates (postnatal day 1, P1) both transcripts were expressed in many tissues although neurturin tended to show a greater expression in most tissues than did GDNF. (see table 3).



Table 3.

		NEURTURIN	GDNF
	Liver	+++	-
5	Blood	+++	+
	Thymus	+	-
	Brain	++	+
	Sciatic nerve	-	+
10	Kidney	++	++
	Spleen	++	+
	Cerebellum	++	+
	Heart	++	+
15	Bone	+	+

As shown in Table 3, differences in the tissue distributions of neurturin and GDNF were noted. In particular, no GDNF was detected in liver and thymus where neurturin expression was detected and no neurturin was detected in sciatic nerve where GDNF was detected.

Neurturin and GDNF mRNA were detected in many tissues in the adult animal, but the tissue-specific pattern of expression for these two genes was very different. (table 4, Figure 5).

Table 4.

		NEURTURIN	GDNF
	Liver	-	-
5	Blood	+	-
	Thymus	+	++
	Brain	+	-
	Sciatic nerve	-	-
10	Kidney	++	+
	Spleen	-	+
	Cerebellum	-	-
	Uterus	++	-
	Bone marrow	++	-
15	Testis	++	++
	Ovary	+	+
	Placenta	+	-
	Skeletal muscle	+	-
20	Spinal cord	+	-
	Adrenal gland	++	++
	Gut	+	++

25           As shown in table 4, neurturin was found to be expressed in brain and spinal cord as well as in blood and bone marrow where no GDNF was detected. The level of expression of neurturin in brain and blood was, however, less than that detected in neonatal tissue.

30           Neurturin was also highly expressed in freshly isolated rat peritoneal mast cells, whereas GDNF showed little or no expression.

#### Example 10

35           This example illustrates the preparation of antisera to neurturin by immunization of rabbits with a neurturin peptide.

The peptide sequence corresponding to amino acids 73-87 of the mature murine neurturin protein was synthesized and coupled to keyhole limpet hemocyanin (KLH) as described earlier (Harlow and Lane, *Antibodies: a laboratory manual*, 1988. Cold Spring Harbor Laboratory, New York, NY. p. 72-81 which is incorporated by reference). The KLH-coupled peptide was submitted to Caltag, Inc. and each of two rabbits were immunized. Immunization was by subcutaneous injection at 7-10 sites. The first injection was with 150 µg KLH-coupled peptide which was resuspended in 0.5 ml saline and emulsified with 0.5 ml complete Freund's adjuvant. Boost injections were begun 4 weeks after the initial injection and were performed once every 7 days as above for a total of 5 injections except that 100 µg of KLH-coupled peptide and incomplete Freund's adjuvant were used. Serum samples were collected 1 week after the fifth boost.

A pooled volume of twenty ml of serum that had been collected from both rabbits one week after the 5th injection was purified. For purification, a peptide affinity column was prepared by coupling the above peptide to cyanogen bromide activated Sepharose 4B according to the manufacturers protocol (Pharmacia Biotech). The serum was diluted 10 fold in 10 mM Tris pH 7.5 buffer and mixed by gentle rocking for 16 hours at 4°C with 0.5 ml of peptide agarose matrix containing 5 mg of coupled peptide. The matrix was placed into a column, washed with 5 ml of 10 mM Tris pH 7.5, 150 mM NaCl, washed with 5 ml of 10 mM Tris pH 7.5 buffer containing 0.4 M NaCl and eluted with 5.5 ml of 100 mM glycine pH 2.5 buffer. One tenth volume of 1.0M Tris pH 8.0 buffer was added to the eluate immediately after elution to neutralize the pH. The glycine eluate was dialyzed overnight against 10 mM Tris pH 7.5, 150 mM NaCl.

The affinity-purified antibodies were used in a western blot to demonstrate specific recognition of

recombinant neurturin protein. Ten ml of conditioned medium collected from DG44CHO5-3(G418)(pCMV-NTN-3-1) cells was purified over SP Sepharose as described in Example 1 and the proteins electrophoresed on a reducing SDS-PAGE gel in the tricine buffer system (Schagger and von Jagow *Analytical Biochemistry* 166:368-379, 1987). The proteins were electroblotted to a nitrocellulose membrane in 25 mM Tris, 192 mM glycine, 0.04% SDS, 17% methanol at 4°C for 16 hr. The membrane was incubated with the affinity-purified anti-neurturin peptide antibodies and then with horseradish peroxidase-coupled sheep anti-rabbit IgG (Harlow and Lane, *supra*, p. 498-510). Bound antibodies were detected with enhanced chemiluminescence (ECL kit, Amersham, Buckinghamshire, England). The anti-neurturin antibodies recognized a single, approximately 11.5 kD protein band in the conditioned medium of the DG44CHO5-3(G418)(pCMV-NTN-3-1) cells. Using these anti-neurturin antibodies, neurturin protein could be detected in 10 ml of conditioned medium from DG44CHO5-3(G418)(pCMV-NTN-3-1) cells but could not be detected in 10 ml of medium conditioned with DG44 cells that had not been transformed with the neurturin expression vector.

25

#### Example 11

The following example illustrates the identification of additional members of the GDNF/neurturin/persephin gene subfamily.

The TGF- $\beta$  superfamily currently contains over 25 different gene members (for review see Kingsley, *Genes and Development* 8: 133-146, 1994 which is incorporated by reference). The individual family members display varying degrees of homology with each other and several subgroups within the superfamily can be defined by phylogenetic analysis using the Clustal V program (Higgins et al, *Comput Appl Biosci* 8: 189-191, 1992 which

is incorporated by reference) and by bootstrap analysis of phylogenetic trees (Felsenstein, *Evolution* 39:783-791, 1985 which is incorporated by reference). Neurturin or persephin is approximately 40% identical to GDNF but less than 20% identical to any other member of the TGF- $\beta$  superfamily. Several sequence regions in neurturin can be identified (Figure 5) that are highly conserved within the GDNF/neurturin/persephin subfamily but not within the TGF- $\beta$  superfamily. These conserved regions are likely to characterize a subfamily containing previously unisolated genes, which can now be isolated using the conserved sequence regions identified by the discovery and sequencing of the neurturin and persephin genes. Regions of high sequence conservation between neurturin, persephin and GDNF allow the design of degenerate oligonucleotides which can be used either as probes or primers. Conserved-region amino acid sequences have been identified herein to include Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser, Thr or Ala and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:108); Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>4</sub>-Gly-Xaa<sub>5</sub>-Cys in which Xaa<sub>1</sub> is Thr, Glu or lys, Xaa<sub>2</sub> is Val, Leu or Ile, Xaa<sub>3</sub> is Leu or Ile, Xaa<sub>4</sub> is Ala or Ser, and Xaa<sub>5</sub> is Ala or Ser, (SEQ ID NO:113); and Cys-Cys-Xaa<sub>1</sub>-Pro-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Xaa<sub>5</sub>-Asp-Xaa<sub>6</sub>-Xaa<sub>7</sub>-Xaa<sub>8</sub>-Phe-Leu-Asp-Xaa<sub>9</sub> in which Xaa<sub>1</sub> is Arg or Gln, Xaa<sub>2</sub> is Thr or Val or Ile, Xaa<sub>3</sub> is Ala or Ser, Xaa<sub>4</sub> is Tyr or Phe, Xaa<sub>5</sub> is Glu, Asp or Ala, Xaa<sub>6</sub> is Glu, Asp or no amino acid, Xaa<sub>7</sub> is val or leu, Xaa<sub>8</sub> is Ser or Thr, and Xaa<sub>9</sub> is Asp or Val (SEQ ID NO:114). Nucleotide sequences containing a coding sequence for the above conserved sequences or fragments of the above conserved sequences can be used as probes. Exemplary probe and primer sequences which can be designed from these regions are as follows.

Forward primers,

35           Primer A (M3119): 5'-GTNDGNGANYTGGGNYTGGGNTA (SEQ ID NO:115) 23 nt which codes for the amino acid

sequence, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Thr, Ser or Ala and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:125);

5       Primer B (M3123): 5'-GANBTNWCNTTTYTNGANG (SEQ ID NO:116) 19 nt which codes for the amino acid sequence, Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser, Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val  
10       (SEQ ID NO:126);

15       Primer C (M3126): 5'-GANBTNWCNTTTYTNGANGW (SEQ ID NO:117) 20 nt which codes for the amino acid sequence, Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser, Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val (SEQ ID NO:126);

20       Primer D (M3121): 5'-TTYMGNTAYTGYDSNGGNDSTG (SEQ ID NO:118) 23 nt which codes for the amino acid sequence, Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys where Xaa<sub>1</sub> is Ser or Ala and Xaa<sub>2</sub> is Ser or Ala (SEQ ID NO:127);

25       Primer E (M3122): 5'-GTNDGNGANYTGGGNYTNGG (SEQ ID NO:119) 20 nt which codes for the amino acid sequence, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly where Xaa<sub>1</sub> is Thr, Ser or Ala and Xaa<sub>2</sub> is Asp or Glu (SEQ ID NO:128); and

30       Primer F (M3176): 5'-GTNDGNGANYTGGGNYTGGGNTT (SEQ ID NO:120) 23 nt which codes for the amino acid sequence, Val-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Phe where Xaa<sub>1</sub> is Thr, Ser or Ala and Xaa<sub>2</sub> is Glu or Asp  
35       (SEQ ID NO:129).

Reverse primers,

Primer G (M3125): 5'-WCNTCNARRAANGWNAVNTC (SEQ ID NO:121) 20 nt whose reverse complementary sequence codes for the amino acid sequence,

5 Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser, Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val (SEQ ID NO:126);

10 Primer H (M3124): 5'-WCNTCNARRAANGWNAVNT (SEQ ID NO:122) 19 nt whose reverse complementary sequence codes for the amino acid sequence,

Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Leu-Xaa<sub>4</sub>-Xaa<sub>5</sub> where Xaa<sub>1</sub> is Asp or Glu, Xaa<sub>2</sub> is Val or Leu, Xaa<sub>3</sub> is Thr or Ser,  
15 Xaa<sub>4</sub> is Asp or Glu, and Xaa<sub>5</sub> is Asp or Val (SEQ ID NO:126);

Primer I (M3120): 5'-CANSHNCCNSHRCARTANCKRAA (SEQ ID NO:123) 23 nt whose reverse complementary sequence codes for the amino acid sequence,  
20 Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys where Xaa<sub>1</sub> is Ser or Ala and Xaa<sub>2</sub> is Ser or Ala (SEQ ID NO:127); and

Primer J (M3118): 5'-CANSHNCCNSHRCARTANCKRAANA (SEQ ID NO:124) 25 nt whose reverse complementary sequence codes for the amino acid sequence,  
25 Xaa<sub>1</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>2</sub>-Gly-Xaa<sub>3</sub>-Cys where Xaa<sub>1</sub> is Ile or Leu, Xaa<sub>2</sub> is Ser or Ala and Xaa<sub>3</sub> is Ser or Ala (SEQ ID NO:130).

30 In addition to the above, the following primers are based upon conserved regions in GDNF and neurturin (SEQ ID NOS:33-35).

Primer 1, GTNWSNGANYTNGGNYTNGGNTA (SEQ ID NO:42) which encodes the amino acid sequence, Val-Xaa<sub>1</sub>-  
35 Xaa<sub>2</sub>-Leu-Gly-Leu-Gly-Tyr where Xaa<sub>1</sub> is Ser or Thr and Xaa<sub>2</sub> is Glu or Asp (SEQ ID NO:33);

Primer 2, TTYMGNTAYTGYDSNGGNDSENTGYGANKCNGC (SEQ ID NO:43) which encodes amino acid sequence Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Ala where Xaa<sub>1</sub> is Ala or Ser, Xaa<sub>2</sub> is Ala or Ser, Xaa<sub>3</sub> is Glu or Asp and Xaa<sub>4</sub> is Ser or Ala (SEQ ID NO:36);

Primer 3 reverse GCNGMNTCRCANSHNCCNSHRTANCKRAA (SEQ ID NO:44) whose reverse complementary sequence encodes amino acid sequence Phe-Arg-Tyr-Cys-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Ala where Xaa<sub>1</sub> is Ala or Ser, Xaa<sub>2</sub> is Ala or Ser, Xaa<sub>3</sub> is Glu or Asp and Xaa<sub>4</sub> is Ser or Ala (SEQ ID NO:37);

Primer 4 reverse TCRTCNTCRWANGCNRYNGGNCKCARCA (SEQ ID NO:45) whose reverse complementary sequence encodes amino acid sequence Cys-Cys-Arg-Pro-Xaa<sub>1</sub>-Ala-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Asp-Xaa<sub>4</sub> where Xaa<sub>1</sub> is Ile or Thr or Val, Xaa<sub>2</sub> Try or Phe, Xaa<sub>3</sub> is Glu or Asp and Xaa<sub>4</sub> is Glu or Asp (SEQ ID NO:38);

Primer 5 reverse TCNARRAANSWNAVNTCRTCNTCRWANGC (SEQ ID NO:46) whose reverse complementary sequence encodes amino acid sequence Ala-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Asp-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Ser-Phe-Leu-Asp where Xaa<sub>1</sub> is Tyr or Phe, Xaa<sub>2</sub> Glu or Asp, Xaa<sub>3</sub> is Glu or Asp, and Xaa<sub>4</sub> is Val or Leu (SEQ ID NO:39);

Primer 6 GARRMNBNTNHTNTTYMGNTAYTG (SEQ ID NO:47) which encodes amino acid sequence Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys where Xaa<sub>1</sub> is Glu or Thr, Xaa<sub>2</sub> is Leu or Val and Xaa<sub>3</sub> is Ile or Leu (SEQ ID NO:40);

Primer 7 GARRMNBNTNHTNTTYMGNTAYTGYDSNGGNDSENTGHGA (SEQ ID NO:48) which encodes amino acid sequence Glu-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Xaa<sub>3</sub>-Phe-Arg-Tyr-Cys-Xaa<sub>4</sub>-Gly-Xaa<sub>5</sub>-



Cys-Xaa<sub>6</sub> where Xaa<sub>1</sub> is Glu or Thr, Xaa<sub>2</sub> is Leu or Val, Xaa<sub>3</sub> is Ile or Leu, Xaa<sub>4</sub> is Ser or Ala, Xaa<sub>5</sub> is Ser or Ala and Xaa<sub>6</sub> is Glu or Asp (SEQ ID NO:41).

5       The above sequences can be used as probes for screening libraries of genomic clones or as primers for amplifying gene fragments from genomic DNA or libraries of genomic clones or from reverse transcribed cDNA using RNA templates from a variety of tissues. Genomic DNA or  
10 libraries of genomic clones can be used as templates because the neurturin, persephin and GDNF coding sequences for the mature proteins are not interrupted by introns.

A degenerate oligonucleotide can be synthesized as  
15 a mixture of oligonucleotides containing all of the possible nucleotide sequences which code for the conserved amino acid sequence. To reduce the number of different oligonucleotides in a degenerate mix, an inosine or universal base (Loakes et al, *Nucleic Acids*  
20 Res 22:4039-43, 1994) can be incorporated in the synthesis at positions where all four nucleotides are possible. The inosine or universal base forms base pairs with each of the four normal DNA bases which are less stabilizing than AT and GC base pairs but which are also  
25 less destabilizing than mismatches between the normal bases (i.e. AG, AC, TG, TC).

To isolate family members a primer above can be end labeled with <sup>32</sup>P using T4 polynucleotide kinase and hybridized to libraries of human genomic clones according  
30 to standard procedures.

A preferred method for isolating family member genes would be to use various combinations of the degenerate primers above as primers in the polymerase chain reaction using genomic DNA as a template. The  
35 various combinations of primers can include sequential PCR reactions utilizing nested primers or the use of a

forward primer paired with an oligo dT primer. In addition, one of the degenerate primers can be used with a vector primer, a single primer can be used in an inverted PCR assay or PCR can be performed with one  
5 degenerate primer and a random primer. As an example using the above set of primers, primer 2 (SEQ ID NO:43) can be used with primer 4 (SEQ ID NO:45) in PCR with 1 ug of human genomic DNA and cycling parameters of 94°C for 30 sec, 50°C for 30 sec, and 72°C for 60 sec. The above  
10 PCR conditions are exemplary only and one skilled in the art will readily appreciate that a range of suitable conditions and primer combinations could be used or optimized such as different temperatures and varying salt concentrations in the buffer medium and the like. It is  
15 preferred that DMSO be added to the PCR reaction to a final concentration of 5% inasmuch as this was found to be necessary for amplification of this region of the neurturin gene. The PCR reaction, when run on an agarose gel, should contain products in the size range of 100-150  
20 base pairs since a one amino acid gap is introduced in the neurturin sequence and a five amino acid gap is introduced in the persephin sequence when either sequence is aligned with GDNF, and thus family member genes might also contain a slightly variable spacing between the  
25 conserved sequences of primers 2 and 4. The PCR products in the range of 100-150 base pairs should contain multiple amplified gene products including GDNF, neurturin and persephin as well as previously unisolated family members. To identify sequences of these products,  
30 they can be gel purified and ligated into the Bluescript plasmid (Stratagene), and then transformed into the XL1-blue E. Coli host strain (Stratagene). Bacterial colonies containing individual subclones can be picked for isolation and plated on nitrocellulose filters in two  
35 replicas. Each of the replicate filters can be screened with an oligonucleotide probe for either unique GDNF or

unique neurturin or unique persephin sequence in the amplified region. Subclones not hybridizing to either GDNF or neurturin or persephin can be sequenced and if found to encode previously unisolated family members, the sequence can be used to isolate full length cDNA clones and genomic clones as was done for neurturin (Example 5). A similar method was used to isolate new gene members (GDF-3 and GDF-9) of the TGF- $\beta$  superfamily based on homology between previously identified genes (McPherron *J Biol Chem* 268: 3444-3449, 1993 which is incorporated by reference).

The inventors herein believe that the most preferred way to isolate family member genes may be to apply the above PCR procedure as a screening method to isolate individual family member genomic clones from a library. This is because there is only one exon for the coding region of both mature neurturin and GDNF. If, for example, the above PCR reaction with primers 2 and 4 generates products of the appropriate size using human genomic DNA as template, the same reaction can be performed using, as template, pools of genomic clones in the P1 vector according to methods well known in the art, for example that used for isolating neurturin human genomic clones (Example 5). Pools containing the neurturin gene in this library have previously been identified and persephin and GDNF-containing pools can be readily identified by screening with GDNF and PSP specific primers. Thus non-neurturin, non-persephin, non-GDNF pools which generate a product of the correct size using the degenerate primers will be readily recognized as previously unisolated family members. The PCR products generated from these pools can be sequenced directly using the automated sequencer and genomic clones can be isolated by further subdivision and screening of the pooled clones as a standard service offered by Genome Systems, Inc.

## Example 12

The following example illustrates the isolation and identification of persephin utilizing the procedures and primers described in Example 11.

5       The degenerate PCR strategy devised by the inventors herein has now been successfully utilized to identify a third factor, persephin, that is approximately 35-50% identical to both GDNF and neurturin. The experimental approach was described above and is provided  
10 in greater detail as follows. Primers corresponding to the amino acid sequence Val-Xaa1-Xaa2-Leu-Gly-Leu-Gly-Tyr where Xaa1 is Ser or Thr and Xaa2 is Glu or Asp (SEQ ID NO:33) [M1996; 5'-GTNWSNGANYTNGGNYTNGGNTA (SEQ ID NO:42)] and Phe-Arg-Tyr-Cys-Xaa1-Gly-Xaa2-Cys-Xaa3-Xaa4-Ala where  
15 Xaa1 is Ala or Ser, Xaa2 is Ala or Ser, Xaa3 is Glu or Asp and Xaa4 is Ser or Ala (SEQ ID NO:37) [M1999; 5'-GCNGMNTCRCANSHNCCNSHRCARTANCKRAA (SEQ ID NO:44)] were used to amplify a 77 nt fragment from rat genomic DNA using Klentaq enzyme and buffer under the following  
20 conditions: 94°C for 30 sec; 44°C for 30 sec; 72°C for 30 sec for 40 cycles. The resulting product was subcloned into the Bluescript KS plasmid and sequenced. All nucleotide sequencing was performed using fluorescent dye terminator technology per manufacturer's instructions  
25 on an Applied Biosystems automated sequencer Model #373 (Applied Biosystems, Foster City, CA). Plasmid DNA for sequencing was prepared using the Wizard Miniprep kit (Promega Corp., Madison, WI) according to the manufacturer's instructions.

30       The sequence of one of the amplified products predicted amino acid sequence data internal to the PCR primers that was different from that of GDNF or neurturin but had more than 20% identity with GDNF and neurturin, whereas the sequences of others we obtained corresponded  
35 to GDNF or neurturin, as would be expected. The novel

sequence was thought to identify a new member of this family which we named persephin.

The sequence of this fragment internal to the primers was 5'-TGCCTCAGAGGAGAAGATTATC (SEQ ID NO:90).

- 5 This encodes the last nucleotide of the Tyr codon, and then encodes the amino acids: Ala-Ser-Glu-Glu-Lys-Ile-Ile (SEQ ID NO:91). This sequence was then aligned with the rat sequences of GDNF and neurturin. This analysis confirmed that persephin was unique.
- 10 LGLGYETKEELIFRYC GDNF (rat) (SEQ ID NO:92)  
 LGLGYTSDETVLFYRC NTN (rat) (SEQ ID NO:93)  
 LGLGYASEEKIIFRYC PSP (rat) (SEQ ID NO:94)

- To obtain additional persephin sequence, primers
- 15 containing portions of the unique 22 nt of the amplified fragment above were used in the rapid amplification of cDNA ends (RACE) technique (Frohman, M.A. *Methods in Enzymology* 218:340-356, 1993) using the Marathon RACE kit (CLONTECH, Palo Alto, CA) per the manufacturer's
- 20 instructions, except that first strand cDNA synthesis was carried out at 50°C using Superscript II reverse transcriptase (Gibco-BRL). Briefly, a double stranded adaptor oligonucleotide was ligated to the ends of double stranded cDNA synthesized from postnatal day 1 rat brain
- 25 mRNA. Using nested forward persephin PCR primers, (10135; 5'-AGTCGGGGTTGGGGTATGCCTCA, SEQ ID NO:95 and M2026; 5'-TATGCCTCAGAGGAGAAGATTATCTT SEQ ID NO:96) in combination with primers to the ligated adaptor supplied in the kit (AP1, AP2), the 3' end of the persephin cDNA
- 30 was amplified by two successive PCR reactions (1st: 10135 and AP1, using 94°C for 30 sec, 60°C for 15 sec and 68°C for 2 min for 35 cycles; 2nd: M2026 and AP2 using 94°C for 30 sec, 60 for 15 sec and 68°C for 2 min for 21 cycles). An approximately 350 nt fragment was obtained
- 35 from this PCR reaction and this fragment was directly sequenced using primer M2026. The sequence of this 3' RACE product resulted in a partial rat persephin cDNA sequence of approximately 350 nt (SEQ ID NO:97). The

predicted amino acid sequence of this cDNA was compared to that of GDNF and neurturin, and found to be approximately 40% homologous to each of these proteins. Importantly, the characteristic spacing of the cyteine residues in members of the TGF- $\beta$  superfamily was present. Furthermore, in addition to the region of similarity encoded by the degenerate primers used to isolate persephin, another region of high homology shared between GDNF and neurturin, but absent in other members of the TGF- $\beta$  superfamily, was also present in persephin

GDNF ACCRPVAFDDDLFLDD (aa 60-76) (SEQ ID NO:98)  
 NTN PCCRPTAYEDEVSKDV (aa 61-77) (SEQ ID NO:99)  
 PSP PCCQPTSYAD-VTFLDD (aa 57-72) (SEQ ID NO:100)

(Amino acid numbering uses the first Cys residue as amino acid 1).

With the confirmation that persephin was indeed a new member of the GDNF/neurturin subfamily, we isolated murine genomic clones of persephin to obtain additional sequence information. Primers (forward, M2026; 5'-TATGCCTCAGAGGAGAAGATTATCTT, SEQ ID NO:96 and reverse, M3028; 5'-TCATCAAGGAAGGTCACATCAGCATA, SEQ ID NO:101) corresponding to rat cDNA sequence were used in a PCR reaction (PCR parameters: 94°C for 30 sec, 55°C for 15 sec and 72°C for 30 sec for 35 cycles) to amplify a 155 nt fragment from mouse genomic DNA which was homologous to rat persephin cDNA sequence. These primers were then used to obtain murine persephin genomic clones from a mouse 129/Sv library in a P1 bacteriophage vector (library screening service of Genome Systems, Inc., St. Louis, MO).

Restriction fragments (3.4 kb Nco I and a 3.3 kb Bam H1) from this P1 clone containing the persephin gene were identified by hybridization with a 210 nt fragment obtained by PCR using mouse genomic DNA with primers (forward, M2026; SEQ ID NO:96 and reverse, M3159; 5'-CCACCACAGCCACAAGCTGCGGSTGAGAGCTG, SEQ ID NO:102) and PCR

parameters: 94°C for 30 sec, 55°C for 15 sec and 72°C for 30 sec for 35 cycles. The Nco I and Bam HI fragments were sequenced and found to encode a stretch of amino acids corresponding to that present in the rat persephin RACE product, as well as being homologous to the mature regions of both neurturin and GDNF (Figure 11).

When the amino acid sequences of murine GDNF, neurturin and persephin are aligned using the first cysteine as the starting point (which is done because alterations in the cleavage sites between family members creates variability in the segments upstream of the first cysteine), persephin (91 amino acids) is somewhat smaller than either neurturin (95 amino acids) or GDNF (94 amino acids). The overall identity within this region is about 50% with neurturin and about 40% with GDNF (Figure 12).

Further nucleotide sequencing of the murine persephin Nco I fragment revealed the nucleotide sequence of the entire murine persephin gene (SEQ ID NO:131;<sup>177</sup> Figure 17A). An open reading frame extends from the sequence coding for an initiator methionine up to a stop codon at positions 244-246. However, somewhere in this sequence there is an apparent anomaly such that the sequence encoding the RXXR cleavage site (nucleotides at positions 257-268) and the sequence corresponding to the mature persephin protein (positions 269-556) are not co-linear with this open reading frame. Instead, a second reading frame encodes the cleavage site and the mature persephin.

Additional sequencing of the rat persephin has also been performed. Rat genomic fragments were amplified by PCR using Klentaq and rat genomic DNA as a template. The forward primer #40266 (5'-AATCCCCAGGACAGGCAGGGAAT; SEQ ID NO:137) corresponding to a region upstream of the mouse persephin gene and a reverse primer M3156 (5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC, SEQ ID NO:138) corresponding to a region within the mature rat persephin

sequence were used with the following parameters (95°C for 15 sec, 55°C for 15 sec, 68°C for 45 sec x 30 cycles). The amplified product was kinased with T4 polynucleotide kinase, the ends were blunted with E. coli DNA polymerase I (Klenow fragment), and cloned into BSKS plasmid.

Nucleotide sequencing was performed to establish the sequence of the entire rat persephin gene (SEQ ID NO:134<sup>186</sup>; Figure 18A). An open reading frame was found to extend from the sequence coding for an initiator methionine up to a stop codon at positions 244-246 as was seen with murine persephin. As was also seen with murine persephin, an anomaly was found to occur between the sequence encoding the initiator methionine and that encoding the cleavage site for the mature rat persephin such that two cogent reading frames exist. Irrespective of this anomaly, mammalian cells were found to express persephin from either the murine or rat full length genomic sequence as illustrated below (see Example 14).

To pursue the genesis of this anomaly, we prepared mammalian expression vectors for both murine and rat persephin. To construct the murine plasmid, a P1 clone containing the murine persephin gene was used as a template in a PCR assay. Primers were designed such that the resulting fragment would contain the persephin gene extending from the initiator Methionine to the stop codon. The PCR reaction utilized a forward primer M3175 [5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA]<sup>140</sup> and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]<sup>138</sup>. To construct the analogous rat plasmid, rat genomic DNA was used as a template in a PCR assay. The PCR reaction utilized a forward primer M3175 [5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA] and reverse primer M3156 [5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC]. The amplified products were cloned into BSKS and sequenced to verify that the correct clone had been obtained. The rat



and murine persephin fragments were excised using Sma I and Hind III and cloned into a Asp718 (blunted) and Hind III sites of the mammalian expression vector pCB6.

COS monkey cells were transfected with either the  
5 rat or murine persephin expression vectors or the non-recombinant vector (pCB6) itself. Forty eight hr later the cells were lysed, the samples were loaded onto a 15% SDS-polyacrylamide gel, and the proteins were separated by electrophoresis. The proteins were then transferred  
10 to nitrocellulose by electroblotting. This nitrocellulose membrane was incubated with anti-persephin antibodies (which we raised to mature persephin produced in bacteria from a pET plasmid) to detect the presence of persephin in the lysates. Lysates from cells transfected  
15 with either the rat or murine persephin expression vectors, but not the lysate from cells transfected with pCB6, contain high amounts of persephin. The size of the persephin detected was 10-15 kD, consistent with the size predicted for the processed (i.e. mature form of  
20 persephin). Conditioned media harvested from these cells also contained mature persephin. These results demonstrate that both the murine and rat persephin genes are capable of directing the synthesis of a properly processed persephin molecule.

25 To pursue the mechanism by which this occurred, we isolated RNA from cells transfected with either rat or murine persephin expression vector. RT/PCR analysis was performed using primers corresponding to the initiator Met and the stop codon. We detected two fragments: one  
30 corresponding to the predicted size of the persephin gene and the other somewhat smaller, suggesting that RNA splicing had occurred. We confirmed this with a number of other primer pairs. Both the large and small persephin fragments were cloned and sequenced. As  
35 expected, the larger fragment corresponded to the persephin gene. The small fragment corresponded to a

spliced version of persephin. A small 88 nt intron within the pro-domain (situated 154 nt downstream of the start codon) had been spliced out. After this splicing event, the "frameshift" was no longer present (i.e. the initiator Met and the mature region are in-frame) in either rat or mouse persephin (see Figures 17B and 18B).

### Example 13

This example illustrates the preparation of a bacterial expression vector for murine persephin and its introduction into an *E. Coli* for expression of recombinant mature persephin.

The persephin polynucleotide encoding the mature murine persephin protein which begins 5 amino acids upstream of the first framework Cys residue (SEQ ID NO:80) was cloned into the pET expression vector pET-30a at the Nde I and Bgl II sites. This persephin polynucleotide was generated by PCR using the murine persephin P1 genomic clone as a template. A forward primer M3157 (5'-GGACTATCATATGGCCCACCACCACCACCACCACCACGACGACGACACAAGGCCTTGGCTGGTTCATGCCGA, SEQ ID NO:139) encoding an Nde I site, 8 histidine residues, and an enterokinase site, and a reverse primer M3156 (5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC, SEQ ID NO:138), which corresponds to the sequence encoding the last 6 amino acid residues of the mature persephin sequence, the stop codon and a Bgl II site, were used. The PCR reaction conditions were 95°C for 15 sec, 55°C for 15 sec, 68°C for 60 sec x 25 cycles. This PCR product was subcloned into the EcoRV site of BSKS plasmid and sequenced to verify that it contained no mutations. The persephin sequence was then excised from this vector using Nde I and Bgl II and cloned into the Nde I (5') and Bgl II (3') sites of the bacterial expression vector pET30a (Novagen, Madison, WI). This expression vector

would, therefore, produce the mature form of the persephin protein possessing an amino terminal tag consisting of 8 histidine residues followed directly by an enterokinase site.

5        The plasmid was introduced into E.coli strain BL21 (DE3). To produce persephin, bacteria harboring this plasmid were grown for 16 hr, harvested, and lysed using 6M guanidine-HCl, 0.1 M  $\text{NaH}_2\text{PO}_4$ , 0.01 M Tris at pH 8.0, and recombinant persephin protein was purified from these  
10 lysates via chromatography over a Ni-NTA resin (Qiagen). The protein was eluted using 3 column volumes of Buffer E containing 8 M urea, 0.1 M  $\text{NaH}_2\text{PO}_4$ , 0.01 M Tris, at pH 4.5. The persephin was then renatured by dialysis in renaturation buffer consisting of 0.1 M  $\text{NaH}_2\text{PO}_4$ , 0.01 M  
15 Tris at pH 8.3, 0.15 M NaCl, 3 mM cysteine, 0.02% Tween-20, 10% glycerol and containing decreasing concentrations of urea beginning with 4 M for 16 hr, followed by 2 M for 16 hr, 1M for 72 hr, and 0.5 M for 16 hr. The persephin concentration was then determined using a Dot Metric  
20 assay (Geno Technology, St. Louis, MO) and stored at 4°C.

This bacterially produced recombinant persephin was used as an immunogen in rabbits to produce antibodies to mature persephin. All of the immunogen injections and blood drawing were performed at Cal Tag Inc. (Healdsburg,  
25 CA). The anti-persephin antiserum was demonstrated to specifically recognize persephin, but not neurturin or GDNF, using protein blot analysis. This persephin-specific antiserum was then used to detect persephin in lysates prepared from transfected COS cells.

30

#### Example 14

This example illustrates the preparation of mammalian expression vectors containing the murine or rat persephin genes and their incorporation into mammalian  
35 cell lines for the production of mature persephin. To construct the murine plasmid, a P1 clone containing the

murine persephin gene was used as a template in a PCR assay. Primers were designed such that the resulting polynucleotide would contain the persephin gene extending from the initiator Methionine codon to the stop codon 3' to the mature persephin coding sequence (SEQ ID NO:131). The PCR reaction utilized a forward primer M3175 (5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA, SEQ ID NO:140) and reverse primer M3156 (5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC, SEQ ID NO:138). To construct the analogous rat plasmid, rat genomic DNA was used as a template in a PCR assay. The PCR reaction utilized a forward primer M3175 (5'-TGCTGTCACCATGGCTGCAGGAAGACTTCGGA, SEQ ID NO:140) and reverse primer M3156 (5'-CGGTACCCAGATCTTCAGCCACCACAGCCACAAGC, SEQ ID NO:138). Both PCR reactions were carried out using KlenTaq and the following parameters: 95°C for 15 sec, 55°C for 15 sec, 68°C for 45 sec x 25 cycles. The amplified products were kinased with T4 polynucleotide kinase, the ends were blunted with E. coli DNA polymerase I (Klenow fragment), and cloned into BSKS plasmid. Nucleotide sequencing was performed to verify that the correct clone was obtained. The rat and murine persephin polynucleotides were excised using Sma I and Hind III and each cloned into a Asp718 (blunted) and Hind III sites of the mammalian expression vector pCB6.

COS monkey cells were transfected with either the rat or murine persephin expression vectors (16 µg per 5 x 10<sup>5</sup> cells) or the non-recombinant vector (pCB6) itself using the calcium phosphate precipitation method (Chen and Okayama, *Mol Cell Biol* 7:2745-2752, 1987 which is incorporated by reference). Forty eight hr later the cells were lysed in IP buffer containing 50 mM Tris at pH 7.5, 300 mM NaCl, 1% Triton X-100, 1% deoxycholate, 10 mM EDTA, 0.1% SDS, 5 µg/ml leupeptin, 7 µg/ml pepstatin, and 250 µM PMSF. The samples were loaded onto a 15% SDS-

polyacrylamide gel and the proteins were separated by electrophoresis. The proteins were then transferred to nitrocellulose by electroblotting. This nitrocellulose membrane was incubated with anti-persephin antibodies to  
 5 detect the presence of persephin in the lysates.

As is shown in Figure 19, lysates from cells transfected with either the rat or murine persephin expression vectors, but not the lysate from cells transfected with pCB6, contain high amounts of persephin.  
 10 The size of the persephin detected was approximately 14 kD which is consistent with the size predicted for the processed, i.e. mature form of persephin. This demonstrates that both the murine and rat persephin genes are capable of directing the synthesis of a properly  
 15 processed persephin molecule.

#### Example 15

The following example illustrates the isolation and identification of human persephin.

20 In order to identify the human homologue of persephin or additional members of the GDNF family, degenerate PCR primers were designed based on the human Neurturin and GDNF sequences and used to amplify human genomic DNA. The following primers were used (SEQ ID  
 25 NOS:225-228):

DhNeurturin1 (DN1)	GTSASYGASYTGGGYCTGGGCTAY	REF:B-46Z
DhNeurturin2 (DN2)	TTYMGSTACTGCRSMGGCKCYTGC	REF:B-46X
DhNeurturin3r (DN3)	RWAGGCSRTSGGKCKGCARCAKGS	REF:B-46V
30 DhNeurturin4r (DN4)	MKCRTCYARRAASGACASSTC	REF:B-46W

Human genomic DNA (Clontech 6550-1 0.1µg/µl) was amplified with all 4 possible primer combinations (DN1-DN3r, DN1-DN4r, DN2-DN3r, DN2-DN4r). Reaction mixtures  
 35 contained 5 µl of 10x Klentaq buffer, 0.5 µl dNTP (20mM); 1 µl human genomic DNA, 0.6 µl Klentaq (Clontech) and 1.5

5  $\mu$ l of each primers (0.1 OD/ $\mu$ l) in a total volume of 50  $\mu$ l. The DNA was amplified by touchdown PCR on Perkin Elmer Gene AMP 9600 in the following conditions: initial denaturation at 98°C for 2', then 5 cycles [98°C 30", 72°C 1.5'], 5 cycles [98°C 30", 70°C 1.5'] and 25 cycles [98°C 30", 68°C 1.5'] followed by a last extension step at 68°C for 5'.

10 PCR products of approximately 130 to 200 bp were identified after electrophoresis on agarose gel, purified and cloned into pCR 2.1 vector using In Vitrogen TA cloning kit (Cat # K2000-01). Clones containing a 130-200bp insert (after EcoR1 digestion) were sequenced and one of them (clone A3) obtained with the primer pair DN1-DN3r had a sequence homologous to mouse persephin and
 15 corresponded to human persephin.

The partial sequence of the human persephin genomic DNA in clone A3 is shown below (SEQ ID NO:229):  
 CGGCTTGTGACCGAGCTGGGCCTGGGCTACGCCTCAGAGGAGAAGGTCATCTTCCGC  
 TACTGCGCCGGCAGCTGCCCCCGTGGTGCCCGCACCCAGCATGGCCTGGCGCTGGCC  
 20 CGGCTGCAGGGCCAGGGCCGAGCCACGGCGGGCCCTGCTGCCGCCCCATGGCC

In order to identify a source from which to isolate a full length cDNA clone of human persephin, cDNA libraries were screened by PCR using exact match primers designed based on the genomic DNA sequence described
 25 above. Two sets of human persephin specific primers were prepared (SEQ ID NOS:230-233),

	hPSP-5'.1	GAGGAGAAGGTCATCTTCCG	REF:B-95K
	hPSP-3'.1	GCCGTGGGCTCGGCCCTGGC	REF:B-95L
	and		
30	hPSP-5'.3	AGAGGAGAAGGTCATCTTCCGCTA	REF:C-62Y
	hPSP-3'.4	CTCGGCCCTGGCCCTGCAGC	REF:C-62X

and used to amplify single stranded DNA from pRK5 cDNA libraries (1 $\mu$ l of 200 ng/ $\mu$ l) or the Stratagene's
 35 Quickscreen panel (3 $\mu$ l of each library) using the same conditions as described above. PCR products of the

expected size (108 bp for hPSP-5'.1 with hPSP-3'.1 and 101 bp for hPSP-5'.3 with hPSP-3'.4) were detected in fetal lung, fetal liver, fetal kidney, small intestine, retina, cerebellum and hT+13 Lymphoblast.

- 5 To isolate cDNA clones encoding human persephin, pRK5 libraries from human tissues were enriched for persephin cDNA clones by extension of single stranded DNA from plasmid libraries grown in a dut<sup>-</sup>/ung<sup>-</sup>-host using either of the following primers (SEQ ID NOS:233-234):

10

hPSP-3'.2	TGCAGCCGGGCCAGCGCCAG	REF:D-68T
hPSP-3'.4	CTCGGCCCTGGCCCTGCAGC	REF:C-62X

- 15 in a reaction containing 10µl of 10x PCR Buffer (Perkin Elmer), 1µl dNTP (20mM), 1µl library DNA (200 ng), 0.5µl primer, 86.5µl H<sub>2</sub>O and 1µl of Amplitaq (Perkin Elmer) added after a hot start. The reaction was denatured for 1 min at 95°C, annealed for 1 min at 50, 60 or 68°C then extended for 20 min at 72°C. DNA was extracted with
- 20 phenol/chloroform, ethanol precipitated, then transformed by electroporation into DH10B host bacteria.

- Approximately 40,000 colonies from each transformation were lifted on nylon membranes and screened with a DNA probe derived from the sequence of
- 25 clone A3 (described above). The fragment was labeled by the random oligonucleotide method using [32P]-dCTP. Filters were hybridized overnight at 42°C in 50% formamide, 5xSSC, 10xDenhardt's, 0.05M sodium phosphate (pH 6.5), 0.1% sodium pyrophosphate, 50 µg/ml of
- 30 sonicated salmon sperm DNA. Filters were then rinsed in 2xSSC and washed in 0.1xSSC, 0.1% SDS then exposed overnight to Kodak X Ray films. Pure positive clones were obtained after secondary screening and the isolated clones were then sequenced. Human persephin clones were
- 35 isolated from fetal lung, fetal kidney and fetal liver libraries. All such persephin clones isolated belong to

two categories: unspliced (10 clones) or chimeric (6 clones). Unspliced clones were ~900bp long and contain a region encoding a fragment corresponding to human persephin. However there is no initiation methionine and signal peptide present in that reading frame (Frame +2). A potential upstream initiation codon (ATG) is present in another reading frame (+1) and is followed by a hydrophobic sequence corresponding to a potential signal peptide. This suggests that such cDNAs are incompletely spliced and that an intron remains between the exons encoding the signal peptide and the persephin protein. Consensus splice donor and acceptor sequences can actually be identified at position 340 and 425, respectively. Splicing of an intron located between these positions would lead to a cDNA where the persephin coding sequence is "in frame" with the initiation methionine. Interestingly, aberrant chimeric clones were identified resulting from the joining of a cDNA encoding the predicted exon 2 of persephin exactly at the splice acceptor site present at position 425. The corresponding transcript was probably generated by aberrant splicing but confirms the presence of a splice acceptor site at position 425.

As an alternative approach to isolate a human persephin cDNA clone, 3 million clones of a human cerebellum cDNA library in lambda ZAP (Stratagene cat #935201) were screened with a DNA probe corresponding to clone A3 labeled by the random oligonucleotide method using [32P]-dCTP. The library was screened under high stringency hybridization conditions. The filters were prehybridized for 2h then hybridized overnight at 42°C in 50% formamide, 5xSSC, 10xDenhardt's, 0.05M sodium phosphate (pH 6.5), 0.1% sodium pyrophosphate, 50 µg/ml of sonicated salmon sperm DNA. Filters were then rinsed in 2xSSC and washed once in 0.1xSSC, 0.1% SDS at 60°C. Filters were exposed overnight to Kodak X Ray films.



Four positive clones (Cere 1.1, 1.2, 6.1, 6.2) were picked and plaque purified. The plasmid contained within the lambda ZAP phage arms was rescued as described per manufacturer's instructions using Ex Assist helper phage.

- 5 Sequencing of the four clones indicated that these clones were siblings and contained 2 silent mutations when compared to the human persephin clones isolated from the pRK5 library described above. These silent mutations occur at positions 30 (T→C) and 360 (T→C) of the sequence  
10 shown in Figure 24. Direct sequencing of the human persephin gene revealed that these silent mutations are actual allelic variations in the gene.

- In order to determine if the correct protein could be expressed from the unspliced cDNA identified above,  
15 constructs were generated where the sequence encoding a Flag tag was inserted just before the stop codon present at position 685 (frame + 1) or at position 746 (frame +2) starting from an ATG codon present at position 46 or 193. All four possible constructs were generated by PCR using  
20 the following primers (SEQ ID NOS:235-238):

hPSP1stMet.F	5'CGC GGA TCC ATG CCT GGA TTC	
	GAG GGT GCA G 3'	REF:B-127R
hPSP2ndMet.F	5' CGC GGA TCC ATG GCC GTA GGG	
25	AAG TTC CTG C 3'	REF:B-127S
hPSP.FLAG.R	5' CTC CCA AGC TTT TAC TTG TCA	
	TCG TCG TCC TTG TAG TCG CCA CCA	
	CAG CCG CAG GCA GCC 3'	REF:A-120C
hPSP.sig.FLAG.R	5' CTC CCA AGC TTT TAC TTG TCA	
30	TCG TCG TCC TTG TAG TCT CGA GGA	
	AGG CCA CGT CGG TG 3'	REF:A-120B

- In all four PCR reactions, the Cere 1.2 clone was used as template and amplified with Pfu polymerase on a  
35 Stratagene Robocycler gradient cycler 96. PCR conditions were 95°C for 2', 30 cycles of [95°C 30", 1' at 52, 56,

60 or 63°C, 72°C for 2 min] followed by a last extension of 5 min at 72°C.

Forward primers have a Bam HI site and the reverse primers have Hind III restriction site. The PCR products  
5 digested with Bam HI and Hind III and were subcloned into these sites in pRK5. DNA from each of the construct was transfected overnight into 293 cells using CaPO4 method. Serum containing media was conditioned for 24h then harvested. Cells were also harvested and divided in two;  
10 1/4 of each plate for RT-PCR and the remaining 3/4 of each plate for immunoprecipitation.

Analysis of expressed proteins was performed by immunoprecipitation. The cell pellet was lysed in 1 ml of lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM  
15 EDTA, 1% NP40, Aprotinin, Leupeptin, PMSF, 1 mM NaF and 1 mM Sodium Vanadate) for 20 min at 4°C. The extract was spun for 10 min at 10K rpm and then the supernatant was transferred to a new tube and precleared with 20 µl Protein A Sepharose for 1h. From here, 1 ml of the  
20 conditioned media was processed in parallel. The protein A sepharose was spun down and 1 µl of anti-Flag antibody (3.6 µg) was added to each tube. After overnight incubation at 4°C, 30 µl of Protein G sepharose were added and the tubes incubated at 4°C for 1 hour. The  
25 protein G beads were then spun down for 1 min, washed 3 times with lysis buffer, resuspended in 20 µl of Laemli buffer in the presence of β-mercapto-ethanol. Samples were denatured for 5 min at 100°C then loaded on a 16% polyacrylamide gel. Proteins were then transferred to  
30 nitrocellulose and analyzed by Western blot using the same anti-Flag antibody overnight at 1µg/ml in blocking buffer (PBS + 0.5% tween + 5% nonfat dry milk +3% Goat serum). Following this an anti-mouse HRP.ECL was used for the detection and the membrane was exposed for 90 sec  
35 to X-Ray film.

A specific band of 16 kDa was detected in the cell pellet of cells transfected with the construct starting at ATG 193 of frame +1 and with the flag inserted in frame +2 and a specific band of approximately 10 kDa could be detected in the corresponding supernatant. No Flag tagged protein could be detected in any other transfection or in mock transfected cells.

The correctly spliced mRNA was identified by RT-PCR as follows. Total RNA was extracted from the transfected cells (1/4 of each pellet) using RNazol B (Tel-Test Inc.) and treated for 40 min at 37°C with DNase. RNA was then purified on an RNAasy column (Promega) and collected in a final volume of 50µl. First strand cDNA was synthesized on 4 µl RNA using superscript RT (GIBCO-BRL) for 1h at 37°C then 5' at 95° to inactivate.

Two µl of each RT reaction were then used as template for amplification by PCR in the presence of the following 2 primers (SEQ ID NOS:236 and 239):

20

hPSP2ndMet.F 5' CGCGGATCCATGGCCGTAGGGAAGTTCCTGC 3'

REF:B-127S

hPSP.stop.R TCAGCCACCACAGCCGCAGGCAGCC

REF:D-103N

on a Stratagene Robocycler gradient cycler 96. PCR conditions were 98°C for 1.5', 28 cycles of [98°C for 30", anneal 1' between 60°C and 76°C, 72°C for 1.5'] followed by a last extension of 5 min at 72°C.

Analysis of the PCR product on agarose gel indicates that PCR using the pRK5.hPSP-FLAG.2 plasmid as template gave the expected product of about 570 bp while the RT PCR product, using RNA from cells transfected with this construct as template, was smaller than 500 bp. PCR product from the latter reaction was subcloned into the pCR 2.1 vector using In Vitrogen TA cloning kit (cat #K2000-01) and sequenced. Sequence analysis revealed

that the predicted 84 bp intron has been spliced out of the transcript.

In summary, the human persephin cDNA has a 471 bp open reading frame encoding a 156 amino acid long protein (predicted Mr 16.6kDa). Cleavage of the 23 amino acid long predicted signal peptide will lead to a 133 amino acid pro-persephin molecule (Mr 14.2 kDa); proteolytic cleavage of the pro-persephin at a RXXR consensus sequence should yield a 96 amino acid mature protein with a molecular weight of 10.3 kDa. This predicted size corresponds to the size of the Flag-tagged protein immunoprecipitated from the conditioned media of transfected 293 cells. Furthermore, amino terminal sequencing of Flag-tagged persephin purified from conditioned media of 293 transfected cells confirmed that the first residue of the mature form is Ala 61. Alignment between human persephin and human Neurturin indicates 38% similarity between the two molecules (50% for the mature region) and that human persephin is 30% similar to human GDNF (40% in the mature region).

#### Example 16

This example illustrates the preparation of chimeric or hybrid polypeptide molecules that contain portions derived from persephin (PSP) and portions derived from neurturin (NTN).

As closely related members of the TGF $\beta$  family, each of persephin and neurturin is predicted to have a very similar overall structure, yet while neurturin promotes the survival of sympathetic neurons, the closely related persephin does not. Two chimeras were produced by essentially replacing portions of persephin with neurturin, with the crossover point located between the two adjacent, highly conserved third and fourth cysteine residues. The first chimera, named PSP/NTN (SEQ ID NO:141, Figure 20), contains the first 63 residues of

mature murine persephin combined with residues 68 through 100 of mature murine neurturin (using *E. coli* preferred codons). To construct this molecule, two PCR reactions were performed: 1) using the forward primer M2012 (5'-  
 5 TAATACGACTCACTATAGGGGAA, SEQ ID NO:142) and reverse primer M2188 (5'-  
 TCGTCTTCGTAAGCAGTCGGACGGCAGCGGTTCGGCCATGGGCTCGAC, SEQ ID NO:143) and the pET30a-murine persephin plasmid as template (see Example 13); and 2) using the forward  
 10 primer M2190 (5'-TGCTGCCGTCCGACTGCTTACGAAGACGA, SEQ ID NO:144) and reverse primer M2186 (5'-  
 GTTATGCTAGTTATTGCTCAGCGGT, SEQ ID NO:145) and the pET30a-murine (*E. coli* preferred codons) neurturin plasmid as template (see Example 6). Both PCR reactions were  
 15 carried out using the following parameters: 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec x 25 cycles. The products of these two PCR reactions were gel purified, mixed together, and a PCR reaction was performed under the following conditions: 94°C for 30 sec, 60°C for 20  
 20 min, 68°C for 5 min. After 8 cycles, an aliquot of this reaction was used as template in a third PCR reaction using the forward primer M2012 and reverse primer M2186 under the following conditions: 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec x 25 cycles. The resulting  
 25 product was kinased with T4 polynucleotide kinase, the ends were blunted with *E. coli* DNA polymerase I (Klenow fragment), and cloned into BSKS plasmid. Nucleotide sequencing was performed to verify that the correct clone was obtained. The PSP/NTN fragment was excised using Nde  
 30 I and Bam HI and cloned into the corresponding sites of the bacterial expression vector pET30a.

The second chimera, named NTN/PSP (SEQ ID NO:146, Figure 20), encodes the converse molecule. It contains the first 67 residues of mature murine neurturin (using  
 35 *E. coli* preferred codons) combined with residues 64 to 96 of mature murine persephin. To construct this molecule,

we performed two PCR reactions: 1) using the forward primer M2012 and reverse primer M2183 (5'-CACATCAGCATAGCTGGTGGGCTGGCAGCACGGGTGAGCACGAGCACGTT, SEQ ID NO:147) and the pET30a-murine (E.coli preferred 5 codons) neurturin plasmid as template; and 2) using the forward primer M2187 (5'-TGCTGCCAGCCCACCAGCTATGCTG, SEQ ID NO:148) and reverse primer M2186 (5'-GTTATGCTAGTTATTGCTCAGCGGT, SEQ ID NO:145) and the pET30a-murine persephin plasmid as template. Both PCR reactions were carried out using the following parameters: 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec x 25 cycles. The products of these two PCR reactions were used to construct the final NTN/PSP pET30a plasmid as detailed above for PSP/NTN except that Bgl II was used instead of Bam HI. These chimeric proteins were produced in E.coli and purified by Ni-NTA chromatography as described above (Example 13).

The purified proteins were assayed for their ability to promote survival in the SCG sympathetic neuron assay. The NTN/PSP protein did not promote survival, whereas the PSP/NTN protein promoted the survival of sympathetic neurons similar to that observed for neurturin itself. These results indicate that neurturin residues lying downstream of the 2 adjacent, highly conserved cysteine residues are critical for activity in promoting survival in SCG sympathetic neurons. In contrast, the corresponding residues of persephin are not sufficient for promoting survival in sympathetic neurons.

30

#### Example 17

This example illustrates the neuronal survival promoting activity of persephin in mesencephalic cells.

The profile of survival promoting activity of persephin is different from that of neurturin and GDNF. In contrast to the survival promoting activity produced by neurturin and GDNF in sympathetic and sensory neurons,

persephin showed no survival promoting activity in these tissues. We further evaluated the neuronal survival promoting activity of persephin in mesencephalic cells.

Timed-pregnant Sprague-Dawley rats were purchased from Harlan Sprague-Dawley. The mesencephalon was taken from rats measuring 1.2 to 1.4 cm in length and time dated to be embryonic day 14. The cranium was removed and the entire mesencephalon was placed in cold L15. The pooled mesencephalic tissue was resuspended in a serum-free medium consisting of DME/Hams F12 (#11330-032, Life Technologies) 1 mg/ml BSA, Fraction V (A-6793, Sigma Chemical Co.), 5  $\mu$ M Insulin (I-5500, Sigma), 10 nM progesterone (P0130, Sigma), 100  $\mu$ M putrescine, (p7505, Sigma), 30 nM Selenium (S07150, Pflatz & Bauer), 10 ng/ml rat transferrin (012-000-050, Jackson Chrompure), 100 U/ml penicillin, and 100 U/ml of streptomycin. The pooled mesencephalic tissues were triturated approximately 80 times using a bent-tip pipette and the cells were plated in a 24-well dish (CoStar) at a density of 15,000 cells in a 100- $\mu$ l drop. The dishes were coated with 125 ng/ml poly-d-lysine (p-7280, Sigma) and 25 ng/ml laminin (#40232, Collaborative Biomedical Products). These dissociated cells were allowed to attach for 2 hours at 37°C in 5% CO<sub>2</sub> and then fed with another 500  $\mu$ l of the above serum-free medium with or without approximately 100 ng/ml of recombinant Persephin. These cells were photographed after 3 days of culture.

Inspection of the cells over the course of 3 days in culture, showed a gradual decrease in cell number. In the absence of any growth factor, almost all of the cells were dead (Figure 21A). In the presence of persephin, a large increase in mesencephalic neuronal cell survival was evident (Figure 21B).

This study was repeated to obtain comparative effects on mesencephalic cell for persephin and the related growth factors, neurturin and GDNF.

Mesencephalic tissue was removed from E14 par pps, pooled and dissociated in dispase for 30 min. Cells were then triturated and plated in supplemented N2 media and plated at a density of 20,000 cells per well in an 8-well chamber slike. The cells in a given well were either untreated or treated with a growth factor at 50 ng/ml for four days. Cells were washed once with PBS, fixed with 4% paraformaldehyde for 30 minutes and stained with tyrosine hydroxylase (TOH) antibody (Chemicon, ABC-Vectastain kit) and counted. TOH staining served as a marker for dopaminergice cells inasmuch as TOH is a synthetic enzyme for dopamine. Figure 22 shows the mean cell counts for untreated and treated cells. Persephin (PSP), neurturin (NTN) and GDNF promoted survival of mesencephalic neuronal cells to a comparable extent.

#### Example 18

This example illustrates the expression of persephin in various tissues.

A survey of persephin expression was performed in adult mouse tissues using semi-quantitative RT/PCR (see Example 9). Poly A RNA was isolated from brain, cerebellum, kidney, lung, heart, ovary, sciatic nerve, dorsal root ganglia, blood and spleen. This was then reverse transcribed to produce cDNA (see Kotzbauer et al. *Nature* 384:467-470, 1996 which is incorporated by reference). The PCR primers used were as follows: forward primer: 5'-CCTCGGAGGAGAAGGTCATCTTC (SEQ ID NO:149) and reverse primer: 5'TCATCAAGGAAGGTCACATCAGCATA (SEQ ID NO:101). PCR was done for 26 cycles with an annealing temperature of 60°C. To control for the presence of genomic DNA, RNA samples which were not reverse transcribed were used for PCR (for example, the tissue control shown in figure 22 is labeled "Kidney no RT"). All the samples were found to be without genomic DNA contamination.



As shown in Figure 23, a band of the correct size (160 bp) was seen in the kidney sample. At higher cycle numbers a persephin band was also seen in brain. Thus, the distribution of expression of persephin in various mouse tissues differs from that of neurturin in rat (Example 8).

Deposit of Strain. The following strain is on deposit under the terms of the Budapest Treaty, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD. The accession number indicated was assigned after successful viability testing, and the requisite fees were paid. Access to said cultures will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 USC 122. All restriction on availability of said cultures to the public will be irrevocably removed upon the granting of a patent based upon the application. Moreover, the designated deposits will be maintained for a period of thirty (30) years from the date of deposit, or for five (5) years after the last request for the deposit, or for the enforceable life of the U.S. patent, whichever is longer. Should a culture become nonviable or be inadvertently destroyed, or, in the case of plasmid-containing strains, lose its plasmid, it will be replaced with a viable culture. The deposited materials mentioned herein are intended for convenience only, and are not required to practice the present invention in view of the description herein, and in addition, these materials are incorporated herein by reference.

30			
	Strain	Deposit Date	ATCC No.
35	DG44CHO-pHSP-NGFI-B	August 25, 1995	CRL 11977

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.

As various changes could be made in the above  
5 methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: JOHNSON, EUGENE M  
 MILBRANDT, JEFFREY D  
 KOTZBAUER, PAUL T  
 LAMPE, PATRICIA A  
 KLEIN, ROBERT  
 DESAUVAGE, FRED

(ii) TITLE OF INVENTION: PERSEPHIN AND RELATED GROWTH FACTOR

(iii) NUMBER OF SEQUENCES: 239

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: HOWELL & HAERKAMP, L.C.  
 (B) STREET: 7733 FORSYTH BOULEVARD, SUITE 1400  
 (C) CITY: ST. LOUIS  
 (D) STATE: MO  
 (E) COUNTRY: USA  
 (F) ZIP: 63105

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
 (B) FILING DATE:  
 (C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: HOLLAND, DONALD R.  
 (B) REGISTRATION NUMBER: 35,197  
 (C) REFERENCE/DOCKET NUMBER: 971486

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 314-727-5188  
 (B) TELEFAX: 314-727-6092

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala	Arg	Leu	Gly	Ala	Arg	Pro	Cys	Gly	Leu	Arg	Glu	Leu	Glu	Val	Arg
1				5					10					15	
Val	Ser	Glu	Leu	Gly	Leu	Gly	Tyr	Ala	Ser	Asp	Glu	Thr	Val	Leu	Phe
			20					25						30	

Arg Tyr Cys Ala Gly Ala Cys Glu Ala Ala Ala Arg Val Tyr Asp Leu  
 35 40 45

Gly Leu Arg Arg Leu Arg Gln Arg Arg Arg Leu Arg Arg Glu Arg Val  
 50 55 60

Arg Ala Gln Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser  
 65 70 75 80

Phe Leu Asp Ala His Ser Arg Tyr His Thr Val His Glu Leu Ser Ala  
 85 90 95

Arg Glu Cys Ala Cys Val  
 100

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 100 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Pro Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser  
 1 5 10 15

Glu Leu Gly Leu Gly Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr  
 20 25 30

Cys Ala Gly Ala Cys Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu  
 35 40 45

Arg Arg Leu Arg Gln Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala  
 50 55 60

His Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu  
 65 70 75 80

Asp Val His Ser Arg Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu  
 85 90 95

Cys Ala Cys Val  
 100

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ser Gly Ala Arg Pro Xaa Gly Leu Arg Glu Leu Glu Val Ser Val Ser  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "SERINE OR CYSTEINE"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Xaa Cys Ala Gly Ala Xaa Glu Ala Ala Val  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "ANY AMINO ACID"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 17
- (D) OTHER INFORMATION: /note= "GLUTAMINE OR GLUTAMIC ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Xaa Xaa Val Glu Ala Lys Pro Cys Cys Gly Pro Thr Ala Tyr Glu Asp  
 1 5 10 15

Xaa Val Ser Phe Leu Ser Val  
20

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 10 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Tyr His Thr Leu Gln Glu Leu Ser Ala Arg  
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 197 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser  
1 5 10 15  
Val Leu Ser Ile Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg  
20 25 30  
Leu Gly Pro Ala Leu Val Pro Leu His Arg Leu Pro Arg Thr Leu Asp  
35 40 45  
Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala  
50 55 60  
Pro Asp Ala Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro  
65 70 75 80  
Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg Ala  
85 90 95  
Arg Leu Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val  
100 105 110  
Ser Glu Leu Gly Leu Gly Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg  
115 120 125  
Tyr Cys Ala Gly Ala Cys Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly  
130 135 140  
Leu Arg Arg Leu Arg Gln Arg Arg Arg Leu Arg Arg Glu Arg Val Arg  
145 150 155 160

Ala Gln Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe  
                             165                            170                            175

Leu Asp Ala His Ser Arg Tyr His Thr Val His Glu Leu Ser Ala Arg  
                             180                            185                            190

Glu Cys Ala Cys Val  
                             195

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 195 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Arg Arg Trp Lys Ala Ala Ala Leu Val Ser Leu Ile Cys Ser Ser  
 1                            5                            10                            15

Leu Leu Ser Val Trp Met Cys Gln Glu Gly Leu Leu Leu Gly His Arg  
                             20                            25                            30

Leu Gly Pro Ala Leu Ala Pro Leu Arg Arg Pro Pro Arg Thr Leu Asp  
                             35                            40                            45

Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala  
                             50                            55                            60

Pro Asp Ala Val Glu Leu Arg Glu Leu Ser Pro Trp Ala Ala Arg Ile  
 65                            70                            75                            80

Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg Pro  
                             85                            90                            95

Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu  
                             100                            105                            110

Leu Gly Leu Gly Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys  
                             115                            120                            125

Ala Gly Ala Cys Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu Arg  
                             130                            135                            140

Arg Leu Arg Gln Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala His  
 145                            150                            155                            160

Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp  
                             165                            170                            175

Val His Ser Arg Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu Cys  
                             180                            185                            190

Ala Cys Val  
                             195

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 306 base pairs

(B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

GCGCGGTTGG GGGCGCGGCC TTGCGGGCTG CGCGAGCTGG AGGTGCGCGT GAGCGAGCTG      60
GGCCTGGGCT ACGCGTCCGA CGAGACGGTG CTGTTCCGCT ACTGCGCAGG CGCCTGCGAG      120
GCTGCCGCGC GCGTCTACGA CCTCGGGCTG CGACGACTGC GCCAGCGGCG GCGCCTGCGG      180
CGGGAGCGGG TGCGCGCGCA GCCCTGCTGC CGCCCACGG CCTACGAGGA CGAGGTGTCC      240
TTCCTGGACG CGCACAGCCG CTACCACAGC GTGCACGAGC TGTCGGCGCG CGAGTGCGCC      300
TGCGTG                                           306
  
```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 300 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

CCGGGGGCTC GGCCTTGTGG GCTGCGCGAG CTCGAGGTGC GCGTGAGCGA GCTGGGCCTG      60
GGCTACACGT CGGATGAGAC CGTGCTGTTC CGCTACTGCG CAGGCGCGTG CGAGGCGGCC      120
ATCCGCATCT ACGACCTGGG CCTTCGGCGC TGCGCCAGC GGAGGCGCGT GCGCAGAGAG      180
CGGGCGCGGG CGCACCCGTG TTGTGCCCCG ACGGCCTATG AGGACGAGGT GTCCTTCCTG      240
GACGTGCACA GCCGCTACCA CACGCTGCAA GAGCTGTCTG CGCGGGAGTG CGCGTGCGTG      300
  
```

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 591 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```

ATGCAGCGCT GGAAGGCGGC GGCCTTGCC TCAGTGCTCT GCAGCTCCGT GCTGTCCATC      60
TGGATGTGTC GAGAGGGCCT GCTTCTCAGC CACCGCCTCG GACCTGCGCT GTTCCCCCTG      120
CACCGCCTGC CTCGAACCCT GGACGCCCGG ATTGCCCCGCC TGGCCCAGTA CCGTGCACTC      180
  
```



```

CTGCAGGGGG CCCCGGATGC GATGGAGCTG CGCGAGCTGA CGCCCTGGGC TGGGCGGCCC      240
CCAGGTCCGC GCCGTCGGGC GGGGCCCCGG CGGCGGCGCG CGCGTGCGCG GTTGGGGGCG      300
CGGCCTTGCG GGCTGCGCGA GCTGGAGGTG CGCGTGAGCG AGCTGGGCCT GGGCTACGCG      360
TCCGACGAGA CGGTGCTGTT CCGCTACTGC GCAGGCGCCT GCGAGGCTGC CGCGCGCGTC      420
TACGACCTCG GGCTGCGACG ACTGCGCCAG CGGCGGCGCC TCGGCGGGA GCGGGTGCGC      480
GCGCAGCCCT GCTGCCGCC GACGGCCTAC GAGGACGAGG TGTCTTCCT GGACGCGCAC      540
AGCCGCTACC ACACGGTGCA CGAGCTGTCG GCGCGCGAGT GCGCCTGCGT G      591

```

## (2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 585 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

ATGAGGCGCT GGAAGGCAGC GGCCCTGGTG TCGTCATCT GCAGCTCCCT GCTATCTGTC      60
TGGATGTGCC AGGAGGGTCT GCTCTTGGGC CACCGCCTGG GACCCGCGCT TGCCCCGCTA      120
CGACGCCCTC CACGCACCCT GGACGCCCGC ATCGCCCGCC TGGCCCAGTA TCGCGCTCTG      180
CTCCAGGGCG CCCCCGACGC GGTGGAGCTT CGAGAACTTT CTCCCTGGGC TGCCCGCATC      240
CCGGGACCGC GCCGTCGAGC GGGTCCCCGG CGTCGGCGGG CGCGGCCGGG GGCTCGGCCT      300
TGTGGGCTGC GCGAGCTCGA GGTGCGCGTG AGCGAGCTGG GCCTGGGCTA CACGTCGGAT      360
GAGACCGTGC TGTTCGCTA CTGCGCAGGC GCGTGCGAGG CGGCCATCCG CATCTACGAC      420
CTGGGCCTTC GGCGCCTGCG CCAGCGGAGG CGCGTGCGCA GAGAGCGGGC GCGGGCGCAC      480
CCGTGTTGTC GCGCGACGGC CTATGAGGAC GAGGTGTCCT TCCTGGACGT GCACAGCCGC      540
TACCACACGC TGCAAGAGCT GTCGGCGCGG GAGTGCGCGT GCGTG      585

```

## (2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 348 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

GGAGGGAGAG CGCGCGGTGG TTTCGTCCGT GTGCCCCGCG CCCGGCGCTC CTCGCGTGGC      60
CCCGCGTCCT GAGCGCGCTC CAGCCTCCCA CGCGCGCCAC CCCGGGGTTC ACTGAGCCCC      120

```

GCGAGCCCGG GGAAGACAGA GAAAGAGAGG CCAGGGGGGG AACCCCATGG CCCGGCCCGT 180  
 GTCCCGCACC CTGTGCGGTG GCCTCCTCCG GCACGGGGTC CCCGGGTGCG CTCGGGTCCC 240  
 CGCGATCCGG ATGGCGCACG CAGTGGCTGG GGCCGGGCCG GGCTCGGGTG GTCGGAGGAG 300  
 TCACCACTGA CCGGGTCATC TGGAGCCCGT GGCAGGCCGA GGCCCAGG 348

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 87 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGCTACCTCA CGCCCCCGA CCTGCGAAAG GGCCTCCCT GCCGACCCTC GCTGAGAACT 60  
 GACTTCACAT AAAGTGTGGG AACTCCC 87

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 19 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser  
 1 5 10 15  
 Val Leu Ser

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 19 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met Arg Arg Trp Lys Ala Ala Ala Leu Val Ser Leu Ile Cys Ser Ser  
 1 5 10 15  
 Leu Leu Ser

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ATGCAGCGCT GGAAGGCGGC GGCCTTGGCC TCAGTGCTCT GCAGCTCCGT GCTGTCC

57

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 57 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATGAGGCGCT GGAAGGCAGC GGCCCTGGTG TCGCTCATCT GCAGCTCCCT GCTATCT

57

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 76 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ile Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg Leu Gly Pro  
1 5 10 15

Ala Leu Val Pro Leu His Arg Leu Pro Arg Thr Leu Asp Ala Arg Ile  
20 25 30

Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala Pro Asp Ala  
35 40 45

Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro Pro Gly Pro  
50 55 60

Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg  
65 70 75

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 228 base pairs

(B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```

ATCTGGATGT GTCGAGAGGG CCTGCTTCTC AGCCACCGCC TCGGACCTGC GCTGGTCCCC    60
CTGCACCGCC TGCCTCGAAC CCTGGACGCC CGGATTGCCG GCCTGGCCCA GTACCGTGCA    120
CTCCTGCAGG GGGCCCCGGA TGCGATGGAG CTGCGCGAGC TGACGCCCTG GGCTGGGCGG    180
CCCCAGGTC CGCGCCGTCG GCGGGGGCCC CGCGGGCGGC GCGCGCGT    228
  
```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 228 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```

GTCTGGATGT GCCAGGAGGG TCTGCTCTTG GGCCACCGCC TGGGACCCGC GCTTGCCCCG    60
CTACGACGCC CTCCACGCAC CCTGGACGCC CGCATCGCCC GCCTGGCCCA GTATCGCGCT    120
CTGCTCCAGG GCGCCCCCGA CGCGGTGGAG CTTGAGAAAC TTTCTCCCTG GGCTGCCCCG    180
ATCCCGGGAC CGCGCCGTCG AGCGGGTCCC CGGCGTCGGC GGGCGCGG    228
  
```

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 76 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```

Val Trp Met Cys Gln Glu Gly Leu Leu Leu Gly His Arg Leu Gly Pro
1              5              10              15
Ala Leu Ala Pro Leu Arg Arg Pro Pro Arg Thr Leu Asp Ala Arg Ile
20              25              30
Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala Pro Asp Ala
35              40              45
Val Glu Leu Arg Glu Leu Ser Pro Trp Ala Ala Arg Ile Pro Gly Pro
50              55              60
  
```

Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg  
65 70 75

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 95 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser  
1 5 10 15  
Val Leu Ser Ile Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg  
20 25 30  
Leu Gly Pro Ala Leu Val Pro Leu His Arg Leu Pro Arg Thr Leu Asp  
35 40 45  
Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala  
50 55 60  
Pro Asp Ala Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro  
65 70 75 80  
Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg  
85 90 95

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 95 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Met Arg Arg Trp Lys Ala Ala Ala Leu Val Ser Leu Ile Cys Ser Ser  
1 5 10 15  
Leu Leu Ser Val Trp Met Cys Gln Glu Gly Leu Leu Leu Gly His Arg  
20 25 30  
Leu Gly Pro Ala Leu Ala Pro Leu Arg Arg Pro Pro Arg Thr Leu Asp  
35 40 45  
Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu Leu Gln Gly Ala  
50 55 60  
Pro Asp Ala Val Glu Leu Arg Glu Leu Ser Pro Trp Ala Ala Arg Ile  
65 70 75 80  
Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg  
85 90 95

## (2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 285 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```

ATGCAGCGCT GGAAGGCGGC GGCCTTGGCC TCAGTGCTCT GCAGCTCCGT GCTGTCCATC      60
TGGATGTGTC GAGAGGGCCT GCTTCTCAGC CACCGCCTCG GACCTGCGCT GGTCCCCCTG      120
CACCGCCTGC CTCGAACCCT GGACGCCCCG ATTGCCCCGCC TGGCCCAGTA CCGTGCACTC      180
CTGCAGGGGG CCCC GGATGC GATGGAGCTG CGCGAGCTGA CGCCCTGGGC TGGGCGGCCC      240
CCAGGTCCGC GCCGTCGGGC GGGGCCCCGG CGGCGGCGCG CGCGT      285

```

## (2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 285 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```

ATGAGGCGCT GGAAGGCAGC GGCCCTGGTG TCGCTCATCT GCAGCTCCCT GCTATCTGTC      60
TGGATGTGCC AGGAGGTCT GCTCTTGGGC CACCGCCTGG GACCCGCGCT TGCCCCGCTA      120
CGACGCCCTC CACGCACCCT GGACGCCCCG ATCGCCCCGCC TGGCCCAGTA TCGCGCTCTG      180
CTCCAGGGCG CCCCCGACGC GGTGGAGCTT CGAGAACTTT CTCCCTGGGC TGCCCGCATC      240
CCGGGACCGC GCCGTCGAGC GGGTCCCCGG CGTCGGCGGG CGCGG      285

```

## (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 169 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```

ATGCAGCGCT GGAAGGCGGC GGCCTTGGCC TCAGTGCTCT GCAGCTCCGT GCTGTCCATC      60
TGGATGTGTC GAGAGGGCCT GCTTCTCAGC CACCGCCTCG GACCTGCGCT GGTCCCCCTG      120

```

CACCGCCTGC CTCGAACCCT GGACGCCCCG ATTGCCCCGCC TGGCCCAGT

169

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 425 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ACCGTGCACT CCTGCAGGGG GCCCCGGATG CGATGGAGCT GCGCGAGCTG ACGCCCTGGG	60
CTGGGCGGCC CCCAGTCCG CGCCGTCGGG CGGGGCCCCG GCGGCGGCGC GCGCGTGCGC	120
GGTTGGGGGC GCGGCCTTGC GGGCTGCGCG AGCTGGAGGT GCGCGTGAGC GAGCTGGGCC	180
TGGGCTACGC GTCCGACGAG ACGGTGCTGT TCCGCTACTG CGCAGGCGCC TGCGAGGCTG	240
CCGCGCGCGT CTACGACCTC GGGCTGCGAC GACTGCGCCA GCGGCGGCGC CTGCGGCGGG	300
AGCGGGTGCG CGCGCAGCCC TGCTGCCGCC CGACGGCCTA CGAGGACGAG GTGTCCTTCC	360
TGGACGCGCA CAGCCGCTAC CACACGGTGC ACGAGCTGTC GGCGCGCGAG TGCGCCTGCG	420
TGTGA	425

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 169 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

ATGAGGCGCT GGAAGGCAGC GGCCCTGGTG TCGTCATCT GCAGTCCCT GCTATCTGTC	60
TGGATGTGCC AGGAGGTCT GCTCTTGGG CACCGCCTGG GACCGCGCT TGCCCCGCTA	120
CGACGCCCTC CACGCACCCT GGACGCCCCG ATCGCCCGCC TGGCCCAGT	169

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 419 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

```

ATCGCGCTCT GCTCCAGGGC GCGCCGACG CGGTGGAGCT TCGAGAACTT TCTCCCTGGG      60
CTGCCCCGCAT CCCGGGACCG CGCCGTCGAG CGGGTCCCCG GCGTCGGCGG GCGCGGCCGG      120
GGGCTCGGCC TTGTGGGCTG CGCGAGCTCG AGGTGCGCGT GAGCGAGCTG GGCCTGGGCT      180
ACACGTCGGA TGAGACCGTG CTGTTCCGCT ACTGCGCAGG CGCGTGCGAG GCGGCCATCC      240
GCATCTACGA CCTGGGCCTT CGGCGCCTGC GCCAGCGGAG GCGCGTGCGC AGAGAGCGGG      300
CGCGGGCGCA CCCGTGTTGT CGCCGACGG CCTATGAGGA CGAGGTGTCC TTCCTGGACC      360
TGCACAGCCG CTACCACACG CTGCAAGAGC TGTCGGCGCG GGAGTGCGCG TCGGTGTGA      419

```

## (2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 94 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

```

Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly
1           5           10           15
Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys
          20           25           30
Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln
          35           40           45
Arg Arg Arg Leu Arg Arg Glu Arg Val Arg Ala Gln Pro Cys Cys Arg
          50           55           60
Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Ala His Ser Arg
          65           70           75           80
Tyr His Thr Val His Glu Leu Ser Ala Arg Glu Cys Ala Cys
          85           90

```

## (2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 94 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

```

Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly
1           5           10           15

```



Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys  
                     20                    25                    30  
 Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln  
                     35                    40                    45  
 Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala His Pro Cys Cys Arg  
                     50                    55                    60  
 Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Val His Ser Arg  
                     65                    70                    75                    80  
 Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu Cys Ala Cys  
                     85                    90

## (2) INFORMATION FOR SEQ ID NO:33:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "SERINE OR THREONINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Val Xaa Xaa Leu Gly Leu Gly Tyr  
 1                    5

## (2) INFORMATION FOR SEQ ID NO:34:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "THREONINE OR GLUTAMIC ACID"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site

(B) LOCATION: 4  
 (D) OTHER INFORMATION: /note= "LEUCINE OR ISOLEUCINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 9  
 (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 11  
 (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 13  
 (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
 ACID"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 14  
 (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Glu	Xaa	Xaa	Xaa	Phe	Arg	Tyr	Cys	Xaa	Gly	Xaa	Cys	Xaa	Xaa	Ala
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 5  
 (D) OTHER INFORMATION: /note= "THREONINE OR VALINE OR  
 ISOLEUCINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 7  
 (D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 8  
 (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
 ACID"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 10  
 (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
 ACID"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site

- (B) LOCATION: 11
- (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Cys	Cys	Arg	Pro	Xaa	Ala	Xaa	Xaa	Asp	Xaa	Xaa	Ser	Phe	Leu	Asp
1				5				10					15	

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 11 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 5
  - (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 7
  - (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 9
  - (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 10
  - (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Phe	Arg	Tyr	Cys	Xaa	Gly	Xaa	Cys	Xaa	Xaa	Ala
1				5				10		

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 11 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 5
  - (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 7

(D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 9
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10
- (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Phe	Arg	Tyr	Cys	Xaa	Gly	Xaa	Cys	Xaa	Xaa	Ala
1				5					10	

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "ISOLEUCINE OR THREONINE OR

VALINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 8
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Cys	Cys	Arg	Pro	Xaa	Ala	Xaa	Xaa	Asp	Xaa
1				5					10

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Ala	Xaa	Xaa	Asp	Xaa	Xaa	Ser	Phe	Leu	Asp
1			5					10	

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR THREONINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "LEUCINE OR VALINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "ISOLEUCINE OR LEUCINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Glu	Xaa	Xaa	Xaa	Phe	Arg	Tyr	Cys
1				5			

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 13 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 2
  - (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR THREONINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 3
  - (D) OTHER INFORMATION: /note= "LEUCINE OR VALINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 4
  - (D) OTHER INFORMATION: /note= "ISOLEUCINE OR LEUCINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 9
  - (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 11
  - (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

- (ix) FEATURE:
  - (A) NAME/KEY: Modified-site
  - (B) LOCATION: 13
  - (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Glu	Xaa	Xaa	Xaa	Phe	Arg	Tyr	Cys	Xaa	Gly	Xaa	Cys	Xaa
1				5					10			

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GTNWSNGANY TNGGNYTNGG NTA

23

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 32 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

TTYMGNTAYT GYDSNGGND NTGYGANKCN GC

32

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 32 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GCNGMNTCRC ANSHNCCNSH RCARTANCKR AA

32

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

TCRTCNTCRW ANGCRNYNGG NCKRCARCA

29

(2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TCNARRAANS WNAVNTCR TC NTCRWANGC

29

(2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GARRMNBNTNH TNTTYMGNTA YTG

23

(2) INFORMATION FOR SEQ ID NO:48:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 38 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GARRMNBNTNH TNTTYMGNTA YTGYSNNGN DSNTGHGA

38

(2) INFORMATION FOR SEQ ID NO:49:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1023 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GGAGGGAGAG CGCGCGGTGG TTTCTGTCCT GTGCCCCGCG CCCGGCGCTC CTCGCGTGGC	60
CCCGCGTCTCT GAGCGCGCTC CAGCCTCCCA CGCGCGCCAC CCCGGGGTTC ACTGAGCCCCG	120
GCGAGCCCCGG GGAAGACAGA GAAAGAGAGG CCAGGGGGGG AACCCCATGG CCCGGCCCCGT	180
GTCCCGCACC CTGTGCGGTG GCCTCCTCCG GCACGGGGTC CCCGGGTGCG CTCCGGTCCC	240
CGCGATCCGG ATGGCGCACG CAGTGGCTGG GGCCGGGCGG GGCTCGGGTG GTCGGAGGAG	300
TCACCACTGA CCGGGTCATC TGGAGCCCGT GGCAGGCCGA GGCCAGGAT GAGGCGCTGG	360
AAGGCAGCGG CCCTGGTGTC GTCATCTGC AGCTCCCTGC TATCTGTCTG GATGTGCCAG	420
GAGGGTCTGC TCTTGGGCCA CCGCCTGGGA CCCGCGCTTG CCCCGCTACG ACGCCCTCCA	480
CGCACCTTGG ACGCCCGCAT CGCCCGCCTG GCCAGTATC GCGCTCTGCT CCAGGGCGCC	540
CCCGACGCGG TGGAGCTTCG AGAACTTTCT CCCTGGGCTG CCCGCATCCC GGGACCGCGC	600
CGTCGAGCGG GTCCCCGGCG TCGGCGGGCG CGGCCGGGGG CTCGGCCTTG TGGGCTGCGC	660
GAGCTCGAGG TGC GCGTGAG CGAGCTGGGC CTGGGCTACA CGTCGGATGA GACCGTGCTG	720
TTCCGCTACT GCGCAGGCGC GTGCGAGGCG GCCATCCGCA TCTACGACCT GGGCCTTCGG	780



CGCCTGCGCC AGCGGAGGCG CGTGCGCAGA GAGCGGGCGC GGGCGCACCC GTGTTGTCGC 840  
 CCGACGGCCT ATGAGGACGA GGTGTCCTTC CTGGACGTGC ACAGCCGCTA CCACACGCTG 900  
 CAAGAGCTGT CGGCGCGGGA GTGCGCGTGC GTGTGATGCT ACCTCAGGCC CCCCAGCTG 960  
 CGAAAGGGCC CTCCCTGCCG ACCCTCGCTG AGAACTGACT TCACATAAAG TGTGGGAACT 1020  
 CCC 1023

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

CCNACNGCNT AYGARGA

17

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 93 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
 20 25 30  
 Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
 35 40 45  
 Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
 50 55 60  
 Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr  
 65 70 75 80  
 His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys  
 85 90

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 base pairs  
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

ARYTCYTGNA RNGTRTGRTA

20

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 28 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

GACGAGGTGT CCTTCCTGGA CGTACACA

28

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 34 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

TAGCGGCTGT GTACGTCCAG GAAGGACACC TCGT

34

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

CAGCGACGAC GCGTGCGCAA AGAGCG

26

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 47 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

TAYGARGACG AGGTGTCCTT CCTGGACGTA CACAGCCGCT AYCAYAC

47

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 26 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GCGGCCATCC GCATCTACGA CCTGGG

26

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

CRTAGGCCGT CGGGCGRCAR CACGGGT

27

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 27 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

GCGCCGAAGG CCCAGGTCGT AGATGCG

27

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 29 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

CGCTACTGCG CAGGCGCGTG CGARGCGGC

29

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

CGCCGACAGC TCTGCAGCG TRTGTA

27

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GAGCTGGGCC TGGGCTACGC GTCCGACGAG

30

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 39 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

GCGACGCGTA CCATGAGGCG CTGGAAGGCA GCGGCCCTG

39

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

GACGGATCCG CATCACACGC ACGCGCACTC

30

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

GACCATATGC CGGGGGCTCG GCCTTGTGG

29

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

GACGGATCCG CATCACACGC ACGCGCACTC

30

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

CAGCGACGAC GCGTGCGCAA AGAGCG

26

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 34 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

TAGCGGCTGT GTACGTCCAG GAAGGACACC TCGT

34

(2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

AAAAATCGGG GGTGYGTCTT A

21

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

CATGCCTGGC CTACYTTGTC A

21

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

CTGGCGTCCC AMCAAGGGTC TTCG

24

(2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

GCCAGTGGTG CCGTCGAGGC GGG

23

## (2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

GGCCCAGGAT GAGGCGCTGG AAGG

24

## (2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

CCACTCCACT GCCTGAWATT CWACCCC

27

## (2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CCATGTGATT ATCGACCATT CGGC

24

## (2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 134 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Ser Pro Asp Lys Gln Met Ala Val Leu Pro Arg Arg Glu Arg Asn Arg  
 1 5 10 15

Gln Ala Ala Ala Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg  
                   20                                  25                                  30  
 Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu  
                   35                                  40                                  45  
 Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile  
                   50                                  55                                  60  
 Phe Arg Tyr Cys Ser Gly Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp  
                   65                                  70                                  75                                  80  
 Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg Arg Leu Val Ser Asp Lys  
                                   85                                  90                                  95  
 Val Gly Gln Ala Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp Leu Ser  
                                   100                                  105                                  110  
 Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala  
                   115                                  120                                  125  
 Lys Arg Cys Gly Cys Ile  
                   130

## (2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 134 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Ser Pro Asp Lys Gln Ala Ala Ala Leu Pro Arg Arg Glu Arg Asn Arg  
 1                                  5                                  10                                  15  
 Gln Ala Ala Ala Ala Ser Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg  
                   20                                  25                                  30  
 Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu  
                   35                                  40                                  45  
 Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile  
                   50                                  55                                  60  
 Phe Arg Tyr Cys Ser Gly Ser Cys Glu Ser Ala Glu Thr Met Tyr Asp  
                   65                                  70                                  75                                  80  
 Lys Ile Leu Lys Asn Leu Ser Arg Ser Arg Arg Leu Thr Ser Asp Lys  
                                   85                                  90                                  95  
 Val Gly Gln Ala Cys Cys Arg Pro Val Ala Phe Asp Asp Asp Leu Ser  
                                   100                                  105                                  110  
 Phe Leu Asp Asp Asn Leu Val Tyr His Ile Leu Arg Lys His Ser Ala  
                   115                                  120                                  125  
 Lys Arg Cys Gly Cys Ile  
                   130

## (2) INFORMATION FOR SEQ ID NO:78:



- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 134 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

```

Ser Pro Asp Lys Gln Ala Ala Ala Leu Pro Arg Arg Glu Arg Asn Arg
1          5          10          15
Gln Ala Ala Ala Ala Ser Pro Glu Asn Ser Arg Gly Lys Gly Arg Arg
20          25          30
Gly Gln Arg Gly Lys Asn Arg Gly Cys Val Leu Thr Ala Ile His Leu
35          40          45
Asn Val Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile
50          55          60
Phe Arg Tyr Cys Ser Gly Ser Cys Glu Ala Ala Glu Thr Met Tyr Asp
65          70          75          80
Lys Ile Leu Lys Asn Leu Ser Arg Ser Arg Arg Leu Thr Ser Asp Lys
85          90          95
Val Gly Gln Ala Cys Cys Arg Pro Val Ala Phe Asp Asp Asp Leu Ser
100         105         110
Phe Leu Asp Asp Ser Leu Val Tyr His Ile Leu Arg Lys His Ser Ala
115         120         125
Lys Arg Cys Gly Cys Ile
130

```

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 89 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

```

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly
1          5          10          15
Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys
20          25          30
Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg
35          40          45
Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr
50          55          60

```

Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln Gln Leu Pro  
 65 70 75 80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
 85

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 96 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Ala Leu Ala Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala  
 1 5 10 15  
 Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
 20 25 30  
 Cys Ala Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val  
 35 40 45  
 Leu Ala Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys  
 50 55 60  
 Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp Gln His His  
 65 70 75 80  
 Trp Gln Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
 85 90 95

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

This sequence is intentionally skipped.

(2) INFORMATION FOR SEQ ID NO:82:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 89 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30  
 Pro Gln Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
 35 40 45  
 Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
 50 55 60  
 Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro  
 65 70 75 80  
 Gln Leu Ser Ala Ala Ala Cys Gly Cys  
 85

## (2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 91 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30  
 Pro Gln Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg  
 35 40 45  
 Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr  
 50 55 60  
 Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro  
 65 70 75 80  
 Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
 85 90

## (2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 267 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

```

TGCCGACTGT GGAGCCTGAC CCTACCAGTG GCTGAGCTGG GCCTGGGCTA TGCCTCGGAG      60
GAGAAGGTCA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGCCCG TACCCAGCAC      120
AGTCTGGTAC TGGCCCCGGCT TCGAGGGCGG GGTGAGCCG ATGGCCGACC CTGCTGCCAG      180
CCCACCAGCT ATGCTGATGT GACCTTCCTT GATGATCAGC ACCATTGGCA GCAGCTGCCT      240
CAGCTCTCAG CTGCAGCTTG TGGCTGT                                           267

```

## (2) INFORMATION FOR SEQ ID NO:85:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 267 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

```

TGCCGGCTGT GGAGCCTGAC CCTACCAGTG GCTGAGCTTG GCCTGGGCTA TGCCTCAGAG      60
GAGAAGATTA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGTCCG TACCCAGCAC      120
AGTCTGGTGC TGGCCCCGTCT TCGAGGGCAG GGTGAGCTC ATGGCAGACC TTGCTGCCAG      180
CCCACCAGCT ATGCTGATGT GACCTTCCTT GATGACCACC ACCATTGGCA GCAGCTGCCT      240
CAGCTCTCAG CCGCAGCTTG TGGCTGT                                           267

```

## (2) INFORMATION FOR SEQ ID NO:86:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 273 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

```

TGCCGGCTGT GGAGCCTGAC CCTACCAGTG GCTGAGCTTG GCCTGGGCTA TGCCTCAGAG      60
GAGAAGATTA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGTCCG TACCCAGCAC      120
AGTCTGGTGC TGGCCCCGTCT TCGAGGGCAG GGTGAGCTC ATGGCAGACC TTGCTGCCAG      180
CCCACCAGCT ATGCTGATGT GACCTTCCTT GATGACCACC ACCATTGGCA GCAGCTGCCT      240
CAGCTCTCAG CCGCAGCTTG TGGCTGTGGT GGC                                           273

```

## (2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 94 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

```

Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly
1           5           10           15

Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys
          20           25           30

Glu Ser Ala Glu Thr Met Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg
          35           40           45

Ser Arg Arg Leu Thr Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro
          50           55           60

Val Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr
65           70           75           80

His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys Ile
          85           90

```

## (2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 95 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

```

Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly
1           5           10           15

Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys
          20           25           30

Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln
          35           40           45

Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala His Pro Cys Cys Arg
          50           55           60

Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Val His Ser Arg
65           70           75           80

Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu Cys Ala Cys Val
          85           90           95

```

## (2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 91 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

```

Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly
1           5           10           15
Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys
20           25           30
Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg
35           40           45
Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr
50           55           60
Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln Gln Leu Pro
65           70           75           80
Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly
85           90

```

## (2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 22 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

TGCCTCAGAG GAGAAGATTA TC

22

## (2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 7 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Ala Ser Glu Glu Lys Ile Ile  
1 5

(2) INFORMATION FOR SEQ ID NO:92:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Leu Gly Leu Gly Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:93:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Leu Gly Leu Gly Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:94:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:95:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

AGTCGGGGTT GGGGTATGCC TCA

23

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 26 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

TATGCCTCAG AGGAGAAGAT TATCTT

26

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 336 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

CCTCAGAGGA GAAGATTATC TTCCGATACT GTGCTGGCAG CTGTCCCCAA GAGGTCCGTA	60
CCCAGCACAG TCTGGTGCTG GCCCGTCTTC GAGGGCAGGG TCGAGCTCAT GGCAGACCTT	120
GCTGCCAGCC CACCAGCTAT GCTGATGTGA CCTTCCTTGA TGACCACCAC CATTGGCAGC	180
AGCTGCCTCA GCTCTCAGCC GCAGCTTGTG GCTGTGGTGG CTGAAGGCGG CCAGCCTGGT	240
CTCTCAGAAT CACAAGCAAG AGGCAGCCTT TGAAAGGCTC AGGTGACGTT ATTAGAAACT	300
TGCATAGGAG AAGATTAAGA AGAGAAAGGG GACCTG	336

(2) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Ala Cys Cys Arg Pro Val Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp  
 1 5 10 15  
 Asp

## (2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Lys Asp  
 1 5 10 15  
 Val

## (2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Pro Cys Cys Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 26 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

TCATCAAGGA AGGTCACATC AGCATA

## (2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 32 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

CCACCACAGC CACAAGCTGC GGSTGAGAGC TG

32

## (2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Ala Leu Ala Gly Ser  
1 5

## (2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

This sequence is intentionally skipped

## (2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 544 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

```

GAGGGACCTG GACGCCCCAT CAGGGTAAGA ATTCCTGGGG GCCTCCCGAC TCCCCAATTC      60
CTTCTCTCAA AGCCCTCACT TTGCCTTACA ATCCTACTCT ACCTTGCACT AGGTAACAAC      120
CATGTCCGTC TTCCAAGAGC CTTGGCTGGT TCATGCCGAC TGTGGAGCCT GACCCACCA      180
GTGGCTGAGC TGGGCCTGGG CTATGCCTCG GAGGAGAAGG TCATCTTCCG ATACTGTGCT      240
GGCAGCTGTC CCCAAGAGGC CCGTACCCAG CACAGTCTGG TACTGGCCCG GCTTCGAGGG      300
CGGGGTCGAG CCCATGGCCG ACCCTGCTGC CAGCCCACCA GCTATGCTGA TGTGACCTTC      360
CTTGATGATC AGCACCATTG GCAGCAGCTG CCTCAGCTCT CAGCTGCAGC TTGTGGCTGT      420
GGTGGCTGAA GGAGGCCAGT CTGGTGTCTC AGAATCACAA GCATGAGACA GGCTGGGCTT      480
TGAAAGGCTC AGGTGACATT ACTAGAAATT TGCATAGGTA AAGATAAGAA GGGAAAGGAC      540
CAGG

```

## (2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 73 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

```

Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys Pro Gln
1           5           10           15
Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg Gly Gln
20          25          30
Gly Arg Ala His Gly Arg Pro Cys Gln Pro Thr Ser Tyr Ala Asp
35          40          45
Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro Gln Leu
50          55          60
Ser Ala Ala Ala Cys Gly Cys Gly Gly
65          70

```

## (2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 391 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

```

TGCCGGCTGT GGAGCCTGAC CCTACCACTG GCTGAGCTTG GCCTGGGCTA TGCCTCAGAG      60
GAGAAGATTA TCTTCCGATA CTGTGCTGGC AGCTGTCCCC AAGAGGTCCG TACCCAGCAC      120
AGTCTGGTGC TGGCCCGTCT TCGAGGGCAG GGTGAGCTC ATGGCAGACC TTGCTGCCAG      180
CCCACCAGCT ATGCTGATGT GACCTTCCTT GATGACCACC ACCATTGGCA GCAGCTGCCT      240
CAGCTCTCAG CCGCAGCTTG TGGCTGTGGT GGCTGAAGGC GGCCAGCCTG GTCTCTCAGA      300
ATCACAAGCA AGAGGCAGCC TTTGAAAGGC TCAGGTGACG TTATTAGAAA CTTGCATAGG      360
AGAAGATTAA GAAGAGAAAG GGGACCTGAT T                                     391

```

## (2) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "SERINE, THREONINE, OR ALANINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

```

Val Xaa Xaa Leu Gly Leu Gly Tyr
1           5

```

## (2) INFORMATION FOR SEQ ID NO:109:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 5
- (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 7
- (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Phe Arg Tyr Cys Xaa Gly Xaa Cys  
1 5

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "ASPARTIC ACID, GLUTAMIC ACID OR NO AMINO ACID"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 4
- (D) OTHER INFORMATION: /note= "SERINE OR THREONINE"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 8
- (D) OTHER INFORMATION: /note= "valine or aspartic acid"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Asp Xaa Xaa Xaa Phe Leu Asp Xaa  
1 5

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 142 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Glu Gly Pro Gly Arg Pro Ile Arg Val Arg Ile Pro Gly Gly Leu Pro  
1 5 10 15

Thr Pro Gln Phe Leu Leu Ser Lys Pro Ser Leu Cys Leu Thr Ile Leu  
20 25 30

Leu Tyr Leu Ala Leu Gly Asn Asn His Val Arg Leu Pro Arg Ala Leu  
35 40 45

Ala Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu  
50 55 60

Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala  
65 70 75 80

Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala  
85 90 95

Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro  
100 105 110

Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln  
115 120 125

Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
130 135 140

## (2) INFORMATION FOR SEQ ID NO:112:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Ala Leu Pro Gly Leu  
1 5

## (2) INFORMATION FOR SEQ ID NO:113:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 2  
(D) OTHER INFORMATION: /note= "THREONINE, GLUTAMIC ACID OR  
LYSINE"

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 3  
(D) OTHER INFORMATION: /note= "VALINE, LEUCINE OR  
ISOLEUCINE"

- (ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 4  
(D) OTHER INFORMATION: /note= "LEUCINE OR ISOLEUCINE"

(ix) FEATURE:

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION: 11
      (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"
```

Glu Xaa Xaa Xaa Phe Arg Tyr Cys Xaa Gly Xaa Cys  
1 5 10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION: 3
      (D) OTHER INFORMATION: /note= "ARGININE OR GLUTAMINE"
```

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION: 6
      (D) OTHER INFORMATION: /note= "ALANINE OR SERINE"
```

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION: 7
      (D) OTHER INFORMATION: /note= "TYROSINE OR PHENYLALANINE"
```

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION: 8
      (D) OTHER INFORMATION: /note= "GLUTAMIC ACID, ASPARTIC
ACID OR ALANINE"
```

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION: 10
      (D) OTHER INFORMATION: /note= "GLUTAMIC ACID, ASPARTIC
ACID OR NO AMINO ACID"
```

```
(ix) FEATURE:
      (A) NAME/KEY: Modified-site
      (B) LOCATION: 11
      (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"
```

48063550.doc

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 16
- (D) OTHER INFORMATION: /note= "ASPARTIC ACID OR VALINE"

Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Phe Leu Asp Xaa  
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

23

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 19 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

19

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

20



## (2) INFORMATION FOR SEQ ID NO:118:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

TTYMGNTAYT GYDSNGGND NTG

23

## (2) INFORMATION FOR SEQ ID NO:119:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

GTNDGNGANY TGGGNYTNGG

20

## (2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

GTNDGNGANY TGGGNYTGGG NTT

23

## (2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

WCNTCNARRA ANGWNAVNTC

20

## (2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

WCNTCNARRA ANGWNAVNT

19

## (2) INFORMATION FOR SEQ ID NO:123:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

CANSHNCCNS HRCARTANCK RAA

23

## (2) INFORMATION FOR SEQ ID NO:124:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

CANSHNCCNS HRCARTANCK RAANA

25

## (2) INFORMATION FOR SEQ ID NO:125:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Modified-site

(B) LOCATION: 2  
 (D) OTHER INFORMATION: /note= "THREONINE, SERINE OR  
 ALANINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 3  
 (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC  
 ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Val Xaa Xaa Leu Gly Leu Gly Tyr  
 1 5

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 7 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 1  
 (D) OTHER INFORMATION: /note= "ASPARTIC ACID OR GLUTAMIC  
 ACID"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 2  
 (D) OTHER INFORMATION: /note= "VALINE OR LEUCINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 3  
 (D) OTHER INFORMATION: /note= "THREONINE OR SERINE"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 6  
 (D) OTHER INFORMATION: /note= "ASPARTIC ACID OR GLUTAMIC  
 ACID"

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 7  
 (D) OTHER INFORMATION: /note= "ASPARTIC ACID OR VALINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Xaa Xaa Xaa Phe Leu Xaa Xaa  
 1 5

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 8 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 5

(D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 7

(D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Phe Arg Tyr Cys Xaa Gly Xaa Cys  
1 5

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2

(D) OTHER INFORMATION: /note= "THREONINE, SERINE OR ALANINE"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 3

(D) OTHER INFORMATION: /note= "ASPARTIC ACID OR GLUTAMIC ACID"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

Val Xaa Xaa Leu Gly Leu Gly  
1 5

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 2

(D) OTHER INFORMATION: /note= "THREONINE, SERINE OR ALANINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 3
- (D) OTHER INFORMATION: /note= "GLUTAMIC ACID OR ASPARTIC

ACID"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Val Xaa Xaa Leu Gly Leu Gly Phe  
1 5

## (2) INFORMATION FOR SEQ ID NO:130:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /note= "ISOLEUCINE OR LEUCINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 6
- (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 8
- (D) OTHER INFORMATION: /note= "SERINE OR ALANINE"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Xaa Phe Arg Tyr Cys Xaa Gly Xaa Cys  
1 5

## (2) INFORMATION FOR SEQ ID NO:131:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 559 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

ATGGCTGCAG GAAGACTTCG GATCCTGTGT CTGCTGCTCC TGTCCTTGCA CCCGAGCCTC	60
GGCTGGGTCC TTGATCTTCA AGAGGCTTCT GTGGCAGATA AGCTCTCATT TGGGAAGATG	120
GCAGAGACTA GAGGGACCTG GACGCCCCAT CAGGGTAAGA ATTCTGGGG GCCTCCCCGAC	180

```

TCCCCAATTC CTTCTCTCAA AGCCCTCACT TTGCCTTACA ATCCTACTCT ACCTTGCACT      240
AGGTAACAAC CATGTCCGTC TTCCAAGAGC CTTGGCTGGT TCATGCCGAC TGTGGAGCCT      300
GACCCTACCA GTGGCTGAGC TGGGCCTGGG CTATGCCTCG GAGGAGAAGG TCATCTTCCG      360
ATACTGTGCT GGCAGCTGTC CCCAAGAGGC CCGTACCCAG CACAGTCTGG TACTGGCCCCG      420
GCTTCGAGGG CGGGGTCGAG CCCATGGCCG ACCCTGCTGC CAGCCCACCA GCTATGCTGA      480
TGTGACCTTC CTTGATGATC AGCACCATTG GCAGCAGCTG CCTCAGCTCT CAGCTGCAGC      540
TTGTGGCTGT GGTGGCTGA                                          559

```

## (2) INFORMATION FOR SEQ ID NO:132:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 133 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

```

Pro Asp Ala Arg Gly Val Pro Val Ala Asp Gly Glu Phe Ser Ser Glu
1          5          10          15
Gln Val Ala Lys Ala Gly Gly Thr Trp Leu Gly Thr His Arg Pro Leu
20        25        30
Ala Arg Leu Arg Arg Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu
35        40        45
Thr Leu Ser Val Ala Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys
50        55        60
Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr
65        70        75        80
Gln His Gly Leu Ala Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His
85        90        95
Gly Gly Pro Cys Cys Arg Pro Thr Arg Tyr Thr Asp Val Ala Phe Leu
100       105       110
Asp Asp Arg His Arg Trp Gln Arg Leu Pro Gln Leu Ser Ala Ala Ala
115       120       125
Cys Gly Cys Gly Gly
130

```

## (2) INFORMATION FOR SEQ ID NO:133:

- (i) SEQUENCE CHARACTERISTICS:

This sequence is intentionally skipped

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Cys	Val	Leu	Thr	Ala	Ile	His	Leu	Asn	Val	Thr	Asp	Leu	Gly	Leu	Gly
1				5					10					15	
Tyr	Glu	Thr	Lys	Glu	Glu	Leu	Ile	Phe	Arg	Tyr	Cys	Ser	Gly	Ser	Cys
			20					25					30		
Glu	Ala	Ala	Glu	Thr	Met	Tyr	Asp	Lys	Ile	Leu	Lys	Asn	Leu	Ser	Arg
		35					40					45			
Ser	Arg	Arg	Leu	Thr	Ser	Asp	Lys	Val	Gly	Gln	Ala	Cys	Cys	Arg	Pro
	50					55					60				
Val	Ala	Phe	Asp	Asp	Asp	Leu	Ser	Phe	Leu	Asp	Asp	Ser	Leu	Val	Tyr
65					70					75					80
His	Ile	Leu	Arg	Lys	His	Ser	Ala	Lys	Arg	Cys	Gly	Cys			
				85				90							

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

Met Ala Ala Gly Arg Leu Arg Ile Leu Cys Leu Leu Leu Leu Ser Leu  
1 5 10 15  
His Pro Ser Leu Gly Trp Val  
20

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 amino acids  
(B) TYPE: amino acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

Met	Ala	Ala	Gly	Arg	Leu	Arg	Ile	Leu	Phe	Leu	Leu	Leu	Ser	Leu
1				5				10					15	
His Leu Gly Leu Gly Trp Val														
20														

(2) INFORMATION FOR SEQ ID NO:137:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

AATCCCCAGG ACAGGCAGGG AAT

23

(2) INFORMATION FOR SEQ ID NO:138:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

CGGTACCCAG ATCTTCAGCC ACCACAGCCA CAAGC

35

(2) INFORMATION FOR SEQ ID NO:139:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 76 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

GGACTATCAT ATGGCCCACC ACCACCACCA CCACCACCAC GACGACGACG ACAAGGCCTT

60



GGCTGGTTCA TGCCGA

76

## (2) INFORMATION FOR SEQ ID NO:140:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 32 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

TGCTGTCACC ATGGCTGCAG GAAGACTTCG GA

32

## (2) INFORMATION FOR SEQ ID NO:141:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 96 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Ala	Leu	Ala	Gly	Ser	Cys	Arg	Leu	Trp	Ser	Leu	Thr	Leu	Pro	Val	Ala
1				5				10					15		
Glu	Leu	Gly	Leu	Gly	Tyr	Ala	Ser	Glu	Lys	Val	Ile	Phe	Arg	Tyr	
		20					25					30			
Cys	Ala	Gly	Ser	Cys	Pro	Gln	Glu	Ala	Arg	Thr	Gln	His	Ser	Leu	Val
		35					40					45			
Leu	Ala	Arg	Leu	Arg	Gly	Arg	Gly	Arg	Ala	His	Gly	Arg	Pro	Cys	Cys
		50				55					60				
Arg	Pro	Thr	Ala	Tyr	Glu	Asp	Glu	Val	Ser	Phe	Leu	Asp	Val	His	Ser
65					70					75				80	
Arg	Tyr	His	Thr	Leu	Gln	Glu	Leu	Ser	Ala	Arg	Glu	Cys	Ala	Cys	Val
				85					90					95	

## (2) INFORMATION FOR SEQ ID NO:142:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

TAATACGACT CACTATAGGG GAA

23

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 49 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

TCGTCTTCGT AAGCAGTCGG ACGGCAGCAG GGTCGGCCAT GGGCTCGAC

49

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

TGCTGCCGTC CGACTGCTTA CGAAGACGA

29

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

GTTATGCTAG TTATTGCTCA GCGGT

25

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 100 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Pro Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser  
 1 5 10 15  
 Glu Leu Gly Leu Gly Tyr Thr Ser Asp Glu Thr Val Leu Phe Arg Tyr  
 20 25 30  
 Cys Ala Gly Ala Cys Glu Ala Ala Ile Arg Ile Tyr Asp Leu Gly Leu  
 35 40 45  
 Arg Arg Leu Arg Gln Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala  
 50 55 60  
 His Pro Cys Cys Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp  
 65 70 75 80  
 Asp Gln His His Trp Gln Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys  
 85 90 95  
 Gly Cys Gly Gly  
 100

## (2) INFORMATION FOR SEQ ID NO:147:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 50 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

CACATCAGCA TAGCTGGTGG GCTGGCAGCA CGGGTGAGCA CGAGCACGTT

50

## (2) INFORMATION FOR SEQ ID NO:148:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 25 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

TGCTGCCAGC CCACCAGCTA TGCTG

25

## (2) INFORMATION FOR SEQ ID NO:149:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

CCTCGGAGGA GAAGTCATC TTC

23

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 98 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

Cys	Cys	Val	Arg	Gln	Leu	Tyr	Ile	Asp	Phe	Arg	Lys	Asp	Leu	Gly	Trp
1				5					10					15	
Lys	Trp	Ile	His	Glu	Pro	Lys	Gly	Tyr	His	Ala	Asn	Phe	Cys	Leu	Gly
			20					25					30		
Pro	Cys	Pro	Tyr	Ile	Trp	Ser	Leu	Asp	Thr	Gln	Tyr	Ser	Lys	Val	Leu
		35					40					45			
Ala	Leu	Tyr	Asn	Gln	His	Asn	Pro	Gly	Ala	Ser	Ala	Ala	Pro	Cys	Cys
		50				55						60			
Val	Pro	Gln	Ala	Leu	Glu	Pro	Leu	Pro	Ile	Val	Tyr	Tyr	Val	Gly	Arg
65					70					75				80	
Lys	Pro	Lys	Val	Glu	Gln	Leu	Ser	Asn	Met	Ile	Val	Arg	Ser	Cys	Lys
				85					90					95	
Cys	Ser														

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 98 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

Cys	Cys	Leu	Arg	Pro	Leu	Tyr	Ile	Asp	Phe	Lys	Arg	Asp	Leu	Gly	Trp
1				5					10					15	

Lys Trp Ile His Glu Pro Lys Gly Tyr Asn Ala Asn Phe Cys Ala Gly  
                   20                  25                  30  
 Ala Cys Pro Tyr Leu Trp Ser Ser Asp Thr Gln His Ser Arg Val Leu  
                   35                  40                  45  
 Ser Leu Tyr Asn Thr Ile Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys  
                   50                  55                  60  
 Val Ser Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Ile Gly Lys  
                   65                  70                  75                  80  
 Thr Pro Lys Ile Glu Gln Leu Ser Asn Met Ile Val Lys Ser Cys Lys  
                   85                  90                  95  
 Cys Ser

## (2) INFORMATION FOR SEQ ID NO:152:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 98 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

Cys Cys Val Arg Pro Leu Tyr Ile Asp Phe Arg Gln Asp Leu Gly Trp  
 1                  5                  10                  15  
 Lys Trp Val His Glu Pro Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly  
                   20                  25                  30  
 Pro Cys Pro Tyr Leu Arg Ser Ala Asp Thr Thr His Ser Thr Val Leu  
                   35                  40                  45  
 Gly Leu Tyr Asn Thr Leu Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys  
                   50                  55                  60  
 Val Pro Gln Asp Leu Glu Pro Leu Thr Ile Leu Tyr Tyr Val Gly Arg  
                   65                  70                  75                  80  
 Thr Pro Lys Val Glu Gln Leu Ser Asn Met Val Val Lys Ser Cys Lys  
                   85                  90                  95  
 Cys Ser

## (2) INFORMATION FOR SEQ ID NO:153:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 106 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

Cys Cys Lys Lys Gln Phe Phe Val Ser Phe Lys Asp Ile Gly Trp Asn  
 1 5 10 15  
 Asp Trp Ile Ile Ala Pro Ser Gly Tyr His Ala Asn Tyr Cys Glu Gly  
 20 25 30  
 Glu Cys Pro Ser His Ile Ala Gly Thr Ser Gly Ser Ser Leu Ser Phe  
 35 40 45  
 His Ser Thr Val Ile Asn His Tyr Arg Met Arg Gly His Ser Pro Phe  
 50 55 60  
 Ala Asn Leu Lys Ser Cys Cys Val Pro Thr Lys Leu Arg Pro Met Ser  
 65 70 75 80  
 Met Leu Tyr Tyr Asp Asp Gly Gln Asn Ile Ile Lys Lys Asp Ile Gln  
 85 90 95  
 Asn Met Ile Val Glu Glu Cys Gly Cys Ser  
 100 105

## (2) INFORMATION FOR SEQ ID NO:154:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 105 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

Cys Cys Arg Gln Gln Phe Phe Ile Asp Phe Arg Leu Ile Gly Trp Asn  
 1 5 10 15  
 Asp Trp Ile Ile Ala Pro Thr Gly Tyr Tyr Gly Asn Tyr Cys Glu Gly  
 20 25 30  
 Ser Cys Pro Ala Tyr Leu Ala Gly Val Pro Gly Ser Ala Ser Ser Phe  
 35 40 45  
 His Thr Ala Val Val Asn Gln Tyr Arg Met Arg Gly Leu Asn Pro Gly  
 50 55 60  
 Thr Val Asn Ser Cys Cys Ile Pro Thr Lys Leu Ser Thr Met Ser Met  
 65 70 75 80  
 Leu Tyr Phe Asp Asp Glu Tyr Asn Ile Val Lys Arg Asp Val Pro Asn  
 85 90 95  
 Met Ile Val Glu Glu Cys Gly Cys Ala  
 100 105

## (2) INFORMATION FOR SEQ ID NO:155:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 101 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

```

Cys Arg Arg Val Lys Phe Gln Val Asp Phe Asn Leu Ile Gly Trp Gly
1          5          10          15
Ser Trp Ile Ile Tyr Pro Lys Gln Tyr Asn Ala Tyr Arg Cys Glu Gly
          20          25          30
Glu Cys Pro Asn Pro Val Gly Glu Glu Phe His Pro Thr Asn His Ala
          35          40          45
Tyr Ile Gln Ser Leu Leu Lys Arg Tyr Gln Pro His Arg Val Pro Ser
          50          55          60
Thr Cys Cys Ala Pro Val Lys Thr Lys Pro Leu Ser Met Leu Tyr Val
          65          70          75          80
Asp Asn Gly Arg Val Leu Leu Glu His His Lys Asp Met Ile Val Glu
          85          90          95
Glu Cys Gly Cys Leu
          100

```

(2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 101 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

```

Cys Lys Arg His Pro Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn
1          5          10          15
Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala Phe Tyr Cys His Gly
          20          25          30
Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala
          35          40          45
Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys Ala
          50          55          60
Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp
          65          70          75          80
Glu Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp Met Val Val Glu
          85          90          95
Gly Cys Gly Cys Arg
          100

```

## (2) INFORMATION FOR SEQ ID NO:157:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 101 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

```

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn
1           5           10           15
Asp Trp Ile Val Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gly
                20           25           30
Asp Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala
                35           40           45
Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Ser Ile Pro Lys Ala
                50           55           60
Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp
65           70           75           80
Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu Met Val Val Glu
                85           90           95
Gly Cys Gly Cys Arg
                100

```

## (2) INFORMATION FOR SEQ ID NO:158:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 102 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

```

Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asp
1           5           10           15
Asp Trp Ile Val Ala Pro Leu Gly Tyr Asp Ala Tyr Tyr Cys His Gly
                20           25           30
Lys Cys Pro Phe Pro Leu Ala Asp His Phe Asn Ser Thr Asn His Ala
                35           40           45
Val Val Gln Thr Leu Val Asn Asn Met Asn Pro Gly Lys Val Pro Lys
50           55           60
Ala Cys Cys Val Pro Thr Gln Leu Asp Ser Val Ala Met Leu Tyr Leu
65           70           75           80

```



Asn Asp Gln Ser Thr Val Val Leu Lys Asn Tyr Gln Glu Met Thr Val  
                     85                    90                    95

Val Gly Cys Gly Cys Arg  
                     100

(2) INFORMATION FOR SEQ ID NO:159:

- (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 102 amino acids  
     (B) TYPE: amino acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln  
   1                    5                    10                    15  
 Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Phe Tyr Cys Asp Gly  
                     20                    25                    30  
 Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala  
                     35                    40                    45  
 Ile Val Gln Thr Leu Val His Leu Met Phe Pro Asp His Val Pro Lys  
                     50                    55                    60  
 Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe  
   65                    70                    75                    80  
 Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val  
                     85                    90                    95  
 Arg Ser Cys Gly Cys His  
                     100

(2) INFORMATION FOR SEQ ID NO:160:

- (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 102 amino acids  
     (B) TYPE: amino acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

Cys Arg Lys His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Gln  
   1                    5                    10                    15  
 Asp Trp Ile Ile Ala Pro Lys Gly Tyr Ala Ala Asn Tyr Cys Asp Gly  
                     20                    25                    30  
 Glu Cys Ser Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala  
                     35                    40                    45

Ile Val Gln Thr Leu Val His Leu Met Asn Pro Glu Tyr Val Pro Lys  
 50 55 60

Pro Cys Cys Ala Pro Thr Lys Leu Asn Ala Ile Ser Val Leu Tyr Phe  
 65 70 75 80

Asp Asp Asn Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val  
 85 90 95

Arg Ala Cys Gly Cys His  
 100

## (2) INFORMATION FOR SEQ ID NO:161:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 102 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg Asp Leu Gly Trp Gln  
 1 5 10 15

Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly  
 20 25 30

Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala Thr Asn His Ala  
 35 40 45

Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Glu Thr Val Pro Lys  
 50 55 60

Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser Val Leu Tyr Phe  
 65 70 75 80

Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr Arg Asn Met Val Val  
 85 90 95

Arg Ala Cys Gly Cys His  
 100

## (2) INFORMATION FOR SEQ ID NO:162:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 102 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

Cys Arg Arg His Glu Leu Tyr Val Ser Phe Gln Asp Leu Gly Trp Leu  
 1 5 10 15

```

Asp Trp Val Ile Ala Pro Gln Gly Tyr Ser Ala Tyr Tyr Cys Glu Gly
    20                      25                      30

Glu Cys Ser Phe Pro Leu Asp Ser Cys Met Asn Ala Thr Asn His Ala
    35                      40                      45

Ile Leu Gln Ser Leu Val His Leu Met Lys Pro Asn Ala Val Pro Lys
    50                      55                      60

Ala Cys Cys Ala Pro Thr Lys Leu Ser Ala Thr Ser Val Leu Tyr Tyr
    65                      70                      75                      80

Asp Ser Ser Asn Asn Val Ile Leu Arg Lys His Arg Asn Met Val Val
    85                      90                      95

Lys Ala Cys Gly Cys His
    100

```

## (2) INFORMATION FOR SEQ ID NO:163:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 102 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

```

Cys Gln Met Gln Thr Leu Tyr Ile Asp Phe Lys Asp Leu Gly Trp His
1                      5                      10                      15

Asp Trp Ile Ile Ala Pro Glu Gly Tyr Gly Ala Phe Tyr Cys Ser Gly
    20                      25                      30

Glu Cys Asn Phe Pro Leu Asn Ala His Met Asn Ala Thr Asn His Ala
    35                      40                      45

Ile Val Gln Thr Leu Val His Leu Leu Glu Pro Lys Lys Val Pro Lys
    50                      55                      60

Pro Cys Cys Ala Pro Thr Arg Leu Gly Ala Leu Pro Val Leu Tyr His
    65                      70                      75                      80

Leu Asn Asp Glu Asn Val Asn Leu Lys Lys Tyr Arg Asn Met Ile Val
    85                      90                      95

Lys Ser Cys Gly Cys His
    100

```

## (2) INFORMATION FOR SEQ ID NO:164:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 103 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

Cys Ala Arg Arg Tyr Leu Lys Val Asp Phe Ala Asp Ile Gly Trp Ser  
 1                      5                      10                      15  
 Glu Trp Ile Ile Ser Pro Lys Ser Phe Asp Ala Tyr Tyr Cys Ser Gly  
                     20                      25                      30  
 Ala Cys Gln Phe Pro Met Pro Lys Ser Leu Lys Pro Ser Asn His Ala  
                     35                      40                      45  
 Thr Ile Gln Ser Ile Val Arg Ala Val Gly Val Val Pro Gly Ile Pro  
                     50                      55                      60  
 Glu Pro Cys Cys Val Pro Glu Lys Met Ser Ser Leu Ser Ile Leu Phe  
 65                      70                      75                      80  
 Phe Asp Glu Asn Lys Asn Val Val Leu Lys Val Tyr Pro Asn Met Thr  
                     85                      90                      95  
 Val Glu Ser Cys Ala Cys Arg  
                     100

## (2) INFORMATION FOR SEQ ID NO:165:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 102 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

Cys Lys Lys Arg His Leu Tyr Val Glu Phe Lys Asp Val Gly Trp Gln  
 1                      5                      10                      15  
 Asn Trp Val Ile Ala Pro Gln Gly Tyr Met Ala Asn Tyr Cys Tyr Gly  
                     20                      25                      30  
 Glu Cys Pro Tyr Pro Leu Thr Glu Ile Leu Asn Gly Ser Asn His Ala  
                     35                      40                      45  
 Ile Leu Gln Thr Leu Val His Ser Ile Glu Pro Glu Asp Ile Pro Leu  
                     50                      55                      60  
 Pro Cys Cys Val Pro Thr Lys Met Ser Pro Ile Ser Met Leu Phe Tyr  
 65                      70                      75                      80  
 Asp Asn Asn Asp Asn Val Val Leu Arg His Tyr Glu Asn Met Ala Val  
                     85                      90                      95  
 Asp Glu Cys Gly Cys Arg  
                     100

## (2) INFORMATION FOR SEQ ID NO:166:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 106 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

```

Cys Arg Ala Arg Arg Leu Tyr Val Ser Phe Arg Glu Val Gly Trp His
1           5           10           15
Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn Tyr Cys Gln Gly
20           25           30
Gln Cys Ala Leu Pro Val Ala Leu Ser Gly Ser Gly Gly Pro Pro Ala
35           40           45
Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala Ala Ala Pro Gly
50           55           60
Ala Ala Asp Leu Pro Cys Cys Val Pro Ala Arg Leu Ser Pro Ile Ser
65           70           75           80
Val Leu Phe Phe Asp Asn Ser Asp Asn Val Leu Arg Gln Tyr Glu
85           90           95
Asp Met Val Val Asp Glu Cys Gly Cys Arg
100          105

```

(2) INFORMATION FOR SEQ ID NO:167:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

```

Cys His Arg His Gln Leu Phe Ile Asn Phe Gln Asp Leu Gly Trp His
1           5           10           15
Lys Trp Val Ile Ala Pro Lys Gly Phe Met Ala Asn Tyr Cys His Gly
20           25           30
Glu Cys Pro Phe Ser Met Thr Thr Tyr Leu Asn Ser Ser Asn Tyr Ala
35           40           45
Phe Met Gln Ala Leu Met His Met Ala Asp Pro Lys Val Pro Lys Ala
50           55           60
Val Cys Val Pro Thr Lys Leu Ser Pro Ile Ser Met Leu Tyr Gln Asp
65           70           75           80
Ser Asp Lys Asn Val Ile Leu Arg His Tyr Glu Asp Met Val Val Asp
85           90           95
Glu Cys Gly Cys Gly
100

```

## (2) INFORMATION FOR SEQ ID NO:168:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 103 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

```

Cys Arg Arg Thr Ser Leu His Val Asn Phe Lys Glu Ile Gly Trp Asp
1           5           10           15
Ser Trp Ile Ile Ala Pro Lys Asp Tyr Glu Ala Phe Glu Cys Lys Gly
          20           25           30
Gly Cys Phe Phe Pro Leu Thr Asp Asn Val Thr Pro Thr Lys His Ala
          35           40           45
Ile Val Gln Thr Leu Val His Leu Gln Asn Pro Lys Lys Ala Ser Lys
          50           55           60
Ala Cys Cys Val Pro Thr Lys Leu Asp Ala Ile Ser Ile Leu Tyr Lys
          65           70           75           80
Asp Asp Ala Gly Val Pro Thr Leu Ile Tyr Asn Tyr Glu Gly Met Lys
          85           90           95
Val Ala Glu Cys Gly Cys Arg
          100

```

## (2) INFORMATION FOR SEQ ID NO:169:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 105 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

```

Cys His Arg Val Ala Leu Asn Ile Ser Phe Gln Glu Leu Gly Trp Glu
1           5           10           15
Arg Trp Ile Val Tyr Pro Pro Ser Phe Ile Phe His Tyr Cys His Gly
          20           25           30
Gly Cys Gly Leu His Ile Pro Pro Asn Leu Ser Leu Pro Val Pro Gly
          35           40           45
Ala Pro Pro Thr Pro Ala Gln Pro Tyr Ser Leu Leu Pro Gly Ala Gln
          50           55           60
Pro Cys Cys Ala Ala Leu Pro Gly Thr Met Arg Pro Leu His Val Arg
          65           70           75           80

```

Thr Thr Ser Asp Gly Gly Tyr Ser Phe Lys Tyr Glu Thr Val Pro Asn  
85 90 95

Leu Leu Thr Gln His Cys Ala Cys Ile  
100 105

(2) INFORMATION FOR SEQ ID NO:170:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 99 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

Cys Ala Leu Arg Glu Leu Ser Val Asp Leu Arg Ala Glu Arg Ser Val  
1 5 10 15  
 Leu Ile Pro Glu Thr Tyr Gln Ala Asn Asn Cys Gln Gly Ala Cys Gly  
20 25 30  
 Trp Pro Gln Ser Asp Arg Asn Pro Arg Tyr Gly Asn His Val Val Leu  
35 40 45  
 Leu Leu Lys Met Gln Ala Arg Gly Ala Thr Leu Ala Arg Pro Pro Cys  
50 55 60  
 Cys Val Pro Thr Ala Tyr Thr Gly Lys Leu Leu Ile Ser Leu Ser Glu  
65 70 75 80  
 Glu Arg Ile Ser Ala His His Val Pro Asn Met Val Ala Thr Glu Cys  
85 90 95  
 Gly Cys Arg

(2) INFORMATION FOR SEQ ID NO:171:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 102 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

Cys Glu Leu His Asp Phe Ser Leu Ser Phe Ser Gln Leu Lys Trp Asp  
1 5 10 15  
 Asn Trp Ile Val Ala Pro His Ser Tyr Asn Pro Ser Tyr Cys Lys Gly  
20 25 30  
 Asp Cys Pro Ser Ala Val Ser His Arg Tyr Gly Ser Pro Val His Thr  
35 40 45

Met Val Gln Asn Met Ile Tyr Glu Lys Leu Asp Pro Ser Val Pro Ser  
 50 55 60

Pro Ser Cys Val Pro Gly Lys Tyr Ser Pro Leu Ser Val Leu Thr Ile  
 65 70 75 80

Glu Pro Asp Gly Ser Ile Ala Tyr Lys Glu Tyr Glu Asp Met Met Ala  
 85 90 95

Thr Ser Cys Thr Cys Arg  
 100

## (2) INFORMATION FOR SEQ ID NO:172:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 94 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly  
 1 5 10 15

Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys  
 20 25 30

Asp Ala Ala Glu Thr Thr Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg  
 35 40 45

Asn Arg Arg Leu Val Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro  
 50 55 60

Ile Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr  
 65 70 75 80

His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys Ile  
 85 90

## (2) INFORMATION FOR SEQ ID NO:173:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 95 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly  
 1 5 10 15

Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys  
 20 25 30



Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln  
                   35                  40                  45

Arg Arg Arg Leu Arg Arg Glu Arg Val Arg Ala Gln Pro Cys Cys Arg  
           50                  55                  60

Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Ala His Ser Arg  
   65                  70                  75                  80

Tyr His Thr Val His Glu Leu Ser Ala Arg Glu Cys Ala Cys Val  
                   85                  90                  95

## (2) INFORMATION FOR SEQ ID NO:174:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 37 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

Leu Asp Leu Gln Glu Ala Ser Val Ala Asp Lys Leu Ser Phe Gly Lys  
   1                  5                  10                  15

Met Ala Glu Thr Arg Gly Thr Trp Thr Pro His Gln Gly Asn Asn His  
                   20                  25                  30

Val Arg Leu Pro Arg  
           35

## (2) INFORMATION FOR SEQ ID NO:175:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 37 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

Leu Asp Leu Gln Glu Ala Pro Ala Ala Asp Glu Leu Ser Ser Gly Lys  
   1                  5                  10                  15

Met Ala Glu Thr Gly Arg Thr Trp Lys Pro His Gln Gly Asn Asn Asn  
                   20                  25                  30

Val Arg Leu Pro Arg  
           35

## (2) INFORMATION FOR SEQ ID NO:176:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 93 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

```

Cys Val Leu Thr Ala Ile His Leu Asn Val Thr Asp Leu Gly Leu Gly
 1             5             10             15
Tyr Glu Thr Lys Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly Ser Cys
      20             25             30
Glu Ser Ala Glu Thr Met Tyr Asp Lys Ile Leu Lys Asn Leu Ser Arg
      35             40             45
Ser Arg Arg Leu Thr Ser Asp Lys Val Gly Gln Ala Cys Cys Arg Pro
      50             55             60
Val Ala Phe Asp Asp Asp Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr
      65             70             75             80
His Ile Leu Arg Lys His Ser Ala Lys Arg Cys Gly Cys
      85             90

```

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 723 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

```

ATGGCTGCAG GAAGACTTCG GATCCTGTGT CTGCTGCTCC TGTCTTGCA CCCGAGCCTC      60
GGCTGGGTCC TTGATCTTCA AGAGGCTTCT GTGGCAGATA AGCTCTCATT TGGGAAGATG      120
GCAGAGACTA GAGGGACCTG GACGCCCCAT CAGGGTAAGA ATTCCTGGGG GCCTCCCGAC      180
TCCCCAATTC CTTCTCTCAA AGCCCTCACT TTGCCTTACA ATCCTACTCT ACCTTGCACT      240
AGGTAACAAC CATGTCCGTC TTCCAAGAGC CTTGGCTGGT TCATGCCGAC TGTGGAGCCT      300
GACCCTACCA GTGGCTGAGC TGGGCTGGG CTATGCCTCG GAGGAGAAGG TCATCTTCCG      360
ATACTGTGCT GGCAGCTGTC CCCAAGAGGC CCGTACCCAG CACAGTCTGG TACTGGCCCG      420
GCTTCGAGGG CGGGGTCGAG CCCATGGCCG ACCCTGCTGC CAGCCCACCA GCTATGCTGA      480
TGTGACCTTC CTTGATGATC AGCACCATTG GCAGCAGCTG CCTCAGCTCT CAGCTGCAGC      540
TTGTGGCTGT GGTGGCTGAA GGAGGCCAGT CTGGTGTCTC AGAATCACAA GCATGAGACA      600
GGCTGGGCTT TGAAAGGCTC AGGTGACATT ACTAGAAATT TGCATAGGTA AAGATAAGAA      660
GGGAAAGGAC CAGGGGTTTT TTGTTCTTT CTTGCTTGC TTGTTAGTTT TTTTTTTTTT      720

```

TTT

723

## (2) INFORMATION FOR SEQ ID NO:178:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 723 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

```

AAAAAAAAA AAAAAACTAA CAAGCAAGCA AAGAAAGAAA CAAAAAACCC CTGGTCCTTT      60
CCCTTCTTAT CTTTACCTAT GCAAATTTCT AGTAATGTCA CCTGAGCCTT TCAAAGCCCA      120
GCCTGTCTCA TGCTTGTGAT TCTGAGACAC CAGACTGGCC TCCTTCAGCC ACCACAGCCA      180
CAAGCTGCAG CTGAGAGCTG AGGCAGCTGC TGCCAATGGT GCTGATCATC AAGGAAGGTC      240
ACATCAGCAT AGCTGGTGGG CTGGCAGCAG GGTCGGCCAT GGGCTCGACC CCGCCCTCGA      300
AGCCGGGGCCA GTACCAGACT GTGCTGGGTA CGGGCCTCTT GGGGACAGCT GCCAGCACAG      360
TATCGGAAGA TGACCTTCTC CTCCGAGGCA TAGCCCAGGC CCAGCTCAGC CACTGGTAGG      420
GTCAGGCTCC ACAGTCGGCA TGAACCAGCC AAGGCTCTTG GAAGACGGAC ATGATTGTGA      480
CCTAGTGCAA GGTAGAGTAG GATTGTAAGG CAAAGTGAGG GCTTTGAGAG AAGGAATTGG      540
GGAGTCGGGA GGCCCCCAGG AATTCTTACC CTGATGGGGC GTCCAGGTCC CTCTAGTCTC      600
TGCCATCTTC CCAAATGAGA GCTTATCTGC CACAGAAGCC TCTTGAAGAT CAAGACCCA      660
GCCGAGGCTC GGGTGCAAGG ACAGGAGCAG CAGACACAGG ATCCGAAGTC TTCCTGCAGC      720
CAT                                                                    723

```

## (2) INFORMATION FOR SEQ ID NO:179:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

```

ATGGCTGCAG GAAGACTTCG GATCCTGTGT CTGCTGCTCC TGTCTTGCA CCCGAGCCTC      60
GGCTGGGTCC TTGATCTTCA AGAGGCTTCT GTGGCAGATA AGCTCTCATT TGGGAAGATG      120
GCAGAGACTA GAGGGACCTG GACGCCCCAT CAGGGTAACA ACCATGTCCG TCTTCCAAGA      180
GCCTTGCTG GTTCATGCCG ACTGTGGAGC CTGACCCTAC CAGTGGCTGA GCTGGGCCTG      240

```

```

GGCTATGCCT CGGAGGAGAA GGTATCTTTC CGATACTGTG CTGGCAGCTG TCCCCAAGAG      300
GCCCCGTACCC AGCACAGTCT GGTACTGGCC CGGCTTCGAG GGCGGGGTCG AGCCCATGGC      360
CGACCCTGCT GCCAGCCCAC CAGCTATGCT GATGTGACCT TCCTTGATGA TCAGCACCAT      420
TGGCAGCAGC TGCCTCAGCT CTCAGCTGCA GCTTGTGGCT GTGGTGGCTG A                471

```

## (2) INFORMATION FOR SEQ ID NO:180:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 471 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

```

TCAGCCACCA CAGCCACAAG CTGCAGCTGA GAGCTGAGGC AGCTGCTGCC AATGGTGCTG      60
ATCATCAAGG AAGGTCACAT CAGCATAGCT GGTGGGCTGG CAGCAGGGTC GGCCATGGGC      120
TCGACCCCGC CCTCGAAGCC GGGCCAGTAC CAGACTGTGC TGGGTACGGG CCTCTTGGGG      180
ACAGCTGCCA GCACAGTATC GGAAGATGAC CTTCTCCTCC GAGGCATAGC CCAGGCCCAG      240
CTCAGCCACT GGTAGGTCA GGCTCCACAG TCGGCATGAA CCAGCCAAGG CTCTTGAAG      300
ACGGACATGG TTGTTACCCT GATGGGGCGT CCAGGTCCTT CTAGTCTCTG CCATCTTCCC      360
AAATGAGAGC TTATCTGCCA CAGAAGCCTC TTGAAGATCA AGGACCCAGC CGAGGCTCGG      420
GTGCAAGGAC AGGAGCAGCA GACACAGGAT CCGAAGTCTT CCTGCAGCCA T                471

```

## (2) INFORMATION FOR SEQ ID NO:181:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

```

ATGGCTGCAG GAAGACTTCG GATCCTGTGT CTGCTGCTCC TGTCTTGCA CCCGAGCCTC      60
GGCTGGGTCC TTGATCTTCA AGAGGCTTCT GTGGCAGATA AGCTCTCATT TGGGAAGATG      120
GCAGAGACTA GAGGGACCTG GACGCCCCAT CAGGGTAACA ACCATGTCCG TCTTCCAAGA      180

```

## (2) INFORMATION FOR SEQ ID NO:182:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 180 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

TCTTGAAGA CGGACATGGT TGTTACCCTG ATGGGGCGTC CAGGTCCCTC TAGTCTCTGC	60
CATCTTCCCA AATGAGAGCT TATCTGCCAC AGAAGCCTCT TGAAGATCAA GGACCCAGCC	120
GAGGCTCGGG TGCAAGGACA GGAGCAGCAG ACACAGGATC CGAAGTCTTC CTGCAGCCAT	180

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

GCCTTGGCTG GTTCATGCCG ACTGTGGAGC CTGACCCTAC CAGTGGCTGA GCTGGGCCTG	60
GGCTATGCCT CGGAGGAGAA GGTCACTTTC CGATACTGTG CTGGCAGCTG TCCCCAAGAG	120
GCCCGTACCC AGCACAGTCT GGTACTGGCC CGGCTTCGAG GCGGGGTCG AGCCCATGGC	180
CGACCCTGCT GCCAGCCAC CAGCTATGCT GATGTGACCT TCCTTGATGA TCAGCACCAT	240
TGGCAGCAGC TGCCTCAGCT CTCAGCTGCA GCTTGTGGCT GTGGTGGCTG A	291

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

TCAGCCACCA CAGCCACAAG CTGCAGCTGA GAGCTGAGGC AGCTGCTGCC AATGGTGCTG	60
ATCATCAAGG AAGGTCACAT CAGCATAGCT GGTGGGCTGG CAGCAGGGTC GGCCATGGGC	120
TCGACCCCGC CCTCGAAGCC GGGCCAGTAC CAGACTGTGC TGGGTACGGG CCTCTTGGGG	180
ACAGCTGCCA GCACAGTATC GGAAGATGAC CTTCTCCTCC GAGGCATAGC CCAGGCCCCAG	240
CTCAGCCACT GGTAGGGTCA GGCTCCACAG TCGGCATGAA CCAGCCAAGG C	291

(2) INFORMATION FOR SEQ ID NO:185:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 156 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

```

Met Ala Ala Gly Arg Leu Arg Ile Leu Cys Leu Leu Leu Leu Ser Leu
1           5           10           15

His Pro Ser Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Ser Val Ala
20           25           30

Asp Lys Leu Ser Phe Gly Lys Met Ala Glu Thr Arg Gly Thr Trp Thr
35           40           45

Pro His Gln Gly Asn Asn His Val Arg Leu Pro Arg Ala Leu Ala Gly
50           55           60

Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu
65           70           75           80

Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser
85           90           95

Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu
100          105          110

Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser
115          120          125

Tyr Ala Asp Val Thr Phe Leu Asp Asp Gln His His Trp Gln Gln Leu
130          135          140

Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly
145          150          155

```

(2) INFORMATION FOR SEQ ID NO:186:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 60 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

```

Met Ala Ala Gly Arg Leu Arg Ile Leu Cys Leu Leu Leu Leu Ser Leu
1           5           10           15

His Pro Ser Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Ser Val Ala
20           25           30

```

Asp Lys Leu Ser Phe Gly Lys Met Ala Glu Thr Arg Gly Thr Trp Thr  
35 40 45

Pro His Gln Gly Asn Asn His Val Arg Leu Pro Arg  
50 55 60

(2) INFORMATION FOR SEQ ID NO:187:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 96 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

Ala Leu Ala Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala  
1 5 10 15  
Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
20 25 30  
Cys Ala Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val  
35 40 45  
Leu Ala Arg Leu Arg Gly Arg Gly Arg Ala His Gly Arg Pro Cys Cys  
50 55 60  
Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp Gln His His  
65 70 75 80  
Trp Gln Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
85 90 95

(2) INFORMATION FOR SEQ ID NO:188:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 559 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

ATGGCTGCAG GAAGACTTCG GATCTTGTTT CTGCTGCTCC TGTCCTTGCA CCTGGGCCTT 60  
 GGCTGGGTCC TTGATCTTCA AGAGGCTCCT GCGGCAGATG AGCTCTCATC TGGGAAATG 120  
 GCAGAGACTG GAAGGACCTG GAAGCCCCAT CAGGGTAAGA ATTCTTGGGG GCCTCCTAAC 180  
 TCTACAGTTC TTCCTCTCAA AGCCCTCACT TTGCCTCACA ATCCTATTCT ACCTTGCACT 240  
 AGGTAACAAC AATGTCCGCC TTCCAAGAGC CTTACCTGGT TTGTGCCGGC TGTGGAGCCT 300  
 GACCCTACCA GTGGCTGAGC TTGGCCTGGG CTATGCCTCA GAGGAGAAGA TTATCTTCCG 360

ATACTGTGCT GGCAGCTGTC CCCAAGAGGT CCGTACCCAG CACAGTCTGG TGCTGGCCCCG 420  
TCTTCGAGGG CAGGGTCGAG CTCATGGCAG ACCTTGCTGC CAGCCCACCA GCTATGCTGA 480  
TGTGACCTTC CTGATGACC ACCACCATTG GCAGCAGCTG CCTCAGCTCT CAGCCGCAGC 540  
TTGTGGCTGT GGTGGCTGA 559

(2) INFORMATION FOR SEQ ID NO:189:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 559 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

TCAGCCACCA CAGCCACAAG CTGCGGCTGA GAGCTGAGGC AGCTGCTGCC AATGGTGGTG 60  
GTCATCAAGG AAGGTCACAT CAGCATAGCT GGTGGGCTGG CAGCAAGGTC TGCCATGAGC 120  
TCGACCCTGC CCTCGAAGAC GGGCCAGCAC CAGACTGTGC TGGGTACGGA CCTCTTGGGG 180  
ACAGCTGCCA GCACAGTATC GGAAGATAAT CTTCTCCTCT GAGGCATAGC CCAGGCCAAG 240  
CTCAGCCACT GGTAGGGTCA GGCTCCACAG CCGGCACAAA CCAGGTAAGG CTCTTGGAAG 300  
GCGGACATTG TTGTTACCTA GTGCAAGGTA GAATAGGATT GTGAGGCAAA GTGAGGGCTT 360  
TGAGAGGAAG AACTGTAGAG TTAGGAGGCC CCCAAGAATT CTTACCCTGA TGGGGCTTCC 420  
AGGTCCTTCC AGTCTCTGCC ATTTTCCCAG ATGAGAGCTC ATCTGCCGCA GGAGCCTCTT 480  
GAAGATCAAG GACCCAGCCA AGGCCAGGT GCAAGGACAG GAGCAGCAGA AACAAGATCC 540  
GAAGTCTTCC TGCAGCCAT 559

(2) INFORMATION FOR SEQ ID NO:190:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 471 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

ATGGCTGCAG GAAGACTTCG GATCTTGTTT CTGCTGCTCC TGTCTTGCA CCTGGGCCTT 60  
GGCTGGGTCC TTGATCTTCA AGAGGCTCCT GCGGCAGATG AGCTCTCATC TGGGAAAATG 120  
GCAGAGACTG GAAGGACCTG GAAGCCCCAT CAGGGTAACA ACAATGTCCG CCTTCCAAGA 180  
GCCTTACCTG GTTTGTGCCG GCTGTGGAGC CTGACCCTAC CAGTGGCTGA GCTTGGCCTG 240



GGCTATGCCT CAGAGGAGAA GATTATCTTC CGATACTGTG CTGGCAGCTG TCCCCAAGAG 300  
 GTCCGTACCC AGCACAGTCT GGTGCTGGCC CGTCTTCGAG GGCAGGGTCG AGCTCATGGC 360  
 AGACCTTGCT GCCAGCCCAC CAGCTATGCT GATGTGACCT TCCTTGATGA CCACCACCAT 420  
 TGGCAGCAGC TGCCTCAGCT CTCAGCCGCA GCTTGTGGCT GTGGTGGCTG A 471

(2) INFORMATION FOR SEQ ID NO:191:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 471 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

TCAGCCACCA CAGCCACAAG CTGCGGCTGA GAGCTGAGGC AGCTGCTGCC AATGGTGGTG 60  
 GTCATCAAGG AAGGTCACAT CAGCATAGCT GGTGGGCTGG CAGCAAGGTC TGCCATGAGC 120  
 TCGACCCTGC CCTCGAAGAC GGGCCAGCAC CAGACTGTGC TGGGTACGGA CCTCTTGGGG 180  
 ACAGCTGCCA GCACAGTATC GGAAGATAAT CTTCTCCTCT GAGGCATAGC CCAGGCCAAG 240  
 CTCAGCCACT GGTAGGGTCA GGCTCCACAG CCGGCACAAA CCAGGTAAGG CTCTTGGAAG 300  
 GCGGACATTG TTGTTACCCT GATGGGGCTT CCAGGTCCTT CCACTCTCTG CCATTTTCCC 360  
 AGATGAGAGC TCATCTGCCG CAGGAGCCTT TTGAAGATCA AGGACCCAGC CAAGGCCCAG 420  
 GTGCAAGGAC AGGAGCAGCA GAAACAAGAT CCGAAGTCTT CCTGCAGCCA T 471

(2) INFORMATION FOR SEQ ID NO:192:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 180 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

ATGGCTGCAG GAAGACTTCG GATCTTGTTT CTGCTGCTCC TGTCTTGCA CCTGGGCCTT 60  
 GGCTGGGTCC TTGATCTTCA AGAGGCTCCT GCGGCAGATG AGCTCTCATC TGGGAAAATG 120  
 GCAGAGACTG GAAGGACCTG GAAGCCCCAT CAGGGTAACA ACAATGTCCG CCTTCCAAGA 180

(2) INFORMATION FOR SEQ ID NO:193:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 180 base pairs  
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

```
TCTTGGAAGG CGGACATTGT TGTTACCCTG ATGGGGCTTC CAGGTCCTTC CAGTCTCTGC      60
CATTTCCTCA GATGAGAGCT CATCTGCCGC AGGAGCCTCT TGAAGATCAA GGACCCAGCC      120
AAGGCCCAGG TGCAAGGACA GGAGCAGCAG AAACAAGATC CGAAGTCTTC CTGCAGCCAT      180
```

(2) INFORMATION FOR SEQ ID NO:194:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

```
GCCTTACCTG GTTGTGCGG GCTGTGGAGC CTGACCCTAC CAGTGGCTGA GCTTGGCCTG      60
GGCTATGCCT CAGAGGAGAA GATTATCTTC CGATACTGTG CTGGCAGCTG TCCCCAAGAG      120
GTCCGTACCC AGCACAGTCT GGTGCTGGCC CGTCTTCGAG GGCAGGGTCG AGTCATGGC      180
AGACCTTGCT GCCAGCCAC CAGCTATGCT GATGTGACCT TCCTTGATGA CCACCACCAT      240
TGGCAGCAGC TGCCTCAGCT CTCAGCCGCA GCTTGTGGCT GTGGTGGCTG A              291
```

(2) INFORMATION FOR SEQ ID NO:195:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

```
TCAGCCACCA CAGCCACAAG CTGCGGCTGA GAGCTGAGGC AGCTGCTGCC AATGGTGGTG      60
GTCATCAAGG AAGGTCACAT CAGCATAGCT GGTGGGCTGG CAGCAAGGTC TGCCATGAGC      120
TCGACCCTGC CCTCGAAGAC GGGCCAGCAC CAGACTGTGC TGGGTACGGA CCTCTGGGG      180
ACAGCTGCCA GCACAGTATC GGAAGATAAT CTTCTCCTCT GAGGCATAGC CCAGGCCAAG      240
CTCAGCCACT GGTAGGGTCA GGCTCCACAG CCGGCACAAA CCAGGTAAGG C              291
```

## (2) INFORMATION FOR SEQ ID NO:196:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 156 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

```

Met Ala Ala Gly Arg Leu Arg Ile Leu Phe Leu Leu Leu Leu Ser Leu
1           5           10           15

His Leu Gly Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Pro Ala Ala
20           25           30

Asp Glu Leu Ser Ser Gly Lys Met Ala Glu Thr Gly Arg Thr Trp Lys
35           40           45

Pro His Gln Gly Asn Asn Asn Val Arg Leu Pro Arg Ala Leu Pro Gly
50           55           60

Leu Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu
65           70           75           80

Gly Tyr Ala Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser
85           90           95

Cys Pro Gln Glu Val Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu
100          105          110

Arg Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser
115          120          125

Tyr Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu
130          135          140

Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly
145          150          155

```

## (2) INFORMATION FOR SEQ ID NO:197:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 60 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

```

Met Ala Ala Gly Arg Leu Arg Ile Leu Phe Leu Leu Leu Leu Ser Leu
1           5           10           15

His Leu Gly Leu Gly Trp Val Leu Asp Leu Gln Glu Ala Pro Ala Ala
20           25           30

```

Asp Glu Leu Ser Ser Gly Lys Met Ala Glu Thr Gly Arg Thr Trp Lys  
           35                          40                          45

Pro His Gln Gly Asn Asn Asn Val Arg Leu Pro Arg  
           50                          55                          60

(2) INFORMATION FOR SEQ ID NO:198:

- (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 96 amino acids  
     (B) TYPE: amino acid  
     (C) STRANDEDNESS:  
     (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

Ala Leu Pro Gly Leu Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala  
   1                          5                          10                          15  
 Glu Leu Gly Leu Gly Tyr Ala Ser Glu Lys Ile Ile Phe Arg Tyr  
           20                          25                          30  
 Cys Ala Gly Ser Cys Pro Gln Glu Val Arg Thr Gln His Ser Leu Val  
           35                          40                          45  
 Leu Ala Arg Leu Arg Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys  
   50                          55                          60  
 Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp His His His  
   65                          70                          75                          80  
 Trp Gln Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
           85                          90                          95

(2) INFORMATION FOR SEQ ID NO:199:

- (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 291 base pairs  
     (B) TYPE: nucleic acid  
     (C) STRANDEDNESS: single  
     (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCTGT CCGTGGCAGA GCTAGGCCTG 60  
 GGCTACGCCT CAGAGGAGAA GGTCATCTTC CGCTACTGCG CCGGCAGCTG CCCCCGTGGT 120  
 GCCCGCACCC AGCATGGCCT GGCGCTGGCC CGGCTGCAGG GCCAGGGCCG AGCCCACGGT 180  
 GGGCCCTGCT GCCGGCCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC 240  
 TGGCAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A 291

(2) INFORMATION FOR SEQ ID NO:200:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

```
TCAGCCACCA CAGCCGCAGG CAGCCGCCGA GAGCTGGGGC AGCCGCTGCC AGCGGTGGCG      60
GTCATCGAGG AAGGCCACGT CGGTGTAGCG AGTGGGCCGG CAGCAGGGCC CACCGTGGGC      120
TCGGCCCTGG CCCTGCAGCC GGGCCAGCGC CAGGCCATGC TGGGTGCGGG CACCACGGGG      180
GCAGCTGCCG GCGCAGTAGC GGAAGATGAC CTTCTCCTCT GAGGCGTAGC CCAGGCCTAG      240
CTCTGCCACG GACAGGGTCA GGCTCCACAG CTGGCATGGA CCAGACAGGG C                291
```

(2) INFORMATION FOR SEQ ID NO:201:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

```
GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCTGT CCGTGGCAGA GCTAGGCCTG      60
GGCTACGCCT CAGAGGAGAA GGTCTCTTTC CGCTACTGCG CCGGCAGCTG CCCCCGTGGT      120
GCCCCGACCC AGCATGGCCT GGCGCTGGCC CGGCTGCAGG GCCAGGGCCG AGCCCACGGC      180
GGGCCCTGCT GCCGGCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC      240
TGCGAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A                291
```

(2) INFORMATION FOR SEQ ID NO:202:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 291 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

```
TCAGCCACCA CAGCCGCAGG CAGCCGCCGA GAGCTGGGGC AGCCGCTGCC AGCGGTGGCG      60
```

GTCATCGAGG AAGGCCACGT CGGTGTAGCG AGTGGGCCGG CAGCAGGGCC CGCCGTGGGC 120  
 TCGGCCCTGG CCCTGCAGCC GGGCCAGCGC CAGGCCATGC TGGGTGCGGG CACCACGGGG 180  
 GCAGCTGCCG GCGCAGTAGC GGAAGATGAC CTTCTCCTCT GAGGCGTAGC CCAGGCCTAG 240  
 CTCTGCCACG GACAGGGTCA GGCTCCACAG CTGGCATGGA CCAGACAGGG C 291

(2) INFORMATION FOR SEQ ID NO:203:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

ATGGCCGTAG GGAAGTTCCT GCTGGGCTCT CTGCTGCTCC TGTCCCTGCA GCTGGGACAG 60  
 GGCTGGGGCC CCGATGCCCC TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTGAACAG 120  
 GTGGCAAAGG CTGGAGGGAC CTGGCTGGGC ACCCACCGCC CCCTTGCCCC CCTGCGCCGA 180  
 GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCTGT CCGTGGCAGA GCTAGGCCTG 240  
 GGCTACGCCT CAGAGGAGAA GGTCATCTTC CGCTACTGCG CCGGCAGCTG CCCCCGTGGT 300  
 GCCCGCACCC AGCATGGCCT GCGCTGGCC CGGCTGCAGG GCCAGGGCCG AGCCACGGT 360  
 GGGCCCTGCT GCCGGCCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC 420  
 TGGCAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A 471

(2) INFORMATION FOR SEQ ID NO:204:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

TCAGCCACCA CAGCCGACAG CAGCCGCCGA GAGCTGGGGC AGCCGCTGCC AGCGGTGGCG 60  
 GTCATCGAGG AAGGCCACGT CGGTGTAGCG AGTGGGCCGG CAGCAGGGCC CACCGTGGGC 120  
 TCGGCCCTGG CCCTGCAGCC GGGCCAGCGC CAGGCCATGC TGGGTGCGGG CACCACGGGG 180  
 GCAGCTGCCG GCGCAGTAGC GGAAGATGAC CTTCTCCTCT GAGGCGTAGC CCAGGCCTAG 240  
 CTCTGCCACG GACAGGGTCA GGCTCCACAG CTGGCATGGA CCAGACAGGG CTCGGCGCAG 300  
 GCGGGCAAAG GGGCGGTGGG TGCCAGCCA GGTCCCTCCA GCCTTTGCCA CCTGTTTACA 360

CGAGAACTCT CCATCGGCCA CGGGAACCCC ACGGGCATCG GGGCCCCAGC CCTGTCCCAG 420

CTGCAGGGAC AGGAGCAGCA GAGAGCCCAG CAGGAACTTC CCTACGGCCA T 471

(2) INFORMATION FOR SEQ ID NO:205:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

ATGGCCGTAG GGAAGTTCCT GCTGGGCTCC CTGCTGCTCC TGTCCCTGCA GCTGGGACAG 60

GGCTGGGGCC CCGATGCCCG TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTGAACAG 120

GTGGCAAAGG CTGGAGGGAC CTGGCTGGGC ACCCACC GCCCCTTGCCCG CCTGCGCCGA 180

GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCTGT CCGTGGCAGA GCTAGGCCTG 240

GGCTACGCCT CAGAGGAGAA GGTCTCTTTC CGCTACTGCG CCGGCAGCTG CCCCCGTGGT 300

GCCCGCACCC AGCATGGCCT GCGCTGGCC CGGCTGCAGG GCCAGGGCCG AGCCCACGGC 360

GGGCCCTGCT GCCGGCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC 420

TGGCAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A 471

(2) INFORMATION FOR SEQ ID NO:206:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

TCAGCCACCA CAGCCGAGG CAGCCGCCGA GAGCTGGGGC AGCCGCTGCC AGCGGTGGCG 60

GTCATCGAGG AAGGCCACGT CGGTGTAGCG AGTGGGCCGG CAGCAGGGCC CGCCGTGGGC 120

TCGGCCCTGG CCCTGCAGCC GGGCCAGCGC CAGGCCATGC TGGGTGCGGG CACCACGGGG 180

GCAGTGCCG GCGCAGTAGC GGAAGATGAC CTTCTCCTCT GAGGCGTAGC CCAGGCCTAG 240

CTCTGCCACG GACAGGGTCA GGCTCCACAG CTGGCATGGA CCAGACAGGG CTCGGCGCAG 300

GCGGGCAAGG GGGCGGTGGG TGCCAGCCA GGTCCCTCCA GCCTTTGCCA CCTGTTTACA 360

CGAGAACTCT CCATCGGCCA CGGGAACCCC ACGGGCATCG GGGCCCCAGC CCTGTCCCAG 420

CTGCAGGGAC AGGAGCAGCA GGGAGCCCAG CAGGAACTTC CCTACGGCCA T 471

## (2) INFORMATION FOR SEQ ID NO:207:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

ATGGCCGTAG GGAAGTTCCT GCTGGGCTCT CTGCTGCTCC TGTCCCTGCA GCTGGGACAG 60  
GGCTGGGGC 69

## (2) INFORMATION FOR SEQ ID NO:208:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

GCCCCAGCCC TGTCCCAGCT GCAGGGACAG GAGCAGCAGA GAGCCCAGCA GGAAGTTCCTCC 60  
TACGGCCAT 69

## (2) INFORMATION FOR SEQ ID NO:209:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

ATGGCCGTAG GGAAGTTCCT GCTGGGCTCC CTGCTGCTCC TGTCCCTGCA GCTGGGACAG 60  
GGCTGGGGC 69

## (2) INFORMATION FOR SEQ ID NO:210:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

GCCCCAGCCC TGTCCAGCT GCAGGGACAG GAGCAGCAGG GAGCCCAGCA GGAAGTTCCC 60  
TACGGCCAT 69

## (2) INFORMATION FOR SEQ ID NO:211:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 111 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

CCCGATGCCC GTGGGGTTCC CGTGGCCGAT GGAGAGTTCT CGTCTGAACA GGTGGCAAAG 60  
GCTGGAGGGA CCTGGCTGGG CACCCACCGC CCCCTTGCCC GCCTGCGCCG A 111

## (2) INFORMATION FOR SEQ ID NO:212:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 111 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

TCGGCGCAGG CGGGCAAGGG GCGGGTGGGT GCCCAGCCAG GTCCCTCCAG CCTTTGCCAC 60  
CTGTTTCAGAC GAGAACTCTC CATCGGCCAC GGAACCCCA CGGGCATCGG G 111

## (2) INFORMATION FOR SEQ ID NO:213:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 180 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

ATGGCCGTAG GGAAGTTCCT GCTGGGCTCT CTGCTGCTCC TGTCCCTGCA GCTGGGACAG 60  
GGCTGGGGCC CCGATGCCCC TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTGAACAG 120

GTGGCAAAGG CTGGAGGGAC CTGGCTGGGC ACCCACC GCCC CCCTTGCCCG CCTGCGCCGA 180

(2) INFORMATION FOR SEQ ID NO:214:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 180 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

TCGGCGCAGG CGGGCAAGGG GGCGGTGGGT GCCCAGCCAG GTCCCTCCAG CCTTTGCCAC 60  
 CTGTTTCAGAC GAGAACTCTC CATCGGCCAC GGGAACCCCA CGGGCATCGG GGCCCCAGCC 120  
 CTGTCCCAGC TGCAGGGACA GGAGCAGCAG AGAGCCCAGC AGGAACTTCC CTACGGCCAT 180

(2) INFORMATION FOR SEQ ID NO:215:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 180 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

ATGGCCGTAG GGAAGTTCCT GCTGGGCTCC CTGCTGCTCC TGTCCCTGCA GCTGGGACAG 60  
 GGCTGGGGCC CCGATGCCCG TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTGAACAG 120  
 GTGGCAAAGG CTGGAGGGAC CTGGCTGGGC ACCCACC GCCC CCCTTGCCCG CCTGCGCCGA 180

(2) INFORMATION FOR SEQ ID NO:216:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 180 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

TCGGCGCAGG CGGGCAAGGG GGCGGTGGGT GCCCAGCCAG GTCCCTCCAG CCTTTGCCAC 60  
 CTGTTTCAGAC GAGAACTCTC CATCGGCCAC GGGAACCCCA CGGGCATCGG GGCCCCAGCC 120  
 CTGTCCCAGC TGCAGGGACA GGAGCAGCAG GGAGCCCAGC AGGAACTTCC CTACGGCCAT 180

## (2) INFORMATION FOR SEQ ID NO:217:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 156 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

```

Met Ala Val Gly Lys Phe Leu Leu Gly Ser Leu Leu Leu Ser Leu
1             5             10             15

Gln Leu Gly Gln Gly Trp Gly Pro Asp Ala Arg Gly Val Pro Val Ala
20            25            30

Asp Gly Glu Phe Ser Ser Glu Gln Val Ala Lys Ala Gly Gly Thr Trp
35            40            45

Leu Gly Thr His Arg Pro Leu Ala Arg Leu Arg Arg Ala Leu Ser Gly
50            55            60

Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu
65            70            75            80

Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser
85            90            95

Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu
100           105           110

Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg
115           120           125

Tyr Thr Asp Val Ala Phe Leu Asp Asp Arg His Arg Trp Gln Arg Leu
130           135           140

Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly
145           150           155

```

## (2) INFORMATION FOR SEQ ID NO:218:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 60 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

```

Met Ala Val Gly Lys Phe Leu Leu Gly Ser Leu Leu Leu Ser Leu
1             5             10             15

Gln Leu Gly Gln Gly Trp Gly Pro Asp Ala Arg Gly Val Pro Val Ala
20            25            30

```

Asp Gly Glu Phe Ser Ser Glu Gln Val Ala Lys Ala Gly Gly Thr Trp  
           35                          40                          45

Leu Gly Thr His Arg Pro Leu Ala Arg Leu Arg Arg  
       50                          55                          60

(2) INFORMATION FOR SEQ ID NO:219:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

Met Ala Val Gly Lys Phe Leu Leu Gly Ser Leu Leu Leu Ser Leu  
   1                          5                          10                          15

Gln Leu Gly Gln Gly Trp Gly  
                           20

(2) INFORMATION FOR SEQ ID NO:220:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 37 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

Pro Asp Ala Arg Gly Val Pro Val Ala Asp Gly Glu Phe Ser Ser Glu  
   1                          5                          10                          15

Gln Val Ala Lys Ala Gly Gly Thr Trp Leu Gly Thr His Arg Pro Leu  
                           20                          25                          30

Ala Arg Leu Arg Arg  
                           35

(2) INFORMATION FOR SEQ ID NO:221:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 96 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

Ala Leu Ser Gly Pro Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala  
 1 5 10 15  
 Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr  
 20 25 30  
 Cys Ala Gly Ser Cys Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala  
 35 40 45  
 Leu Ala Arg Leu Gln Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys  
 50 55 60  
 Arg Pro Thr Arg Tyr Thr Asp Val Ala Phe Leu Asp Asp Arg His Arg  
 65 70 75 80  
 Trp Gln Arg Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly  
 85 90 95

## (2) INFORMATION FOR SEQ ID NO:222:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 267 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

TGCCAGCTGT GGAGCCTGAC CCTGTCCGTG GCAGAGCTAG GCCTGGGCTA CGCCTCAGAG 60  
 GAGAAGGTCA TCTTCCGCTA CTGCGCCGGC AGCTGCCCCC GTGGTGCCCG CACCCAGCAT 120  
 GGCTGGGCGC TGGCCCGGCT GCAGGGCCAG GGCCGAGCCC ACGGTGGGCC CTGTGCCGG 180  
 CCCACTCGCT ACACCGACGT GGCCTTCCTC GATGACCGCC ACCGCTGGCA GCGGCTGCCC 240  
 CAGCTCTCGG CGGCTGCCTG CGGCTGT 267

## (2) INFORMATION FOR SEQ ID NO:223:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 89 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

Cys Gln Leu Trp Ser Leu Thr Leu Ser Val Ala Glu Leu Gly Leu Gly  
 1 5 10 15  
 Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala Gly Ser Cys  
 20 25 30  
 Pro Arg Gly Ala Arg Thr Gln His Gly Leu Ala Leu Ala Arg Leu Gln  
 35 40 45

Gly Gln Gly Arg Ala His Gly Gly Pro Cys Cys Arg Pro Thr Arg Tyr  
 50 55 60

Thr Asp Val Ala Phe Leu Asp Asp Arg His Arg Trp Gln Arg Leu Pro  
 65 70 75 80

Gln Leu Ser Ala Ala Ala Cys Gly Cys  
 85

(2) INFORMATION FOR SEQ ID NO:224:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 5 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:

Ala Leu Ser Gly Pro  
 1 5

(2) INFORMATION FOR SEQ ID NO:225:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 24 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

GTSASYGASY TGGGYCTGGG CTAY

24

(2) INFORMATION FOR SEQ ID NO:226:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 24 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

TTYMGSTACT GCRSMGGCKC YTGC

24

(2) INFORMATION FOR SEQ ID NO:227:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

RWAGGCSRTS G GKCKGCARC AKGS

24

(2) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 21 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

MKCRTCYARR AASGACASST C

21

(2) INFORMATION FOR SEQ ID NO:229:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 168 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

CGGCTTGTGA CCGAGCTGGG CCTGGGCTAC GCCTCAGAGG AGAAGGTCAT CTCGCTAC 60

TGCGCCGGCA GCTGCCCCCG TGGTGCCCGC ACCCAGCATG GCCTGGCGCT GGCCCGGCTG 120

CAGGGCCAGG GCCGAGCCCA CGGCGGGCCC TGCTGCCGCC CCATGGCC 168

(2) INFORMATION FOR SEQ ID NO:230:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

GAGGAGAAGG TCATCTTCCG

20

(2) INFORMATION FOR SEQ ID NO:231:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

GCCGTGGGCT CGGCCCTGGC

20

(2) INFORMATION FOR SEQ ID NO:232:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

AGAGGAGAAG GTCATCTTCC GCTA

24

(2) INFORMATION FOR SEQ ID NO:233:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

CTCGGCCCTG GCCCTGCAGC

20

(2) INFORMATION FOR SEQ ID NO:234:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

TGCAGCCGGG CCAGCGCCAG

20

(2) INFORMATION FOR SEQ ID NO:235:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 31 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

CGCGGATCCA TGCCTGGATT CGAGGGTGCA G

31

(2) INFORMATION FOR SEQ ID NO:236:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 31 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

CGCGGATCCA TGGCCGTAGG GAAGTTCCTG C

31

(2) INFORMATION FOR SEQ ID NO:237:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 60 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

CTCCCAAGCT TTTACTTGTC ATCGTCGTCC TTGTAGTCGC CACCACAGCC GCAGGCAGCC

60

(2) INFORMATION FOR SEQ ID NO:238:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 59 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

CTCCCAAGCT TTTACTTGTC ATCGTCGTCC TTGTAGTCTC GAGGAAGGCC ACGTCGGTG 59

(2) INFORMATION FOR SEQ ID NO:239:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

TCAGCCACCA CAGCCGCAGG CAGCC 25

48063550.doc

What is Claimed is:

1. An isolated and purified growth factor comprising persephin or fragment thereof or conservatively substituted variant thereof.

2. The isolated and purified growth factor of claim 1 comprising a polypeptide sequence which has at least about 75% sequence identity with SEQ ID NO:79, SEQ ID NO:82 or SEQ ID NO:223 or conservatively substituted  
5 variants thereof.

3. The isolated and purified growth factor of claim 2 comprising a polypeptide sequence as set forth in SEQ ID NO:187, SEQ ID NO:198, SEQ ID NO:221 or conservatively substituted variants thereof.

4. The isolated and purified growth factor of claim 3 which promotes survival in mesencephalic cells.

5. An isolated and purified polypeptide comprising:

(a) a pre-pro persephin as set forth in SEQ ID NO:217, SEQ ID NO:185, or SEQ ID NO:196;

5 (b) a prepro- region of persephin as set forth in SEQ ID NO:218, SEQ ID NO:186, or SEQ ID NO:197;

(c) a pre- region of persephin as set forth in SEQ ID NO:219;

(d) a pro- region of persephin as set forth in SEQ  
10 ID NO:220; or

(e) conservatively substituted variants thereof.

6. The isolated and purified growth factor of claim 1 comprising a polypeptide containing a sequence of amino acids having at least about 65% sequence identity with SEQ ID NO:79 or SEQ ID NO:82, or SEQ ID NO:223  
5 wherein the growth factor is from a non-mammalian species.

7. A method for obtaining a neurturin-persephin-GDNF family member growth factor comprising:

(a) isolating (1) from a human genomic or cDNA library, a clone that hybridizes with a polynucleotide

5 comprising a persephin, neurturin or GDNF sequence or  
fragments thereof or (2) from a human genomic or cDNA  
template, a clone using a polymerase chain reaction  
method with degenerate primers of a conserved region of  
any two of persephin, neurturin or GDNF or fragments of  
10 said conserved regions; and

(b) sequencing said clone.

8. An isolated and purified growth factor that is  
a neurturin-persephin-GDNF family member comprising a  
polypeptide having between about 30% and about 75%  
sequence identity with persephin, between about 30% and  
5 about 75% sequence identity with neurturin and between  
about 30% and about 75% sequence identity with GDNF  
wherein said factor is comprised of a conserved region  
sequence of amino acids having at least a 62.5 percent  
sequence identity with SEQ ID NO:108 or at least a 62.5  
10 percent sequence identity with SEQ ID NO:109 or at least  
a 50 percent sequence identity with SEQ ID NO:110.

13. A pan-growth factor comprising a fragment of  
the persephin polypeptide according to claim 1 and a  
fragment of at least one growth factor from the TGF- $\beta$   
superfamily other than persephin.

14. An isolated and purified nucleic acid molecule  
or nucleic acid molecule complementary thereto comprising  
a nucleotide sequence encoding a growth factor of claim 1  
or a fragment of said nucleotide sequence consisting of  
5 at least 15 contiguous nucleotides.

15. The isolated and purified nucleic acid  
molecule or nucleic acid molecule complementary thereto  
of claim 14 comprising a nucleotide sequence encoding a  
persephin polypeptide that promotes survival in  
5 mesencephalic cells wherein said nucleic acid molecule or  
complement thereto specifically hybridizes to SEQ ID  
NO:183, SEQ ID NO:184, SEQ ID NO:194, SEQ ID NO:195, SEQ  
ID NO:199, SEQ ID NO:200, SEQ ID NO:201, or SEQ ID  
NO:202.

16. The isolated and purified nucleic acid molecule or nucleic acid molecule complementary thereto of claim 15 comprising SEQ ID NO:183, SEQ ID NO:194, SEQ ID NO:199 or SEQ ID NO:201.

17. A vector comprising expression regulatory elements operably linked to a nucleic acid molecule of claim 14.

18. A host cell transformed with the vector of claim 17.

19. An isolated and purified nucleic acid molecule comprising:

(a) a pre-pro persephin nucleotide sequence as set forth in SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, or SEQ ID NO:206 or a polynucleotide that specifically hybridizes to SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, or SEQ ID NO:206;

10 (b) a pre-pro region of a persephin polynucleotide as set forth in SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, or SEQ ID NO:216;

15 (c) a pre- region of a persephin polynucleotide as set forth in SEQ ID NOS:207, SEQ ID NO:208, SEQ ID NO:209, or SEQ ID NO:210;

(d) a pro- region of a persephin polynucleotide as set forth in SEQ ID NO:211, or SEQ ID NO:212; or

20 (e) fragment thereof comprising at least 15 contiguous nucleotides.

20. A recombinant method comprising:

(a) subcloning a polynucleotide encoding the growth factor of claim 1 into an expression vector comprising regulatory elements operably linked to the polynucleotide;

(b) transforming a host cell with the expression vector;

(c) growing the host cell in a host cell culture;  
and

(d) harvesting the growth factor and/or the polynucleotide from the host cell culture.

21. Isolated and purified antibodies which are capable of reacting with a growth factor as defined in claim 1 or an epitope thereof.

22. A method for detecting the presence of a growth factor in a sample from a patient comprising reacting antibodies according to claim 21 with a growth factor present in the sample and detecting a binding of  
5 the antibodies with the growth factor.

23. A kit for detecting the presence of a growth factor in a sample from a patient comprising antibodies of claim 21 which are capable of detectably reacting with said growth factor, packaged in a container.

24. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising administering to the individual a therapeutically effective amount of the growth factor of claim 1 or a  
5 polynucleotide encoding the growth factor of claim 1.

25. The method of claim 24 wherein the cellular degeneration or insufficiency is (a) neuronal degeneration resulting from peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease,  
5 Parkinson's disease, Huntington's disease, Ischemic stroke, acute brain injury, acute spinal cord injury, nervous system tumors, multiple sclerosis, or infection; (b) hematopoietic cell degeneration or insufficiency resulting from eosinopenia, basopenia, lymphopenia,  
10 monocytopenia, neutropenia, anemias, thrombocytopenia, or stem-cell insufficiencies therefor; or (c) cardiac muscle degeneration or insufficiency resulting from cardiomyopathy or congestive heart failure.

26. A method for preventing or treating cellular degeneration or insufficiency in an individual comprising

implanting into the individual, cells that express the growth factor of claim 1.

27. A method for detecting the presence of a growth factor in a sample from a patient comprising detecting and/or quantitating the presence in the sample of mRNA encoding a growth factor of claim 1.

28. A method for detecting persephin gene alterations comprising detecting the presence of a non-intact persephin gene in a cell wherein presence of the non-intact gene indicates the presence of gene  
5 alterations.

29. A method for promoting the growth and/or differentiation of a cell in a culture medium comprising adding to the culture medium the growth factor of claim 1.

30. An isolated and purified persephin antisense polynucleotide comprising a sequence complementary to a nucleic acid sequence of claim 14 and capable of hybridizing to a naturally-occurring DNA or mRNA  
5 polynucleotide sequence encoding persephin to prevent transcription and/or translation of an encoded persephin polypeptide.

31. A method for treating a disease condition mediated by expression of persephin by a population of cells comprising administering to said cells an inhibitory effective amount of the antisense  
5 polynucleotide of claim 30.

PERSEPHIN AND RELATED GROWTH FACTORSAbstract of the Disclosure

A novel growth factor, persephin, which belongs to the GDNF/neurturin family of growth factors, is disclosed. The human, mouse and rat amino acid sequences  
5 have been identified. Human, mouse and rat persephin genomic DNA sequences have been cloned and sequenced and the respective cDNA sequences identified. In addition, methods for treating degenerative conditions using persephin, methods for detecting persephin gene  
10 alterations and methods for detecting and monitoring patient levels of persephin are provided. Methods for identifying additional members of the persephin-neurturin-GDNF family of growth factors are also provided.






Figure 1

100 90 80 70 60 50 40 30 20 10 0

fraction: M L 21 22 23 24 25 26 27 28 29 30 31 32




Figure 2a




Figure 2b

Figure 3a NGF




Figure 3b Anti-NGF





Figure 3c Anti-NGF  
+  
Neurturin






Figure 4

1	S	P	D	K	Q	H	A	V	L	P	R	R	E	R	N	R	Q	A	A	A	A	N	P	E	N	S	R	G	K	G	hGDNF
1	S	P	O	K	Q	A	A	A	L	P	R	R	E	R	N	R	Q	A	A	A	A	S	P	E	N	S	R	G	K	G	mGDNF
1	S	P	O	K	Q	A	A	A	L	P	R	R	E	R	N	R	Q	A	A	A	A	S	P	E	N	S	R	G	K	G	rGDNF
1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	hNTN
1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	mNTN
31	R	R	G	Q	R	G	K	N	R	G	C	V	L	T	A	I	H	L	N	V	T	D	L	G	L	G	Y	E	T	K	hGDNF
31	R	R	G	Q	R	G	K	N	R	G	C	V	L	T	A	I	H	L	N	V	T	D	L	G	L	G	Y	E	T	K	mGDNF
31	R	R	G	Q	R	G	K	N	R	G	C	V	L	T	A	I	H	L	N	V	T	D	L	G	L	G	Y	E	T	K	rGDNF
1	-	-	-	A	R	L	G	A	R	P	C	G	L	R	E	L	E	V	R	V	S	E	L	G	L	G	Y	A	S	D	hNTN
1	-	-	-	-	P	G	A	R	P	C	G	L	R	E	L	E	V	R	V	S	E	L	G	L	G	Y	T	S	D	mNTN	
61	E	E	L	I	F	R	Y	C	S	G	S	C	E	S	A	E	T	T	Y	D	K	I	L	K	N	L	S	R	N	R	hGDNF
61	E	E	L	I	F	R	Y	C	S	G	S	C	E	S	A	E	T	T	Y	D	K	I	L	K	N	L	S	R	S	R	mGDNF
61	E	E	L	I	F	R	Y	C	S	G	S	C	E	A	A	E	T	T	Y	D	K	I	L	K	N	L	S	R	S	R	rGDNF
28	E	T	V	L	F	R	Y	C	A	G	A	C	E	A	A	A	R	V	Y	D	L	G	L	R	R	L	R	Q	R	R	hNTN
26	E	T	V	L	F	R	Y	C	A	G	A	C	E	A	A	I	R	I	Y	D	L	G	L	R	R	L	R	Q	R	R	mNTN
91	R	L	V	S	D	K	V	-	G	Q	A	C	C	R	P	I	A	F	D	D	D	L	S	F	L	D	D	N	L	V	hGDNF
91	R	L	T	S	D	K	V	-	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	D	N	L	V	mGDNF
91	R	L	T	S	D	K	V	-	G	Q	A	C	C	R	P	V	A	F	D	D	D	L	S	F	L	D	D	S	L	V	rGDNF
58	R	L	R	R	E	R	V	R	A	Q	P	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	A	H	S	R	hNTN
56	R	V	R	R	E	R	A	R	A	H	P	C	C	R	P	T	A	Y	E	D	E	V	S	F	L	D	V	H	S	R	mNTN
120	Y	H	I	L	R	K	H	S	A	K	R	C	G	C	I	-	hGDNF														
120	Y	H	I	L	R	K	H	S	A	K	R	C	G	C	I	-	mGDNF														
120	Y	H	I	L	R	K	H	S	A	K	R	C	G	C	I	-	rGDNF														
88	Y	H	T	V	H	E	L	S	A	R	E	C	A	C	V	-	hNTN														
86	Y	H	T	L	Q	E	L	S	A	R	E	C	A	C	V	-	mNTN														

Figure 5



# RT-PCR Analysis of Neurturin and GDNF




Figure 6

ATGCAGCGCTGGAAGGCGGCGGCCCTTGGCCTCAGTGCTCTGCAGCTCCGTGCTGTCCATC 60  
Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser Val Leu Ser Ile  
 TGGATGTGTCGAGAGGGCCTGCTTCTCAGCCACCGCCTCGGACCTGCGCTGGTCCCCCTG 120  
Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg Leu Gly Pro Ala Leu Val Pro Leu  
 CACCGCCTGCCTCGAACCCTGGACGCCCCGATTGCCCGCCTGGCCCCAGTACCGTGCACTC 180  
His Arg Leu Pro Arg Thr Leu Asp Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu  
 CTGCAGGGGGCCCCGGATGCGATGGAGCTGCGCGAGCTGACGCCCTGGGCTGGGCGGCCCC 240  
Leu Gln Gly Ala Pro Asp Ala Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro  
 CCAGGTCCGCGCCGTCGGGCGGGGCCCCGGCGGGCGGCGCGCGTGC GCGGTTGGGGGCG 300  
Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg Ala Arg Leu Gly Ala  
 CGGCCTTGCGGGCTGCGCGAGCTGGAGGTGCGCGTGAGCGAGCTGGGCCTGGGCTACGCG 360  
Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly Tyr Ala  
 TCCGACGAGACGGTGCTGTTCGCTACTGCGCAGGCGCCTGCGAGGCTGCCGCGCGCGCTC 420  
Ser Asp Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys Glu Ala Ala Ala Arg Val  
 TACGACCTCGGGCTGCGACGACTGCGCCAGCGGCGGCGCCTGCGGCGGGAGCGGGTGCGC 480  
Tyr Asp Leu Gly Leu Arg Arg Leu Arg Gln Arg Arg Arg Leu Arg Arg Glu Arg Val Arg  
 GCGCAGCCCTGCTGCCGCCCGACGGCCTACGAGGACGAGGTGTCCTTCCTGGACGCGCAC 540  
Ala Gln Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Ala His  
 AGCCGCTACCACACGGTGACAGAGCTGTCGGCGCGCGAGTGCGCCTGCGTGTGA 594  
Ser Arg Tyr His Thr Val His Glu Leu Ser Ala Arg Glu Cys Ala Cys Val

Figure 7

ATGAGGCGCTGGAAGGCAGCGGCCCTGGTGTGCTCATCTGCAGCTCCCTGCTATCTGTC 60  
Met Arg Arg Trp Lys Ala Ala Ala Leu Val Ser Leu Ile Cys Ser Ser Leu Leu Ser Val  
 TGGATGTGCCAGGAGGGTCTGCTCTTGGGCCACCGCCTGGGACCCGCGCTTGCCCCGCTA 120  
Trp Met Cys Gln Glu Gly Leu Leu Leu Gly His Arg Leu Gly Pro Ala Leu Ala Pro Leu  
 CGACGCCCTCCACGCACCCTGGACGCCCGCATCGCCCGCCTGGCCCAGTATCGCGCTCTG 180  
Arg Arg Pro Pro Arg Thr Leu Asp Ala Arg Ile Ala Arg Leu Ala Gln Tyr Arg Ala Leu  
 CTCCAGGGCGCCCCGACGCGGTGGAGCTTCGAGAACTTCTCCCTGGGCTGCCCGCATC 240  
Leu Gln Gly Ala Pro Asp Ala Val Glu Leu Arg Glu Leu Ser Pro Trp Ala Ala Arg Ile  
 CCGGGACCGCGCCGTCGAGCGGGTCCCCGGCGTCGGCGGGCGCGGCCGGGGGCTCGGCCT 300  
Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Arg Ala Arg Pro Gly Ala Arg Pro  
 TGTGGGCTGCGCGAGCTCGAGGTGCGCGTGAGCGAGCTGGGCCTGGGCTACACGTCGGAT 360  
Cys Gly Leu Arg Glu Leu Glu Val Arg Val Ser Glu Leu Gly Leu Gly Tyr Thr Ser Asp  
 GAGACCGTGCTGTTCCGCTACTGCGCAGGCGCGTGCGAGGCGGCCATCCGCATCTACGAC 420  
Glu Thr Val Leu Phe Arg Tyr Cys Ala Gly Ala Cys Glu Ala Ala Ile Arg Ile Tyr Asp  
 CTGGGCCTTCGGCGCCTGCGCCAGCGGAGGCGCGTGCGCAGAGAGCGGGCGCGGGCGCAC 480  
Leu Gly Leu Arg Arg Leu Arg Gln Arg Arg Arg Val Arg Arg Glu Arg Ala Arg Ala His  
 CCGTGTTGTGCCCCGACGGCCTATGAGGACGAGGTGTCTTCTGACGTGCACAGCCGC 540  
Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe Leu Asp Val His Ser Arg  
 TACCACACGCTGCAAGAGCTGTCGGCGCGGGAGTGCGCGTGTGTGA 588  
Tyr His Thr Leu Gln Glu Leu Ser Ala Arg Glu Cys Ala Cys Val

Figure 8

GGAGGGAGAGCGCGCGGTGGTTTCGTCCGTGTGCCCCGCGCCCGGCGC	-301
TCCTCGCGTGGCCCCGCGTCCTGAGCGCGCTCCAGCCTCCCACGCGCGCC	-251
ACCCCGGGGTTCAGTGAAGCCGCGAGCCCGGGGAAGACAGAGAAAGAGA	-201
GGCCAGGGGGGGAACCCCATGGCCCCGGCCCGTGTCCCGCACCCCTGTGCGG	-151
TGGCCTCCTCCGGCAAGGGGTCCCCGGGTGCGCTCCGGTCCCCGCGATCC	-101
GGATGGCGCACGCAGTGGCTGGGGCCGGGCCGGGCTCGGGTGGTCGGAGG	-51
AGTCACCACTGACCGGGTCATCTGGAGCCCGTGGCAGGCCGAGGCCAGG	-1
<u>ATGAGGCGCTGGAAGGCAGCGGCCCTGGTGTGCTCATCTGCAGCTCCCT</u>	50
<u>GCTATCTGTCTGGATGTGCCAGGAGGGTCTGCTCTTGGGCCAACGCTGG</u>	100
<u>GACCCGCGCTTGCCCCGCTACGACGCCCTCCACGCACCCTGGAAGCCCGC</u>	150
<u>ATCGCCCGCTGGCCAGTATCGCGCTCTGCTCCAGGGCGCCCCGACGC</u>	200
<u>GGTGGAGCTTCGAGAACTTTCTCCCTGGGCTGCCCCGATCCCGGGACCGC</u>	250
<u>GCGCTCGAGCGGGTCCCCGGCGTTCGGCGGGCGGGCCGGGGGCTCGGCCT</u>	300
<u>TGTGGGCTGCGCGAGCTCGAGGTGCGCGTGAGCGAGCTGGGCCTGGGCTA</u>	350
<u>CACGTGGATGAGACCGTGCTGTTCCGCTACTGCGCAGGCGGTGCGAGG</u>	400
<u>CGGCCATCCGCATCTACGACCTGGGCCTTCGGGCGCTGCGCCAGCGGAGG</u>	450
<u>CGCGTGCGCAGAGAGCGGGCGGGCGCACCCGTGTTGTGCGCCGACGGC</u>	500
<u>CTATGAGGACGAGGTGTCCTTCCTGGACGTGCACAGCCGCTACCACAGC</u>	550
<u>TGCAAGAGCTGTCGGCGCGGGAGTGCGCGTGCGTGATGCTACCTCAG</u>	600
CCCCCGACCTGCGAAAGGGCCCTCCCTGCCGACCCTCGCTGAGAACTGA	650
CTTCACATAAAGTGTGGGAACTCCC	675

Figure 9




Figure 10

GAGGGACCTGGACGCCCCATCAGGGTAAGAATTCTGGGGGCCTCCCGACTCCCCAATTC	60
Glu Gly Pro Gly Arg Pro Ile Arg Val Arg Ile Pro Gly Gly Leu Pro Thr Pro Gln Phe	20
CTTCTCTCAAAGCCCTCACTTTGCCTTACAATCCTACTCTACCTTGCACTAGGTAACAAC	120
Leu Leu Ser Lys Pro Ser Leu Cys Leu Thr Ile Leu Leu Tyr Leu Ala Leu Gly Asn Asn	40
CATGTCCGTCTTCCAAGAGCCTTGGCTGGTTCATGCCGACTGTGGAGCCTGACCCTACCA	180
His Val Arg Leu Pro Arg Ala Leu Ala Gly Ser Cys Arg Leu Trp Ser Leu Thr Leu Pro	60
GTGGCTGAGCTGGGCCTGGGCTATGCCTCGGAGGAGAAGGTCATCTTCCGATACTGTGCT	240
Val Ala Glu Leu Gly Leu Gly Tyr Ala Ser Glu Glu Lys Val Ile Phe Arg Tyr Cys Ala	80
GGCAGCTGTCCCCAAGAGGCCCCGTACCCAGCACAGTCTGGTACTGGCCCCGGCTTCGAGGG	300
Gly Ser Cys Pro Gln Glu Ala Arg Thr Gln His Ser Leu Val Leu Ala Arg Leu Arg Gly	100
CGGGGTCGAGCCCATGGCCGACCCCTGCTGCCAGCCCACCAGCTATGCTGATGTGACCTTC	360
Arg Gly Arg Ala His Gly Arg Pro Cys Cys Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe	120
CTTGATGATCAGCACCATTTGGCAGCAGCTGCCTCAGCTCTCAGCTGCAAGCTTGTGGCTGT	420
Leu Asp Asp Gln His His Trp Gln Gln Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys	140
GGTGGCTGAAGGAGGCCAGTCTGGTGTCTCAGAATCACAAGCATGAGACAGGCTGGGCTT	480
Gly Gly	142
TGAAAGGCTCAGGTGACATTACTAGAAATTTGCATAGGTAAAGATAAGAAGGGAAAGGAC	540
CAGG	544

Figure 11




Figure 12

CCTCAGAGGAGAAGATTATCTTCCGATACTGTGCTGGCAGCTGTCCCCAAGAGGTCCGTACC	62
Ser Glu Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys Pro Gln Glu Val Arg Thr	20
CAGCACAGTCTGGTGCTGGCCCCGTCTTCGAGGGGCAGGGTCGAGCTCATGGCAGACCTTGC	122
Gln His Ser Leu Val Leu Ala Arg Leu Arg Gly Gln Gly Arg Ala His Gly Arg Pro Cys	40
TGCCAGCCCACCAGCTATGCTGATGTGACCTTCCTTGATGACCACCACCATTTGGCAGCAG	182
Cys Gln Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln	60
CTGCCTCAGCTCTCAGCCGCAGCCTTGTGGCTGTGGTGGCTGAAGGCGGCCAGCCTGGTCT	242
Leu Pro Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly	73
CTCAGAATCACAAGCAAGAGGCAGCCTTTGAAAGGCTCAGGTGACGTTATTAGAAACTTG	302
CATAGGAGAAGATTAAGAAGAGAAAAGGGGACCTG	336

Figure 13



TGCCGGCTGTGGAGCCTGACCCTACCAGTGGCTGAGCTTGGCCTGGGCTATGCCTCAGAG	60
Cys Arg Leu Trp Ser Leu Thr Leu Pro Val Ala Glu Leu Gly Leu Gly Tyr Ala Ser Glu	20
GAGAAGATTATCTTCCGATACTGTGCTGGCAGCTGTCCCCAAGAGGTCCGTACCCAGCAC	120
Glu Lys Ile Ile Phe Arg Tyr Cys Ala Gly Ser Cys Pro Gln Glu Val Arg Thr Gln His	40
AGTCTGGTGCTGGCCCCGTCTTCGAGGGCAGGGTCGAGCTCATGGCAGACCTTGCTGCCAG	180
Ser Leu Val Leu Ala Arg Leu Arg Gly Gln Gly Arg Ala His Gly Arg Pro Cys Cys Gln	60
CCCACCAGCTATGCTGATGTGACCTTCCTTGATGACCACCACCATTGGCAGCAGCTGCCT	240
Pro Thr Ser Tyr Ala Asp Val Thr Phe Leu Asp Asp His His His Trp Gln Gln Leu Pro	80
CAGCTCTCAGCCGCAGCTTGTGGCTGTGGTGGCTGAAGGCGGCCAGCCTGGTCTCTCAGA	300
Gln Leu Ser Ala Ala Ala Cys Gly Cys Gly Gly	91
ATCACAAGCAAGAGGCAGCCTTTGAAAGGCTCAGGTGACGTTATTAGAAACTTGCATAGG	360
AGAAGATTAAGAAGAGAAAGGGGACCTGATT	391

Figure 14



	10	20	30	
1	A L A G S C R L W S L T L P V A E L G L G Y A S E E K V I F			mPSP
1	A L P G L C R L W S L T L P V A E L G L G Y A S E E K I I F			rPSP
1	A L S G P C Q L W S L T L S V A E L G L G Y A S E E K V I F			hPSP
31	R Y C A G S C P Q E A R T Q H S L V L A R L R G R G R A H G	40	50	60
31	R Y C A G S C P Q E V R T Q H S L V L A R L R G R G R A H G			mPSP
31	R Y C A G S C P R G A R T Q H G L A L A R L Q G Q G R A H G			rPSP
				hPSP
61	R P C C Q P T S Y A D V T F L D D Q H H W Q Q L P Q L S A A	70	80	90
61	R P C C Q P T S Y A D V T F L D D Q H H W Q Q L P Q L S A A			mPSP
61	G P C C R P T R Y T D V A F L D D R H R W Q Q L P Q L S A A			rPSP
				hPSP
91	A C G C G G			rPSP
91	A C G C G G			rPSP
91	A C G C G G			hPSP

Figure 15B

EQ D 0:	GROWTH FACTOR	SEQUENCE
50	TGFβ1	CCVRQLYIDFRKDLGWK-WIHEPKGYHANFCLGPCPYIWSLDT-----QYSKVLALYNQHNPGASAA-PCCV--PQALEPLPIVYVGRKPKV--EQLSNMIVRSCKCS
51	TGFβ2	CCLRPPLYIDFKRDLGWK-WIHEPKGYANFCAGACPYLWSSDT-----QHSRVLSLYNTINPEASAS-PCCV--SQDLEPLTILYIGKTPKI--EQLSNMIVKSCCKS
52	TGFβ3	CCVRPLYIDFRQDLGWK-WHEPKGYANFCSGPCPYLRSADT-----THSTVLGLYNTLNPEASAS-PCCV--PQDLEPLTILYVGRTPKV--EQLSNMIVKSCCKS
53	INHβA	CKKQOFFVSFK-DIGWNDWIIAPSGYHANYCEGECPSHIAG-TSGSLSFHSVTINHYMRGRHSFANLKSSCV--PTKLRPMSMLYYDDGQNII-KKDIQNMIIVEEGCS
54	INHβB	CCRQOFFIDFR-LIGWNDWIIAPTGYGYNYCEGSCPAYLAG-VPGSASSFHTAWNQYMRGLNP-GTWNSCCI--PTKLSHMSMLYFDDEYNIV-KRDVPMNMIIVEEGCA
55	NODAL	CRRVKFOVDEN-LIGWSWIIYPKOYNAYRCEGECPNVGEFFHT----NHAYIQSLKRYQPHR-VPSTCCA-PVKTPLSMLYVDNGR--VLLEHHKDMIVEEGCL
56	BMP2	CKRHPLYVDFS-DVGWNDWIVAPPGYHAFYCHGECPEFLADHLNST----NHAIVQTLVNSVNS-K-IPKACCV--PTELSAISMLYDENEKVVK-NYQDMVVEGCGR
57	BMP4	CRRHSLYVDFS-DVGWNDWIVAPPGYQAFYCHGDCPEFLADHLNST----NHAIVQTLVNSVNS-S-IPKACCV--PTELSAISMLYDEYDKVVK-NYQDMVVEGCGR
58	DPP	CRRHSLYVDFS-DVGWDDWIVAPLGYDAYYCHGKCPFLADHFNST----NHAWQTLVNNMNPVK-K-IPKACCV--PTQLDSVAMLYLNDQSTVLK-NYQDMVVEGCGR
59	BMP5	CKKHELYVSFR-DLGWQDWIIAPEGYAAYFCDCGECSPFLNAHMNAT----NHAIVQTLVHLMPDH-VPKPCCA--PTKLNAISVLYFDDSSNVLK-KYRNMVVRSCGCH
60	BMP6	CKKHELYVSFQ-DLGWQDWIIAPKGYAANYCDGECSPFLNAHMNAT----NHAIVQTLVHLMPDY-VPKPCCA--PTKLNAISVLYFDDSSNVLK-KYRNMVVRACGCH
61	BMP7	CKKHELYVSFR-DLGWQDWIIAPEGYAAYCEGECAPFLNSYMNAT----NHAIVQTLVHFINPET-VPKPCCA--PTQLNAISVLYFDDSSNVLK-KYRNMVVRACGCH
62	BMP8	CRRHELYVSFQ-DLGWLDWIIAPOGYSAYYCEGECSPFLDSCMNAT----NHAIQSLVHLMPNA-VPKACCA--PTKLSATSVLYYDSSNVLK-KYRNMVVRACGCH
63	60A	COMQTLYIDFK-DLGWHDWIIAPEGYGAFYCSGECNFPFLNAHMNAT----NHAIVQTLVHLLEPKK-VPKPCCA--PTRLGALPVLVHLNDENVLK-KYRNMVVRACGCH
64	BMP3	CARRYLYVDFA-DIGWSEWIIIPKSFDAYYCSGACOFPMPSKPKS-----NHATIQSIVRAVGVPVGTPEPCCV--PEKMSLSILFFDENKNVLK-VYPMVTVESACR
65	VG1	CKKRHLVYEFK-DVGWQNWIIAPQGYMANYCYGECPPVLTIELNGS-----NHAILQTLVHSIEPED-IPLPCCV--PTKMSPIISMLFYDNDNDNVLR-HYENMAVDEGCR
66	GDF1	CRARRLYVSFR-EVGHWRWIIAPRGLFANYCQGCAPLVALSGSGPPALNHAVALRALMHAAAPGA-ADLPCCV--PARLSPISVLFYDNDNDNVLR-QYEDMVVDEGCR
67	GDF3	CHRHOLFYNFQ-DLGWKHWIIAPKGFMANHYCHGECPSMTYLNSS----NYAFMQALMHMAADP-K-VLPKACCV--PTKLSPISMLYQDSDKNVILR-HYEDMVVDEGCG
68	DORSLN	CRRTSLHVNFK-EIGWDSWIIAPKDYAEAFCKGCFEPLTDNVNTP-----KHAIVQTLVHLQNPVK--ASKACCV--PTKLDAISILYKDDAGVPTLIYNEGKMWACGCR
69	INHα	CHRVALNLSF-OELGWERWIVYPPSFIFHYCHGGGLHIPPNLISLPVGPAPPTPAQPYSL-----PGAQPCCAALPGTMRPLHVRTSDGYSFKYETVPNLLTQHCACI
70	MIS	CALRELSVDLRAERS----VLIPETYQANNCQACGMPQSDR----NPRYGNHVVLLKMQARGATLARPPCCV--PTAYT--GKLLISLSEERISAHVPMNVAETEGCR
71	GDF9	CELDHFSLSFS-QLKWDNWIIAPHSYNPSYCKGDCPSAVSHRYGSPV-----HTWQNMIIYE-KLDPSVPSPSCV--PGKYSPLSVLTIEPDGSIAYK-EYEDMMATSTCTCR
72	GDNF	CVLTAILHNVT-DLGLG--YETKEELIFRYCSGSCD-AAETTYDKILKNLSRN-----RRLVSDKV-GQACCRPIAFD-DDLSFL-----DDNLVYHILKHSKRGCGCI
73	NTN	CGLRELEVRYS-ELGLG--YASDETIVLERYCAGACE-AAARVYDLGLRLRQR-----RRLRERVRAPQCCRPATYE-DEVSFL-----DAHSRYHTVHLSARECACI

FIGURE 16

1	ATGGCTGCAG	GAAGACTTCG	GATCCTGTGT	CTGCTGCTCC	TGTCCTTGCA	CCCGAGCCTC
	TACCGACGTC	CTTCTGAAGC	CTAGGACACA	GACGACGAGG	ACAGGAACGT	GGGCTCGGAG
61	GGCTGGGTCC	TTGATCTTCA	AGAGGCTTCT	GTGGCAGATA	AGCTCTCATT	TGGGAAGATG
	CCGACCCAGG	AACTAGAAGT	TCTCCGAAGA	CACCGTCTAT	TCGAGAGTAA	ACCCTTCTAC
121	GCAGAGACTA	GAGGGACCTG	GACGCCCCAT	CAGGGTAAGA	ATTCCTGGGG	GCCTCCCGAC
	CGTCTCTGAT	CTCCCTGGAC	CTGCGGGGTA	GTCCCATTCT	TAAGGACCCC	CGGAGGGCTG
181	TCCCCAATTC	CTTCTCTCAA	AGCCCTCACT	TTGCCTTACA	ATCCTACTCT	ACCTTGCACT
	AGGGGTTAAG	GAAGAGAGTT	TCGGGAGTGA	AACGGAATGT	TAGGATGAGA	TGGAACGTGA
241	AGGTAACAAC	CATGTCCGTC	TTCCAAGAGC	CTTGGCTGGT	TCATGCCGAC	TGTGGAGCCT
	TCCATTGTTG	GTACAGGCAG	AAGGTTCTCG	GAACCGACCA	AGTACGGCTG	ACACCTCGGA
301	GACCCTACCA	GTGGCTGAGC	TGGGCCTGGG	CTATGCCTCG	GAGGAGAAGG	TCATCTTCCG
	CTGGGATGGT	CACCGACTCG	ACCCGGACCC	GATACGGAGC	CTCCTCTTCC	AGTAGAAGGC
361	ATACTGTGCT	GGCAGCTGTC	CCCAAGAGGC	CCGTACCCAG	CACAGTCTGG	TACTGGCCCG
	TATGACACGA	CCGTCGACAG	GGGTTCTCCG	GGCATGGGTC	GTGTCAGACC	ATGACCGGGC
421	GCTTCGAGGG	CGGGGTCGAG	CCCATGGCCG	ACCCTGCTGC	CAGCCCACCA	GCTATGCTGA
	CGAAGCTCCC	GCCCCAGCTC	GGGTACCGGC	TGGGACGACG	GTCGGGTGGT	CGATACGACT
481	TGTGACCTTC	CTTGATGATC	AGCACCATTG	GCAGCAGCTG	CCTCAGCTCT	CAGCTGCAGC
	ACACTGGAAG	GAACTACTAG	TCGTGGTAAC	CGTCGTCGAC	GGAGTCGAGA	GTCGACGTCG
541	TTGTGGCTGT	GGTGGCTGAA	GGAGGCCAGT	CTGGTGTCTC	AGAATCACAA	GCATGAGACA
	AACACCGACA	CCACCGACTT	CCTCCGGTCA	GACCACAGAG	TCTTAGTGTT	CGTACTCTGT
601	GGCTGGGCTT	TGAAAGGCTC	AGGTGACATT	ACTAGAAATT	TGCATAGGTA	AAGATAAGAA
	CCGACCCGAA	ACTTTCCGAG	TCCACTGTAA	TGATCTTTAA	ACGTATCCAT	TTCTATTCTT
661	GGGAAAGGAC	CAGGGGTTTT	TTGTTTCTTT	CTTTGCTTGC	TTGTTAGTTT	TTTTTTTTTT
	CCCTTTCCTG	GTCCCCAAAA	AACAAAGAAA	GAAACGAACG	AACAATCAAA	AAAAAAAAAA
721	TTT					
	AAA					

Figure 17A

1	ATGGCTGCAG	GAAGACTTCG	GATCCTGTGT	CTGCTGCTCC	TGTCCTTGCA	CCCGAGCCTC
	TACCGACGTC	CTTCTGAAGC	CTAGGACACA	GACGACGAGG	ACAGGAACGT	GGGCTCGGAG
1	M A A G	R L R	I L C	L L L L	S L H	P S L
61	GGCTGGGTCC	TTGATCTTCA	AGAGGCTTCT	GTGGCAGATA	AGCTCTCATT	TGGGAAGATG
	CCGACCCAGG	AACTAGAAGT	TCTCCGAAGA	CACCGTCTAT	TCGAGAGTAA	ACCCTTCTAC
21	G W V / L	D L Q	E A S	V A D K	L S F	G K M
				↓		
121	GCAGAGACTA	GAGGGACCTG	GACGCCCCAT	CAGGGTAACA	ACCATGTCCG	TCTTCCAAGA
	CGTCTCTGAT	CTCCCTGGAC	CTGCGGGGTA	GTCCCATTTGT	TGGTACAGGC	AGAAGGTTCT
41	A E T R	G T W	T P H	Q G N N	H V R	L P R
181	GCCTTGGCTG	GTTTCATGCCG	ACTGTGGAGC	CTGACCCTAC	CAGTGGCTGA	GCTGGGGCCTG
	CGGAACCGAC	CAAGTACGGC	TGACACCTCG	GACTGGGATG	GTCACCGACT	CGACCCGGAC
61	A L A G	S C R	L W S	L T L P	V A E	L G L
241	GGCTATGCCT	CGGAGGAGAA	GGTCATCTTC	CGATACTGTG	CTGGCAGCTG	TCCCAAGAG
	CCGATACGGA	GCCTCCTCTT	CCAGTAGAAG	GCTATGACAC	GACCGTCGAC	AGGGGTTCTC
81	G Y A S	E E K	V I F	R Y C A	G S C	P Q E
301	GCCCGTACCC	AGCACAGTCT	GGTACTGGCC	CGGCTTCGAG	GGCGGGGTCG	AGCCCATGGC
	CGGGCATGGG	TCGTGTCAGA	CCATGACCGG	GCCGAAGCTC	CCGCCCCAGC	TCGGGTACCG
101	A R T Q	H S L	V L A	R L R G	R G R	A H G
361	CGACCCTGCT	GCCAGCCCAC	CAGCTATGCT	GATGTGACCT	TCCTTGATGA	TCAGCACCAT
	GCTGGGACGA	CGGTCGGGTG	GTCGATACGA	CTACACTGGA	AGGAACTACT	AGTCGTGGTA
121	R P C C	Q P T	S Y A	D V T F	L D D	Q H H
421	TGGCAGCAGC	TGCCTCAGCT	CTCAGCTGCA	GCTTGTGGCT	GTGGTGGCTG	A
	ACCGTCGTCG	ACGGAGTCGA	GAGTCGACGT	CGAACACCGA	CACCACCGAC	T
141	W Q Q L	P Q L	S A A	A C G C	G G	.

Figure 17B

1	ATGGCTGCAG	GAAGACTTCG	GATCTTGTTT	CTGCTGCTCC	TGTCCTTGCA	CCTGGGCCTT
	TACCGACGTC	CTTCTGAAGC	CTAGAACAAA	GACGACGAGG	ACAGGAACGT	GGACCCGGAA
61	GGCTGGGTCC	TTGATCTTCA	AGAGGGCTCCT	GCGGCAGATG	AGCTCTCATC	TGGGAAAATG
	CCGACCCAGG	AACTAGAAGT	TCTCCGAGGA	CGCCGTCTAC	TCGAGAGTAG	ACCCTTTTAC
121	GCAGAGACTG	GAAGGACCTG	GAAGCCCCAT	CAGGGTAAGA	ATTCTTGGGG	GCCTCCTAAC
	CGTCTCTGAC	CTTCCTGGAC	CTTCGGGGTA	GTCCCATCT	TAAGAACCCC	CGGAGGATTG
181	TCTACAGTTC	TTCCTCTCAA	AGCCCTCACT	TTGCCTCACA	ATCCTATTCT	ACCTTGCACT
	AGATGTCAAG	AAGGAGAGTT	TCGGGAGTGA	AACGGAGTGT	TAGGATAAGA	TGGAACGTGA
241	AGGTAACAAC	AATGTCCGCC	TTCCAAGAGC	CTTACCTGGT	TTGTGCCGGC	TGTGGAGCCT
	TCCATTGTTG	TTACAGGCGG	AAGGTTCTCG	GAATGGACCA	AACACGGCCG	ACACCTCGGA
301	GACCCTACCA	GTGGCTGAGC	TTGGCCTGGG	CTATGCCTCA	GAGGAGAAGA	TTATCTTCCG
	CTGGGATGGT	CACCGACTCG	AACCGGACCC	GATACGGAGT	CTCCTCTTCT	AATAGAAGGC
361	ATACTGTGCT	GGCAGCTGTC	CCCAAGAGGT	CCGTACCCAG	CACAGTCTGG	TGCTGGCCCG
	TATGACACGA	CCGTCGACAG	GGGTTCTCCA	GGCATGGGTC	GTGTCAGACC	ACGACCGGGC
421	TCTTCGAGGG	CAGGGTCGAG	CTCATGGCAG	ACCTTGCTGC	CAGCCCACCA	GCTATGCTGA
	AGAAGCTCCC	GTCCCAGCTC	GAGTACCGTC	TGGAACGACG	GTCGGGTGGT	CGATACGACT
481	TGTGACCTTC	CTTGATGACC	ACCACCATTG	GCAGCAGCTG	CCTCAGCTCT	CAGCCGCAGC
	ACACTGGAAG	GAACTACTGG	TGGTGGTAAC	CGTCGTCGAC	GGAGTCGAGA	GTCGGCGTCG
541	TTGTGGCTGT	GGTGGCTGA				
	AACACCGACA	CCACCGACT				

Figure 18A

1	ATGGCTGCAG	GAAGACTTCG	GATCTTGTTT	CTGCTGCTCC	TGTCCTTGCA	CCTGGGCCTT
	TACCGACGTC	CTTCTGAAGC	CTAGAACAAA	GACGACGAGG	ACAGGAACGT	GGACCCGGAA
1	M A A G	R L R	I L F	L L L L	S L H	L G L
61	GGCTGGGTCC	TTGATCTTCA	AGAGGCTCCT	GCGGCAGATG	AGCTCTCATC	TGGGAAAATG
	CCGACCCAGG	AACTAGAAGT	TCTCCGAGGA	CGCCGTCTAC	TCGAGAGTAG	ACCCTTTTAC
21	G W V L	D L Q	E A P	A A D E	L S S	G K M
121	GCAGAGACTG	GAAGGACCTG	GAAGCCCCAT	CAGGGTAACA	ACAATGTCCG	CCTTCCAAGA
	CGTCTCTGAC	CTTCCTGGAC	CTTCGGGGTA	GTCCCATTGT	TGTTACAGGC	GGAAGGTTCT
41	A E T G	R T W	K P H	Q G N N	N V R	L P R
181	GCCTTACCTG	GTTTGTGCCG	GCTGTGGAGC	CTGACCCTAC	CAGTGGCTGA	GCTTGGCCTG
	CGGAATGGAC	CAAACACGGC	CGACACCTCG	GACTGGGATG	GTCACCGACT	CGAACCGGAC
61	A L P G	L C R	L W S	L T L P	V A E	L G L
241	GGCTATGCCT	CAGAGGAGAA	GATTATCTTC	CGATACTGTG	CTGGCAGCTG	TCCCCAAGAG
	CCGATACGGA	GTCTCCTCTT	CTAATAGAAG	GCTATGACAC	GACCGTCGAC	AGGGGTTCTC
81	G Y A S	E E K	I I F	R Y C A	G S C	P Q E
301	GTCCGTACCC	AGCACAGTCT	GGTGCTGGCC	CGTCTTCGAG	GGCAGGGTCG	AGCTCATGGC
	CAGGCATGGG	TCGTGTCAGA	CCACGACCGG	GCAGAAGCTC	CCGTCCCAGC	TCGAGTACCG
101	V R T Q	H S L	V L A	R L R G	Q G R	A H G
361	AGACCTTGCT	GCCAGCCCAC	CAGCTATGCT	GATGTGACCT	TCCTTGATGA	CCACCACCAT
	TCTGGAACGA	CGGTCGGGTG	GTCGATACGA	CTACACTGGA	AGGAACTACT	GGTGGTGGTA
121	R P C C	Q P T	S Y A	D V T F	L D D	H H H
421	TGGCAGCAGC	TGCCTCAGCT	CTCAGCCGCA	GCTTGTGGCT	GTGGTGGCTG	A
	ACCGTCGTCG	ACGGAGTCGA	GAGTCGGCGT	CGAACACCGA	CACCACCGAC	T
141	W Q Q L	P Q L	S A A	A C G C	G G	.

Figure 18B



PCB6  
Rat PSP  
Murine PSP  
COS cell lysate  
Mature PSP (E.coli)




Figure 19

## FIGURE 20A

PSP/NTN (SEQ ID NO:137)


ALAGSCLWSLTLPVAELGLGYASEEKVIFRYCAGSCPQEARTQHSLVLA 50  
↓  
RLRGRGRAHGRPCCRPTAYEDEVSFLDVHSRYHTLQELSARECACV 96

## FIGURE 20B

NTN/PSP (SEQ ID NO:142)

PGARPCGLRELEVVRVSELGLGYTSDETVLFRYCAGACEAAIRIYDLGLRR 50  
↓  
LRQRRRVRRERARAHPCCPQTSYADVTFLLDDQHHWQQLPQLSAAACGCGG 100

Figure 21a



U.S. GOVERNMENT PRINTING OFFICE: 1964 O 344-111

Figure 21b



TOH labeled cells in E14 mesencephalic cultures




Figure 22




Figure 23

1 ATGGCCGTAG GGAAGTTCCT GCTGGGCTCT CTGCTGCTCC TGTCCCTGCA GCTGGGACAG  
TACCGGCATC CCTTCAAGGA CGACCCGAGA GACGACGAGG ACAGGGACGT CGACCCTGTC  
1 M A V G K F L L G S L L L L S L Q L G Q

61 GGCTGGGGCC CCGATGCCCCG TGGGGTTCCC GTGGCCGATG GAGAGTTCTC GTCTGAACAG  
CCGACCCCGG GGCTACGGGC ACCCCAAGGG CACCGGCTAC CTCTCAAGAG CAGACTTGTC  
21 G W G P D A R G V P V A D G E F S S E Q  
\*\*

121 GTGGCAAAGG CTGGAGGGAC CTGGCTGGGC ACCCACC GCCC CTCTTGCCCCG CCTGCGCCGA  
CACCGTTTCC GACCTCCCTG GACCGACCCG TGGGTGGCGG GGAACGGGC GGACGCGGCT  
41 V A K A G G T W L G T H R P L A R L R R

181 GCCCTGTCTG GTCCATGCCA GCTGTGGAGC CTGACCCTGT CCGTGGCAGA GCTAGGCCTG  
CGGGACAGAC CAGGTACGGT CGACACCTCG GACTGGGACA GGCACCGTCT CGATCCGGAC  
61 A L S G P C Q L W S L T L S V A E L G L  
\*

241 GGCTACGCCT CAGAGGAGAA GGTCATCTTC CGCTACTGCG CCGGCAGCTG CCCCCGTGGT  
CCGATGCGGA GTCTCCTCTT CCAGTAGAAG GCGATGACGC GGCCGTCGAC GGGGGCACCA  
81 G Y A S E E K V I F R Y C A G S C P R G

301 GCCCGCACCC AGCATGGCCT GGCGCTGGCC CGGCTGCAGG GCCAGGGCCG AGCCACCGGT  
CGGGCGTGGG TCGTACCGGA CCGCGACCGG GCCGACGTCC CCGTCCCCGC TCGGGTGCCA  
101 A R T Q H G L A L A R L Q G Q G R A H G

361 GGGCCCTGCT GCCGGCCCCAC TCGCTACACC GACGTGGCCT TCCTCGATGA CCGCCACCGC  
CCCGGGACGA CGGCCGGGTG AGCGATGTGG CTGCACCGGA AGGAGCTACT GGCGGTGGCG  
121 G P C C R P T R Y T D V A F L D D R H R

421 TGGCAGCGGC TGCCCCAGCT CTCGGCGGCT GCCTGCGGCT GTGGTGGCTG A  
ACCGTCGCCG ACGGGGTCGA GAGCCGCCGA CGGACGCCGA CACCACCGAC T  
141 W Q R L P Q L S A A A C G C G G .

Figure 24

COPY

Express Mail #EL110672445US

PATENT

Attorney's Docket No. 6029-1486

**COMBINED DECLARATION AND POWER OF ATTORNEY**

(Original, Design, National Stage of PCT or CIP Application)

Inventors: Eugene M. Johnson, Jeffrey D. Milbrandt, Paul T. Kotzbauer, Patricia A. Lampe, Robert Klein and Fred DeSavage

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed above) or an original, first and joint inventor along with those listed above (if plural names are listed above) of the subject matter which is claimed and for which a patent is sought on the invention entitled: PERSEPHIN AND RELATED GROWTH FACTORS

the specification of which: (Complete (a), (b) or (c) for type of application)

**REGULAR OR DESIGN APPLICATION**

- (a) \_\_\_ is attached hereto.
- (b) X was filed on September 16, 1997 as Application Serial No. 08/931,858 and was amended on \_\_\_ (if applicable).

**PCT FILED APPLICATION ENTERING NATIONAL STAGE**

- (c) \_\_\_ was described and claimed in International Application No. \_\_\_ filed on \_\_\_ and as amended on \_\_\_ (if any).

**ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR**

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

\_\_\_ In compliance with this duty there is attached an information disclosure statement.  
37 CFR 1.97.



## PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

[Complete (d) or (e)]

(d) \_\_\_ no such applications have been filed.

(e) \_\_\_ such applications have been filed as follows.

### EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION

Country	Application No.	Date of filing (day, month, year)	Date of issue (day, month, year)	Priority Claimed
				___ YES NO ___
				___ YES NO ___

### ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION


## CONTINUATION-IN-PART

(Complete this part only if this is a continuation-in-part application)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

<u>08/881,172</u>	<u>06/23/97</u>	<u>Pending</u>	
(Application Serial No.)	(Filing Date)	(Status)	(Patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status)	(Patented, pending, abandoned)

## POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney and/or agent to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith, before all competent international authorities in connection with any international application, and before all foreign patent offices in connection with the national phase of any international application or any foreign application, and to appoint any associate attorneys in connection with any application, either domestic, international or foreign national.

John M. Howell (25,261); Richard E. Haferkamp (29,072); Kenneth Solomon (31,427); Joseph M. Rolnicki (32,653); Joseph E. Walsh, Jr. (36,959); Alan H. Norman (32,285); Donald R. Holland (35,197); Bryan K. Wheelock (31,441); Charles E. Dunlap (35,124); Anthony G. Simon (40,813); Alan L. Cassel (35,842); Michael J. Thomas (39,857); Thomas A. Polcyn (41,256); and Melodie W. Henderson (37,848)

Send Correspondence To  
Donald R. Holland  
HOWELL & HAVERKAMP, L.C.  
7733 Forsyth Boulevard  
Suite 1400  
St. Louis, Missouri 63105

Direct Telephone Calls To  
Donald R. Holland  
(314) 727-5188

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor Eugene M. Johnson

Inventor's signature

Date Country of Citizenship US

Residence 13233 Amiot Drive, St. Louis, Missouri 63146

Post Office Address 13233 Amiot Drive, St. Louis, Missouri 63146

Full name of second inventor Jeffrey D. Milbrandt

Inventor's signature

Date Country of Citizenship US

Residence 75 Aberdeen Place, St. Louis, Missouri 63105

Post Office Address 75 Aberdeen Place, St. Louis, Missouri 63105

Full name of third inventor Paul T. Kotzbauer

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship US

Residence 17 Bishops Drive, Aston, Pennsylvania 19014

Post Office Address 17 Bishops Drive, Aston, Pennsylvania 19014

Full name of fourth inventor Patricia A. Lampe

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship US

Residence 10323 Grant Forest Lane, St. Louis, Missouri 63123

Post Office Address 10323 Grant Forest Lane, St. Louis, Missouri 63123

Full name of fifth inventor Robert Klein


Inventor's signature 

Date 2/4/98 Country of Citizenship US

Residence 1044 Webster Street, Palo Alto, California 94301

Post Office Address 1044 Webster Street, Palo Alto, California 94301

Full name of sixth inventor Fred DeSavage

Inventor's signature 

Date 1/3/98 Country of Citizenship Belgium

Residence 166 Beach Park Boulevard, Foster City, California 94404

Post Office Address 166 Beach Park Boulevard, Foster City, California 94404

---

**COMBINED DECLARATION AND POWER OF ATTORNEY**

(Original, Design, National Stage of PCT or CIP Application)

---

Inventors: Eugene M. Johnson, Jeffrey D. Milbrandt, Paul T. Kotzbauer, Patricia A. Lampe, Robert Klein and Fred DeSavage

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed above) or an original, first and joint inventor along with those listed above (if plural names are listed above) of the subject matter which is claimed and for which a patent is sought on the invention entitled: PERSEPHIN AND RELATED GROWTH FACTORS

---

the specification of which: (Complete (a), (b) or (c) for type of application)

**REGULAR OR DESIGN APPLICATION**

- (a)   X   is attached hereto.
- (b)        was filed on        as Application Serial No.  
and was amended on        (if applicable).

**PCT FILED APPLICATION ENTERING NATIONAL STAGE**

- (c)        was described and claimed in International Application No.  
filed on        and as amended on        (if any).

**ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR**

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

       In compliance with this duty there is attached an information disclosure statement.  
37 CFR 1.97.

## PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

[Complete (d) or (e)]

(d) \_\_\_ no such applications have been filed.

(e) \_\_\_ such applications have been filed as follows.

### EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION

Country	Application No.	Date of filing (day, month, year)	Date of issue (day, month, year)	Priority Claimed
				___ YES NO ___
				___ YES NO ___

### ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION

--	--	--	--

## CONTINUATION-IN-PART

(Complete this part only if this is a continuation-in-part application)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

<u>08/881,172</u>	<u>06/23/97</u>	<u>Pending</u>	
(Application Serial No.)	(Filing Date)	(Status)	(Patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status)	(Patented, pending, abandoned)

## POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney and/or agent to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith, before all competent international authorities in connection with any international application, and before all foreign patent offices in connection with the national phase of any international application or any foreign application, and to appoint any associate attorneys in connection with any application, either domestic, international or foreign national.

John M. Howell (25,261); Richard E. Haferkamp (29,072); Kenneth Solomon (31,427); Joseph M. Rolnicki (32,653); Joseph E. Walsh, Jr. (36,959); Alan H. Norman (32,285); Donald R. Holland (35,197); Bryan K. Wheelock (31,441); Charles E. Dunlap (35,124); Anthony G. Simon (40,813); Alan L. Cassel (35,842); Michael J. Thomas (39,857); Thomas A. Polcyn (41,256); and Melodie W. Henderson (37,848)

Send Correspondence To  
Donald R. Holland  
HOWELL & HAFERKAMP, L.C.  
7733 Forsyth Boulevard  
Suite 1400  
St. Louis, Missouri 63105

Direct Telephone Calls To  
Donald R. Holland  
(314) 727-5188

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor Eugene M. Johnson

Inventor's signature

Date

9/29/97

Country of Citizenship US

Residence 13233 Amiot Drive, St. Louis, Missouri 63146

Post Office Address 13233 Amiot Drive, St. Louis, Missouri 63146

Full name of second inventor Jeffrey D. Milbrandt

Inventor's signature

Date

9/25/97

Country of Citizenship US

Residence 75 Aberdeen Place, St. Louis, Missouri 63105

Post Office Address 75 Aberdeen Place, St. Louis, Missouri 63105

Full name of third inventor Paul T. Kotzbauer

Inventor's signature *Paul T. Kotzbauer*

Date 10-14-97 Country of Citizenship US

Residence 17 Bishops Drive, Aston, Pennsylvania 19014

Post Office Address 17 Bishops Drive, Aston, Pennsylvania 19014

Full name of fourth inventor Patricia A. Lampe

Inventor's signature *Patricia A. Lampe*

Date 9/30/97 Country of Citizenship US

Residence 10323 Grant Forest Lane, St. Louis, Missouri 63123

Post Office Address 10323 Grant Forest Lane, St. Louis, Missouri 63123

Full name of fifth inventor Robert Klein

Inventor's signature *Robert Klein*

Date 12/1/97 Country of Citizenship USA

Residence 1044 Webster St., Palo Alto, CA 94301

Post Office Address \_\_\_\_\_

Full name of sixth inventor Fred DeSavage

Inventor's signature *Fred DeSavage*

Date 11/14/97 Country of Citizenship Belgium

Residence 166 Beach Park Blvd Foster City CA 94404

Post Office Address \_\_\_\_\_